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RESUMEN 
 
Mecanismos de unión a la hélice MPER en la interfase 
de membrana por anticuerpos anti-VIH y su implicación 
para la neutralización del virus 
 
Introducción 
 
El VIH (virus de la inmunodeficiencia humana) es el agente causante del 
SIDA (síndrome de inmunodeficiencia adquirida). Fue aislado por primera vez 
en 1983 y, a pesar de los innumerables avances en el campo de la virología y 
farmacología, a día de hoy se desconoce un tratamiento antiretroviral que cure 
o una vacuna efectiva que prevenga la enfermedad. Esto ha conllevado a que 
el VIH se haya convertido en un problema de salud mundial con 
aproximadamente 36.7 millones de personas infectadas a finales de 2015 
según los datos recogidos por la organización mundial de la salud (Informe de 
2016). 
 
El diseño de una vacuna constituye una de las estrategias con mayor 
potencial para la lucha contra el VIH. La diana para el desarrollo de dicha 
vacuna es la proteína de envoltura (Env) denominada gp160 que se localiza en 
la superficie de la membrana viral. Cada unidad funcional de gp160 está 
constituida por un trímero de heterodímeros, formados a su vez por las 
glicoproteínas gp120 y gp41 (Wyatt and Sodroski, 1998). La subunidad gp41 
está constituída por varios dominios que incluyen un péptido de fusión (FP), los 
dominios helicoidales (NHR y CHR), una región externa próxima a la 
membrana (MPER), un dominio transmembrana (TMD) que actúa de anclaje de 
cada monómero a la membrana del virus y un dominio citoplasmático (CTD) 
(FIG 21A).  
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El proceso de infección comienza con el reconocimiento de la célula 
diana mediante la unión de la subunidad soluble gp120 al receptor CD4/ co-
receptores CXCR4/CCR5 de los linfocitos T (Klatzmann et al., 1984). Dicho 
proceso desencadena una serie de cambios conformacionales que culminan 
con la inserción del FP en la membrana celular. La posterior reorganización de 
las regiones HR1 y HR2 en una estructura de 6 hélices de bajo contenido 
energético (Melikyan, 2008) provoca el acercamiento de las membranas 
(Blumenthal et al., 2012; Melikyan, 2011). FP y MPER desestabilizan la 
membrana celular (Apellaniz et al., 2014a) y viral (Apellaniz et al., 2014b; 
Suarez et al., 2000; Vishwanathan and Hunter, 2008), respectivamente, 
contribuyendo a su fusión y, por tanto, a la liberación del material genético del 
virus en el citoplasma de la célula diana.  
 
A pesar del esfuerzo realizado en el desarrollo de una vacuna en los 
últimos años, únicamente se ha logrado alcanzar un 31 % de protección frente 
a la infección por el VIH (Haynes et al., 2012a; Rerks-Ngarm et al., 2009). El 
escaso éxito en la búsqueda de una vacuna anti-HIV se debe en cierta medida 
a los mecanismos de evasión que ha desarrollado el virus (Johnson and 
Desrosiers, 2002). La hipervariabilidad genética del virus provocada por la falta 
de actividad exonucleasa de la polimerasa del VIH (Parvin et al., 1986) 
constituye uno de los factores mas importantes en la habilidad del virus para 
evadir el sistema inmunitario. Sin embargo, la secuencia MPER presenta un 
alto grado de conservación debido a su importante función como agente 
promotor de la fusión requerida para la entrada del virus en la célula diana 
(Apellaniz et al., 2011; Apellaniz et al., 2014b; Salzwedel et al., 1999). Como 
consecuencia, los anticuerpos dirigidos contra esta región son denominados 
anticuerpos de alto espectro ya a que son capaces de neutralizar una gran 
variedad de cepas y aislados clínicos del virus (Binley et al., 2004; Huang et al., 
2012; Kwong and Mascola, 2012; Stiegler et al., 2001).  
 
Entre los anticuerpos anti-MPER de mayor espectro descritos 
actualmente se encuentran los anticuerpos 4E10 y 10E8. La actividad 
neutralizante de estos anticuerpos es dependiente de residuos hidrofóbicos 
localizados en el extremo de la región determinante de complementariedad de 
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la cadena pesada 3 (CDR-H3) (Alam et al., 2007; Cardoso et al., 2005; Huang 
et al., 2012; Sanchez-Martinez et al., 2006a; Scherer et al., 2010). Dichos 
residuos no están implicados en la interacción directa con el epítopo. Sin 
embargo, y debido al carácter anfipático del MPER que localiza esta región en 
la interfase de la membrane del virus, son imprescindibles para mediar la unión 
del anticuerpo al MPER en el contexto de una membrana lipídica (capítulos 3-
6). Como consecuencia, el anticuerpos 4E10 presentan cierto grado de 
auto/polireactividad como demuestra su capacidad para interaccionar 
directamente con membranas celulares (Alam et al., 2007; Alam et al., 2009; 
Scherer et al., 2010). Sin embargo, y a pesar de reconocen secuencias 
solapadas de MPER, el anticuerpo 10E8 no es capaz de reconocer membranas 
lipídicas (Huang et al., 2012) sugiriendo mecanismos distintos en el bloqueo del 
virus. 
 
Resultados y discusión 
 
En esta tesis, se ha llevado a cabo un estudio detallado de la función 
que desempeña el lazo CDR-H3 de los anticuerpos 4E10 y 10E8 en la unión y 
neutralización del VIH, así como de la contribución de la unión directa a lípidos 
en el mecanismo de neutralización del anticuerpo 4E10. Por ello, uno de los 
objetivos de esta tesis ha consistido en poner a punto la expresión de Fab-s 
recombinantes en E. coli. La expresión en bacterias facilita la manipulación 
genética de estos especímenes para su uso en cristalografía, y ha permitido la 
realización de diferentes ensayos biofísicos que requieren altas 
concentraciones de material y marcajes con amino ácidos no-naturales o 
moléculas fluorescentes.  
 
Por otra parte, el diseño racional de un inmunógeno capaz de inducir la 
producción de anticuerpos funcionales similares al 4E10 y 10E8 constituye un 
aspecto fundamental en el desarrollo de vacunas anti-MPER. Estudios 
estructurales recientes sobre la estructura del dominio MPER-N-TMD 
(671NWFDITNWLWYIK683-684LFIMIVGGLV693) por resonancia magnética nuclear 
(RMN) (Apellaniz et al., 2015) revelan la existencia de una hélice continua 
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delimitada por dos regiones flexibles (subrayados). Estos datos cuestionan el 
modelo actual que propone que la hélice MPER se dispone de forma paralela 
la membrana hasta la Lys-683, que presuntamente marca el inicio de la TMD, o 
dominio de anclaje de la proteína a la membrana del virus, el cual adoptaría 
una orientación perpendicular a ésta. Por lo tanto, este modelo implica un giro 
en la hélice de aproximadamente 90º y un ángulo de aproximación de los 
anticuerpos al MPER perpendicular a la membrana. En el capítulo 3 se 
comparó la afinidad del anticuerpo 4E10 por un péptido que abarca la hélice 
ininterrumpida MPER-N-TMD (MPER(671-693)) con la de un péptido truncado en 
posición Lys-683 (MPER(656-683)). Los datos revelaron que preservar la hélice 
MPER-N-TMD no solo favorece la unión del anticuerpo 4E10 a su epítopo sino 
que inhabilita su reconocimiento por anticuerpos no neutralizantes 
(desprovistos del extremo del CDR-H3) cuando éste es presentado en un 
contexto de membrana. 
 
Con el objetivo de establecer las bases moleculares que expliquen 
aspectos funcionales del anticuerpo 4E10 como su unión al virus y mecanismo 
de neutralización, en primer lugar se investigó el papel que desempeña el lazo 
CDR-H3 en dichos procesos (capítulo 4). Para ello se llevó a cabo un estudio 
comparativo del anticuerpo neutralizante 4E10 en presencia y ausencia del 
péptido MPER(671-683) y así como de dos versiones no neutralizantes del mismo 
(W/D-W/D y Δloop). Los datos revelan que la unión de dichos anticuerpos al 
péptido MPER(671-683) en solución es indistinguible desde un punto de vista 
estructural y energético. Por lo tanto, la diferencia entre el anticuerpo 
neutralizante y los no neutralizantes está relacionada con la capacidad de 
reconocer la gp41 en el contexto de la proteína nativa inserta en membranas 
biológicas.  
 
La información extraída de los resultados cristalográficos en presencia y 
ausencia de ligando, revela que la unión al péptido supone una menor 
disminución de la flexibilidad el lazo CDR-H3 en comparación con el resto de 
lazos implicados en la unión. Esta observación, indica la posible existencia de 
interacciones adicionales entre el CDR-H3 y el antígeno que no están 
satisfechas en la unión al péptido MPER(671-683). En línea con esta hipótesis en 
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los capítulos 5 y 6 se han identificado interacciones específicas no covalentes 
entre el Trp100bHC del CDR-H3 de los anticuerpos 4E10 y 10E8 con la TMD. 
Además se ha establecido una correlación entre la formación de dichas 
interacciones en la interfase de la membrana y la capacidad neutralizante de 
ambos anticuerpos. Estos datos sugieren la formación de un complejo péptido-
lípido-anticuerpo de alta estabilidad capaz de fijar la conformación del MPER 
de modo que inhabilite su función desestabilizadora de la membrana viral 
interrumpiendo así con el proceso de fusión.  
 
Es probable que la potencia del anticuerpo dependa en parte del estadío 
de la fusión en el cual cada anticuerpo sea capaz de unirse. Se ha descrito 
previamente que el anticuerpo 10E8 es capaz de unirse a viriones en un estado 
prefusogénico (Huang et al., 2012) mientras que el 4E10 reconoce un 
intermediario de fusión (Frey et al., 2008) tras el reconocimiento de los 
receptores/correceptores en la célula diana (Binley et al., 2003; Dimitrov et al., 
2007). La estructura del complejo 10E8-MPER(664-690) resuelta por rayos X en el 
capítulo 5 demuestra la capacidad del anticuerpo 10E8 de rotar su dominio 
constante disminuyendo así los impedimentos estéricos ejercidos por la 
subunidad gp120 y facilitando así su unión a la Env en estado prefusogénico. 
Además, la orientación de la región C-terminal del péptido MPER(664-690) en 
dicha estructura sugiere que el anticuerpo adquiere una posición paralela al 
plano de la membrana al unirse a la gp41, consistente con la estructura 
obtenida por Cryo-EM de la Env native unida al 10E8. Por lo tanto, estos datos 
refuerzan la existencia de una hélice ininterrumpida que engloba el MPER y la 
parte N terminal de la TMD, la cual penetraría en la membrana con un grado de 
inclinación.  
 
A diferencia del 10E8, el 4E10 no es capaz de unirse a viriones en el 
estado prefusogénico y por consiguiente, una vez producida la activación, 
dispone de un intervalo de tiempo limitado para unirse a su epítopo (Binley et 
al., 2003; Dimitrov et al., 2007). El estudio llevado a cabo en el capítulo 7 
sugiere que el anticuerpo 4E10 se comporta como una proteína periférica de 
membrane. Así, este anticuerpo habría adquirido la habilidad de interaccionar 
con membranas cargadas negativamente (membrana viral) para maximizar la 
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eficiencia de unión del anticuerpo a su epítopo en el corto intervalo de tiempo 
que dura el proceso de fusión. Los datos sugieren que dicha capacidad 
incrementa la velocidad del anticuerpo 4E10 de unirse a su epítopo presentado 
en la membrane del virus.  
 
En conclusión, los datos obtenidos en esta tesis aportan información 
relevante para el diseño racional de vacunas anti-MPER capaces de generar 
anticuerpos con características similares al 4E10 y el 10E8. 
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In 1983, the human retrovirus that was ultimately termed Human 
Immunodeficiency Virus type 1 (HIV-1) (Coffin et al., 1986) was isolated for the 
first time (Barre-Sinoussi et al., 1983; Gallo et al., 1984; Levy et al., 1984). This 
virus constitutes the causative agent of the Acquired Immune Deficiency 
Syndrome (AIDS), one of the current leading global health problems. Despite of 
the innumerable advances in virology, pharmacology and clinical fields 
throughout these years, 36.7 million people remained infected by HIV by the 
end of 2015 (WHO, 2016), turning AIDS into a worldwide pandemic.  
 
Zidovudin (AZT) was the first anti-HIV drug approved by the U.S. Food 
and Drug Administration (FDA) in 1987. However, it was not until the mid-1990 
when antiretroviral therapy (ART) based on protease inhibitors allowed a 
sustained control of viral replication, resulting in a sharp decrease in morbidity 
and mortality caused by HIV infection (Palella et al., 1998). Since then, 23 
additional antiretroviral agents inhibiting different steps of the viral life-cycle 
have been identified. Combination of different ART agents gave rise to the 
standard treatment known today as “Highly Active Antiretroviral Therapy” 
(HAART) that progressively turned HIV infection into a chronic controllable 
disease. Hence, HAART provides a long-term therapy, favoring immune system 
recovery, reducing the risk of transmission and, hence, hampering virus spread. 
However, HAART is unable to eradicate HIV infection. Moreover, exposure to 
long-term medication often causes undesirable side-effects in the treated 
patients. These shortcomings strengthen the need of developing a protective 
vaccine. In this regard, RV144 constitutes to date the most successful vaccine 
trial, which provided a modest protection (31 %) against HIV infection (Haynes 
et al., 2012a; Rerks-Ngarm et al., 2009).  
 
In addition, the passive administration of broadly neutralizing antibodies 
(bNAbs) has been proposed as a plausible alternative for infection treatment. 
These antibodies can act antivirally by targeting conserved regions on the 
surface envelope protein (Env). As a proof-of-concept, bNAb-based therapies 
have been proven effective against the chimeric simian-human 
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immunodeficiency virus (SHIV) in macaques (Barouch et al., 2013; Moldt et al., 
2012; Shingai et al., 2013) and against HIV-1 in humanized rodent models 
(Balazs et al., 2012; Gruell et al., 2013; Halper-Stromberg et al., 2014; Klein et 
al., 2012b; Veselinovic et al., 2012). Moreover, transient viral control has also 
been observed in humans passively administrated with bNAbs in a phase 1 
study (Caskey et al., 2015). Besides, viral suppression can be achieved after 
medication interruption (Scheid et al., 2016) further supporting the efficacy of 
bNAbs-based therapies.  
 
1.1. NEW TECHNIQUES FOR HUMAN MONOCLONAL 
ANTIBODY ISOLATION  
 
Isolation of monoclonal antibodies (mAb) that arise from an effective 
immune response might constitute the starting point for the so-called “structural 
vaccinology” methodology. This approach proposes the use of isolated bNAbs 
for structural definition of antigens that can guide vaccine design as has been 
succesfully demonstrated for the respiratory syncytial virus (McLellan et al., 
2013). Until recently, a mayor bottleneck in the field was the absence of high-
throughput methods for the selection of specimens. Antibody production was 
limited by the use of immortalized B-cell lines (Kohler and Milstein, 1975; 
Lanzavecchia et al., 2007; Steinitz et al., 1977). The yield of this methodology is 
remarkably low and time consuming. Besides, only a fraction of the B-cell 
population becomes immortalized resulting in the loss of a vast amount of 
relevant antibodies.  
 
Another method for mAb isolation is based on the phage display 
technology (Barbas et al., 1991; McCafferty et al., 1990) (FIG 1). This method 
requires the generation of cDNA libraries of variable heavy (VH) and variable 
light (VL) chain fragments. For that, mRNA encoding both chains is isolated 
from a pool of B-cells, converted into cDNA by reverse transcription (RT)-PCR 
and subsequently cloned into the M13 phage vector. Either the VH or the VL 
gene is fused to the structural protein PIII gene and the resulting plasmid used 
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to transform E. coli in the presence of a helper phage (Schofield et al., 2007). 
The phages secreted from E.coli display on their surface a fusion protein 
consisting on the phage PIII protein and a specific antibody properly paired in 
the periplasm of the bacteria through a disulfide bond (FIG 1). Surface 
exposure of the antibody in the bacteriophage coat allows the specific selection 
in a subsequently antigen-binding screening, an enrichment step known as 
“panning”. Bound phages can be amplified by E. coli reinfection and the 
selected VH and VL sequences isolated and further sequenced. However, since 
chain pairing occurs in vitro in a random fashion, the resulting antibodies do not 
necessarily represent the natural antibody repertory. Besides, phage selection 
is based on binding screenings, limiting the use of this technology to the 
isolation of antibodies targeting known epitopes, but missing those targeting 
new, undefined ones. 
 
 
FIG 1. Phage display methodology for antibody selection. This technology is used for the 
generation of DNA libraries encoding the heavy and light chains of the antibodies generated by 
a B-cell population. The cDNA is inserted into filamentous phage genes codifying for phage 
coat protein. The antibody is expressed as a fusion protein displayed in the phage surface. 
Specific monoclonal antibodies (mAbs) selection is performed by repetitive cycle of screening, 
bacteria infection and amplification. 
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In the last few years, several methodologies for the rapid and efficient 
generation of human mAbs have been developed. Single-cell sorting coupled to 
RT-PCR represents an important advance in this field (Tiller et al., 2008). This 
method uses specific cell-surface markers of B-cell subtypes as baits for the 
identification of a desired B-cells population. Targeting of such markers with a 
fluorescent antibody enables isolation of specific single B-cells by using 
fluorescence-activated cell sorting (FACS). In addition, immunogens based on 
protein scaffolds can also be used as baits in this procedure (Scheid et al., 
2009). Antigenic positive cells are placed on individual wells for amplification by 
RT-PCR, allowing further sequencing of the cDNA encoding the antibody chain 
segments produced by a particular B-lymphocyte. (Li et al., 2010). Moreover, 
improved methods for B-cell culturing and activation based on cytokine-
secreting feeder cells, together with high-throughput binding and functional 
screening (Smith et al., 2009) have also contributed to the discovery of new 
generations of human mAbs with a broad spectrum of biological activity.  
 
1.2. THE HIV-ENVELOPE SPIKE: A TARGET FOR BROADLY 
NEUTRALIZING ANTIBODIES  
 
HIV-1 genome is composed of 9 genes organized in 3 open reading 
frames that encode all viral proteins. Among them, gag, pol and env are the 
most important viral genes of HIV. Gag and pol encode the structural and 
enzymatic proteins necessary for viral assembly and replication, respectively 
(Freed, 2015). Env encodes the envelope spike responsible for viral entry into 
host cells. The precursor polyprotein termed gp160, undergoes oligomerization 
(mainly trimers) (Earl et al., 1990; Schawaller et al., 1989) and several 
posttranslational modifications in the endoplasmic reticulum (ER) and Golgi, in 
its route to the plasma membrane, from where nascent virions bud (FIG 2).  
 
Posttranslational modifications involve massive glycosylation (50 % of 
the final mass) (Doores et al., 2010) and protein cleavage by furin-like 
proteases (Hallenberger et al., 1992). Protease cleavage renders the soluble 
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gp120 and the membrane-bound gp41 subunits that remain linked through non-
covalent interactions (see section 1.2.1). Hence, the HIV-1 envelope 
glycoprotein (Env) exposed on the surface of the virus, is comprised by trimers 
of non-covalently associated heterodimers. Furthermore, Env trimeric spikes 
incorporate at very low density into virions (8-14 spikes/virion) (Zanetti et al., 
2006; Zhu et al., 2006). This is supposed to hamper B-cell activation since the 
wide spacing between spikes disfavors B-cell receptor cross-linking. 
Consequently, B-cell activation as an initial step in the generation of antibodies 
capable of blocking the virus becomes very challenging and not trivial.  
 
 
FIG 2. HIV replicative cycle. HIV assembly, release and maduration steps are shown. The 
Env glycoprotein is synthesized and posttranslationally modified in the endoplasmic reticulum 
(ER) and the Golgi and transported via the secretory pathway to the plasma membrane. 
Oligomers of Gag bound to viral RNA are anchored to the plasma membrane through 
interaction of its amino-terminal myristate with phosphatidylinositol-(4,5)-bisphosphate 
(PI(4,5)P2). The resulting complex constitutes the immature virion that buds from the plasma 
membrane. Subsequent cleavage of Gag gives rise to mature virions with conical capside 
cores. Adapted from (Freed, 2015). 
 
The Env glycoprotein complex gp120/gp41 also promotes fusion of viral 
and host cell membranes, a process required for gaining access to the 
cytoplasm of host cells and initiating the infectious replicative cycle. The soluble 
subdomain gp120 is responsible for recognition of the CD4 receptor (Klatzmann 
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et al., 1984) and CXCR4/CCR5 coreceptors (Deng et al., 1996; Feng et al., 
1996) in host cells. Typically receptor/coreceptor engagement triggers 
subsequent conformational changes that remodel Env trimers from a close to 
an open state competent in fusion (FIG 3). 
 
The N- and C- termini of gp120 are positioned close to each other and 
encircled by four helices of gp41, composing a structural motif that stabilizes the 
heterodimer configuration (Pancera et al., 2014) (FIG 3ii). Moreover, insertion of 
a methionine residue into a tryptophan clasp fastens the native metastable 
conformation of gp41 (Pancera et al., 2014) (FIG 3i). Gp41 contains two distinct 
types of structural elements that take part in the subsequent steps of the fusion 
process. The first type is constituted by the membrane-transferring fusion 
peptide (FP) and the membrane-residing regions membrane-proximal external 
region (MPER) and transmembrane domain (TMD). The open conformation of 
Env triggered by receptor/coreceptor binding causes contact loss between 
gp120 and gp41 and opening of the tryptophan clasp that holds gp41. 
Consequently, FP is released from its native state conformation and poised for 
insertion into the target cell membrane. The second type of elements comprise 
the heptad repeat helical domains (NHR and CHR) that upon gp120-receptor 
binding, assemble into an energetically stable 6-helix bundle (6-HB) (Melikyan, 
2008) (FIG 3iii). Consequently, FP (inserted in the membrane host) and 
MPER/TMD (anchored to the viral membrane through the TMD) are placed into 
spatial proximity enabling membrane merge (Blumenthal et al., 2012; Melikyan, 
2011).  
 
However, close approximation of membranes pulled together by a 
growing 6-HB is hampered by the strong, repulsive hydration and electrostatic 
forces operating at their surfaces, which consequently prevent the initial mixing 
of their lipid constituents (Chernomordik and Kozlov, 2003; Kozlov et al., 2010). 
Thus, it has been argued that, beyond the anchoring effect, the N-terminal FP 
inserted into the target membrane could generate focal points of dehydration 
and hydrophobic destabilization required for fusion (Apellaniz et al., 2014a). 
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Complementarily, it has been suggested that MPER/TMD domain might prime 
the opposing viral membrane for fusion (Apellaniz et al., 2014b; Suarez et al., 
2000; Vishwanathan and Hunter, 2008).  
 
The extended gp41 structure that presumably precedes 6-HB formation 
is denoted as the pre-hairpin intermediate. The mature form of gp160 
represents the only viral target for bNAbs. Due to the high dynamism of Env 
during fusion, conformational information of each of the intermediate states 
constitutes a powerful tool for the rational design of effective immunogens.  
 
 
FIG 3. Conformational rearrangement of HIV-1 Env glycoprotein upon fusion activation. 
Before receptor/coreceptor binding Env trimer alternates between a closed and a slightly more 
open conformation referred to as relaxed conformation. The equilibrium between both Env 
states is known as Env breathing. Upon CD4 binding, the clasp formed between gp41 M530 
and the surrounding W residues (i) is broken leading to the disassembly of the collar helix (red) 
that wraps the N- and C- terminus of gp120 (ii). Consequently, the non-covalent interactions 
displayed in (ii), that kept gp120 and gp41 together, are lost (residues in green and blue belong 
to gp120 and gp41, respectively). Gp120 release leads to the exposure of the gp41 fusion 
peptide (FP) that was protected within the subdomains interface. The FP (pink) anchors the 
plasma membrane of the target cell and the formation of the stable coiled-coil (6-HB) (iii) brings 
both membranes in close proximity. Finally, the plasma and viral membrane destabilization 
induced by the FP and MPER, respectively, culminate the fusion process. PDB entries: 4TVP 
(SOSIP) and 2EZO (6-HB). 
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1.2.1. Three-dimensional structure of the HIV Env glycoprotein. 
 
Over the last 15 years, extensive effort has been focalized on the 
production of a high-quality recombinant protein suitable for solving with high-
resolution the trimeric structure of the HIV Env. The poor stability of the 
gp120/gp41complex hampered initial attempts in the field. Several strategies 
such as the removal of the furin-cleavage site or the addition of heterologous 
trimerization motifs were followed (Pancera et al., 2005; Yang et al., 2002). 
However, the resulting trimers failed to adopt a native-like fold (Ringe et al., 
2013). A stable trimeric architecture of the complex was finally achieved after 
incorporation of two modifications in the gp120/gp41 sequence: i) a disulfide 
bond (SOS) between residues 501 of gp120 and 605 of gp41 (Binley et al., 
2000) and ii) an isoleucine-to-proline substitution at position 559 in HR1 of gp41 
(IP) (Sanders et al., 2002). The resulting Env trimer based on a clade A BG505 
background and truncated at residue 664 provided a high-resolution view of the 
trimeric structure of Env at 4.7 and 5.8 Å using X-ray crystallography (Julien et 
al., 2013) and cryo-EM (Lyumkis et al., 2013), respectively. Both initial 
structures were solved in complex with anti-gp120 bNAbs. However, the 
antibodies did not alter the native conformation of the protein, as confirmed by 
the high structural similarity between these initial structures and a recent ligand-
free trimer stabilized by an additional disulfide bond within gp120 (Kwon et al., 
2015). 
 
The high-resolution structures of the BG505-SOSIP trimer exhibit the 
antigenic surface of the HIV-envelope glycoprotein in the prefusion state (FIG 
4). Gp120 subunit is organized into two parallel major domains (inner and outer 
domain) linked by a bridging sheet built by four antiparallel strands. This subunit 
contains different variable loops located at the outside of the structure. Loops 
V1 and V2 adopt a 4- stranded greek-key β-sheet motif at the top of the trimer 
forming the trimer apex and maintaining the integrity of the protomer (Julien et 
al., 2013; Lyumkis et al., 2013). Underneath these loops sit the two anti-parallel 
β-strands that form the β-hairpin structure of V3, responsible for coreceptor 
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(CCR5/CXCR4) engagement. On the contrary, V4 and V5 project outward from 
the surface of gp120 without making contacts with other variable loops. In 
addition, the surface of gp120 is coated mainly with the high-mannose glycan 
(Bonomelli et al., 2011; Doores et al., 2010). As compared to the more complex 
glycans present in monomeric gp120 or gp140 recombinant proteins (Pritchard 
et al., 2015), the presence of this type of glycan in large proportions (46 % to 
98 % of the total glycans) is consistent with the tight assembly of the gp160 
trimer that prevents glycan maturation in the Golgi during its biogenesis. 
 
 
FIG 4. Three-dimensional structure of the prefusion HIV envelope spike. The gp41 subunit 
constitutes a central stalk of the trimer with the heptad repeat helical domains, NHR (orange) 
and CHR (red), oriented perpendicular and diagonal to the membrane, respectively. The fusion 
peptide (pink) is partially solved and adopts an extended conformation. The structure and 
location of the functional domains within one protomer of gp120 are also highlighted. The 
hypervariable V1/V2 loops (green) occupy the apex of the trimer, partialy masking V3 loop 
(yellow) located underneath. The bottom diagram represents the solved residues within gp120 
and gp41 and the position of the glycans within each subunit. The structure was rendered by 
overlapping Env trimer structures with PDB codes 4RCO and 4TPV. 
 
A more complete picture of the structural organization of gp41 could be 
obtained from the crystal structure of the SOSIP trimer solved at a higher 
resolution (3.5 Å) (Pancera et al., 2014). As mentioned before, this new 
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ectodomain structure revealed gp120 N- and C- terminal strands anchored into 
a hydrophobic pocket formed by a gp41 helix collar at the base of the structure 
(FIG 3ii). Furthermore, resolution of the protomer structure highlights the 
complete set of non-covalent interactions between both subunits: i) Leu 523 
within a non-structured segment of the N terminus of gp41 interacts 
hydrophobically with residues Trp 45 and Ile 84 from gp120; ii) the gp41 
cysteine loop (Cys 598–Cys 604 disulfide) establishes hydrogen bonds with the 
N terminus of gp120 and iii) the gp41–gp120 interface builds a hydrophobic 
pocket where part of the FP is shielded from the solvent until activation of the 
fusion cascade. 
 
In addition, this structural arrangement provides the grounds to 
understand fusion activation at the molecular level. In the prefusion 
conformation state a shorter helix (572–595) of HR1 forms a parallel coiled-coil 
at the center of the trimer in a position perpendicular to the membrane. On the 
contrary, a helix (628-664) encompassing most of HR2 forms a long curved 
helix at the periphery of the protein adopting a diagonal orientation to the 
membrane (FIG 4). Upon fusion activation, helix (572–595) is extended and 
arranged with the helices from the neighboring protomers in a coiled-coil 
conformation. This arrangement leaves hydrophobic grooves on the outer 
surface of the coiled-coil where HR2 helixes from each protomer of the trimer 
will bind in an antiparallel fashion (FIG 3iii). The resulting stable core formed by 
a bundle of 6 helixes represents the post fusion state of gp41.  
 
The 6-HB structure encompassing HR1 and HR2, extended towards the 
FP (531-581) and MPER (628-681), respectively, has been solved by X-ray 
crystallography (Buzon et al., 2010). Unfortunately, structural atomic information 
of residues located beyond Asp664 in the context of the native state of the 
trimer is missing despite the availability of the CryoEM structure at 8.8 Å of a 
SOSIP trimer harbouring the MPER and TM domains (Lee et al., 2016). 
However, the NMR structure of overlapping peptides in membrane mimetics 
suggests that the MPER/TMD region is organized as a continuous helical 
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structure with a flexible element at position 690 (Apellaniz et al., 2015). Hence, 
in a prefusion state, the MPER-TMD region is proposed to insert into the 
membrane with a tilted orientation and twist at the residue Gly690 to follow a 
direction parallel to the bilayer normal (FIG 5). This conformation would satisfy 
most of the aromatic interactions with the membrane interface at its N-terminus 
and adjust the length of the TMD anchor to the membrane thickness. This 
structural arrangement is in good agreement with the recent NMR structure of 
the trimeric TMD solved in a bicelle membrane model (Dev et al., 2016). 
Similarly, this structure exhibits a kink within a continuous helical TMD 
monomer dividing the TMD segment into two halves stabilized by different 
modes of assembly. The N- terminal part is stabilized by a coiled-coil motif 
(686-696) while the C-terminal part is held together by polar contacts within the 
hydrophilic core (704-712) (FIG 5).  
 
 
FIG 5. Modelling of the prefusion conformation of the full HIV Env glycoprotein. The 
overall structure was obtained by overlapping of structures with PDB entries 4TVP (SOSIP), 
2MG1, 2MG2 and 2M8M (TMD and MPER) and 5JYN (TMD trimer). The MPER domain is 
extended towards the TMD as an uninterrupted helix with a flexible kink at position 690 
(Apellaniz et al., 2015). This kink bends the TMD helix possibly providing flexibility to the whole 
trimer to breath between a closed and a relaxed conformation. Close up view of the TMD 
trimeric domain to highlight the two main interactions responsible for its trimerization. 
Hydrophobic residues (displayed in red) within the N-terminal half of the structure form a well-
defined coiled-coil motif while the C terminal hydrophilic core of the trimer (green) is stabilized 
by polar contacts. 
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1.2.2. Anti-HIV broadly neutralizing antibodies 
 
In spite of the accessible location of HIV-1 Env on the virus surface, 
elicitation of a protective response occurs only in 10-25 % of HIV-infected 
individuals (Doria-Rose et al., 2009; Stamatatos et al., 2009) of which only 1 % 
(elite neutralizers) exhibits high neutralization breadth and potency (Simek et 
al., 2009). The reason for the low frequency of patients capable of developing 
bNAbs resides on several mechanisms evolved by the virus to escape immune 
surveillance (Johnson and Desrosiers, 2002). One escape mechanism is based 
on the poor stability of the gp41/gp120 complex that often causes gp120 
dissociation leaving non-functional gp41 stumps on the surface of the virus. 
These complexes are highly immunogenic and deviate the humoral response to 
other areas, precluding the development of antibodies that recognize and block 
functionally relevant, native Env structures (Moore et al., 2006). Moreover, the 
high mutational rate that arises from the HIV error-prone reverse transcriptase 
(Parvin et al., 1986), leads to an estimated 35 % sequence variation between 
virus subtypes known as clades (Gaschen et al., 2002). Another important 
feature of the virus that contributes to its escape from host immune responses 
relies on the extensive glycosylation of HIV Env that counts with an average of 
24 potential N-glycosylation sites (PNGS) on gp120 and 4 on gp41. The high 
dense shield of glycans results in functional and conserved epitope masking. In 
addition, the viral membrane also plays a role in masking the conserved MPER 
segment possibly by interfering with the generation of an immune response 
against this region.  
 
1.2.2.1. Epitopes targeted by HIV bNAbs: Sites of vulnerability 
 
The evolutionary pressure imposed by antibody recognition has shaped 
the properties of the HIV Env glycoprotein. However, sequence and structural 
conservation of certain regions are required for viral function. Antibody targeting 
to those key sites known as “sites of vulnerability”, results in viral inhibition (FIG 
6A). Production of stable native-like trimmers, accessibility to large cohorts of 
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infected individuals and development of multiple approaches for antibody 
isolation has led to identification of multiple, unprecedented bNAbs (Table 1 and 
FIG 6B). As a result, four main conserved sites susceptible to antibody 
neutralization were initially delineated within the HIV-Env spike: CD4-binding 
site on gp120 (CD4bs), V1/V2 site on gp120, glycan-V3 site on gp120 and 
MPER on gp41. More recently, new sites targeted by bNAbs have been 
identified on the gp120-gp41 interface (Sattentau, 2014) and within the FP of 
gp41 (Kong et al., 2016) targeted by bNAbs have been identified.  
 
 
FIG 6. Sites of vulnerability recognized by bNAbs. A) Top and side views of regions on the 
surface of the HIV-1 Env trimer targeted by bNAbs. Reprinted from (Ward and Wilson, 2015). 
B) Breadth (percentage of viral clades neutralized with an IC50< 50µg/mL) plotted against their 
potency of neutralization (median inhibitory concentration for all neutralization-sensible 
viruses). The bNAbs are colored according to the region targeted in A. Adapted from (Burton 
and Hangartner, 2016). 
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Table 1. List of bNAbs against HIV. Binding site specificity, total number of somatic 
hypermutations (SHM) in the light and heavy chains, length of the CDR-H3 and the tendency to 
be poly-/autoreactive are listed. Adapted from (Burton and Hangartner, 2016). 
Env binding 
site 
bNAb ID 
CDR-H3 
length 
SHM (%) nt Auto/Poly 
reactivity 
Ref 
Heavy Light 
CD4bs  
on gp120 
b12 9 13.8 13.4 No 
(Barbas et al., 1992; 
Burton et al., 1994) 
VRC01 14 29.7 16.6 No (Wu et al., 2010) 
3BNC117 12 23.5 16.6 Yes (Klein et al., 2012a) 
CH103 15 18.0 10.7 Yes (Liao et al., 2013) 
V1/V2 site  
on gp120 
PG9 30 12.0 9.2 No (Walker et al., 2009) 
PG16 30 13.1 12.2 No (Walker et al., 2009) 
PGT145 33 16.2 15.5 n.d. (Walker et al., 2011) 
CAP256-
VRC26.09 
39 12.8 9.7 n.d. (Doria-Rose et al., 2014) 
PGDM1400 34 24.3 11.3 No (Sok et al., 2014) 
Glycan-v3 site  
on gp120 
2G12 16 20.3 12.2 Yes 
(Buchacher et al., 1994; 
Trkola et al., 1996) 
PGT121 26 17.8 15.5 n.d. (Walker et al., 2011) 
PGT124 26 15.0 16.6 n.d. (Walker et al., 2011) 
PGT128 21 19.0 8.7 n.d. (Walker et al., 2011) 
PGT135 20 17.1 15.9 n.d. (Walker et al., 2011) 
10-1074 26 26.7 30.1 n.d. (Mouquet et al., 2012) 
gp120-gp41 
interface 
PGT151 28 18.5 12.6 No 
(Blattner et al., 2014; 
Falkowska et al., 2014) 
35O22 16 21.9 22.4 No (Huang et al., 2014) 
8ANC195 22 27.2 14.9 Yes (Scharf et al., 2014) 
MPER  
on gp41 
2F5 24 12.1 11.8 Yes 
(Buchacher et al., 1994; 
Conley et al., 1994; 
Muster et al., 1993) 
4E10 20 6.8 4.7 Yes 
(Buchacher et al., 1994; 
Zwick et al., 2001) 
10E8 22 19.4 14.2 No (Huang et al., 2012) 
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Glycans were originally considered to decrease HIV immunogenicity 
since they are derived from the host ER and Golgi pathways during HIV 
replication. However, due to the immature nature of the glycans and its high 
dense clustering (not present in host glycoproteins), they constitute key motifs 
present in many of the binding sites of bNAbs. Specifically, the CD4bs and 
V1/V2 sites include the N-linked glycan at residue N160 on gp120, whereas the 
V3 site includes the N-linked glycan at residue N332 on gp120.  
 
The CD4bs is built by the combination of regions from gp120 inner and 
outer domain together with the bridging sheet (Julien et al., 2013; Lyumkis et 
al., 2013). This functional site is located between gp120 subunits and therefore 
shielded by glycans from its own and other adjacent gp120 protomers. This 
location imposes significant steric constraints for antibody engagement and 
CD4bs has to be targeted with a specific angle of approach (Ryu and 
Hendrickson, 2012). Consequently, antibody evolution has evolved towards 
including gp120 loops D (276–283) and V5 (455-462) and glycan at residue 
N276 from neighboring gp120 as part of their epitopes (Diskin et al., 2011). 
V1/V2 site represents a glycopeptide epitope for bNAbs. The peripheral location 
pointing away from the core of the trimer allows sequence, length and 
glycosylation pattern diversity of this region without compromising gp120 
structure. Hence, bNAbs targeting the V1/V2 loops have evolved to recognize a 
quaternary-structure involving both glycan contacts and to establish 
electrostatic sequence-independent interactions between a cationic protein 
surface in Env and the protruding tyrosine-sulfated anionic CDR-H3 (Gorman et 
al., 2016; McLellan et al., 2011). Similarly to V1/V2, the glycan-V3 site 
constitutes a carbohydrate-dependent epitope associated with a protein epitope 
(Kong et al., 2013; Mouquet et al., 2012; Walker et al., 2011). However, binding 
to pure high-mannose sugar clusters (Calarese et al., 2003) has been also 
reported. Consistent with the idea that glycan patches represent immunogenic 
regions, gp41-gp120 interface includes a glycan patch that extends from gp120 
into gp41 (Huang et al., 2014; Scharf et al., 2014).  
 
 18 
1.2.2.2. Antibody development during natural infection: unique 
features of anti HIV-1 bNAbs 
 
Production of bNAbs capable of providing a protective response requires 
affinity maturation of the surface immunoglobulin (Ig) B-cell receptor (BCR) 
through somatic hypermutation and isotype-switching (FIG 7). This process is 
initiated with antigen recognition by the BCR of naïve B-cells that drives 
crosslinking of antigen receptor causing B-cell activation (Batista and Harwood, 
2009). The antigen is internalized, processed and presented in the context of 
the class II mayor histocompatibility complex (MHC-II). The complex composed 
of the peptide and the MHC-II is recognized by specific helper T cells that 
trigger the signaling pathways required for B-cell proliferation. These events 
occur in the germinal centers of secondary lymphoid organs (Parker, 1993). 
Normally, helper T cells need to be activated by the same antigen to ensure 
self-tolerance. However, for virus particles, this linked recognition is less 
restrictive and do not necessarily require activation of B and T cells through 
exactly the same protein from the virus. 
 
During B-cell proliferation, each cell division is accompanied by somatic 
mutations in the V-gene of the Ig, at a rate of 1 per 103 bases, 105-106 fold 
greater than the normal rate of mutation across the genome. This event, known 
as somatic hypermutation (SHM), has the potential to generate create B-cells 
with modified affinity for a certain antigen (Xu et al., 2007). B-cells with 
mutations that increase binding affinity for the antigen are selected and 
continuously subjected to rounds of division and mutation (FIG 7). Upon affinity 
maturation, selected B-cells can differentiate into plasma cells secreting high-
affinity antibodies. Secretion requires isotype switching, a process that involves 
rearrangement of the C-gene. Alternatively, mature B-cells can differentiate into 
memory B-cells that confer long-lasting protection against subsequent 
encounters with the antigen (MacLennan, 1994; Rajewsky, 1996).  
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FIG 7. B-cell affinity maturation in the germinal centre (GC). Sequential recombination of 
the heavy (VDJ) and light (VJ) chain genes gives rise to antigen specific B-cell receptors (BCR) 
for antigen recognition. The BCR-antigen complex is presented to T cells for its activation and 
entry to the GC where B-cells undergo affinity maturation through somatic hypermutation 
(SHM). The resulting BCRs with a slightly different affinity for the antigen are selected by 
follicular dentritic cells (FDC) to die through apoptosis (mutations that decrease affinity) or to 
survive (mutations that increase affinity). Surviving B-cells can either undergo the same affinity 
maturation process to further increase their affinity and specificity for the antigen, or exit the GC 
as plasma cells or memory B-cells. Plasma cells undergo isotype-switching resulting in the 
secretion of high-affinity soluble antibody molecules. Adapted from (Heesters et al., 2014). 
 
Chronic HIV infection, caused by an evolving virus, leads to the 
continuous exposure of variable antigens to B-cells. Hence B-cells have to 
undergo extensive cycles of affinity maturation in order to yield a high-affinity 
BCRs (Breden et al., 2011). Consequently, bNAbs isolated from HIV-1 infected 
individuals are generated 3-4 years after infection (Gray et al., 2011) and 
contain an unusually high level of SHM (Haynes et al., 2012b) (Table 1). As 
note before, extensive SHM usually occurs in the CDRs of the Ig gene. 
However, in the case of HIV bNAbs, the structural framework regions (FWR) 
also undergo substantial SHM, which is critical for broad neutralization (Klein et 
al., 2013a). Another remarkable feature of HIV-1 bNAbs is their long heavy 
chain CDR-H3 sequences (Table 1). Antibodies targeting the V1/V2 or V3 loops 
and the MPER sequence use long CDR-H3s to penetrate the glycan shield or 
the viral membrane, respectively. CDR-H3 loops of some bNAb can reach up to 
34 residues in length (Table 1) compared to the average of 16 residues for 
other human Ig CDR-H3s (Tiller et al., 2007). A recent deep-sequencing study 
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identified up to 3.5 % of human mature naïve B-cells bearing CDR-H3s of a 
length ≥ 24 amino acids and an even smaller population of 0.43 % with CDR-
H3s spanning 28 residues or more (Briney et al., 2012).  This low occurrence is 
due to the auto-reactivity induced by long CDR-H3s that provokes the negative 
selection of those clones during B-cell development (Wardemann et al., 2003). 
Nevertheless, pre-existence of mature naïve B-cells with long CDR-H3s might 
be a prerequisite for generating some of the HIV-bNAbs that reach epitopes 
deeply located within the Env spike.  
 
Most HIV-1 bNAbs, likely due to the extensive SHM, show very low or no 
detectable binding to Env when reverted to its non-mutated germline precursor 
(Kwon et al., 2016a; Ota et al., 2012; Xiao et al., 2009). Consequently, an 
increasing number of studies focus on B-cell ontogeny of each bNAb in order to 
identify Env immunogens responsible for their elicitation at different stages of 
development (Bonsignori et al., 2016; Doria-Rose et al., 2014; Liao et al., 
2013). Furthermore, many of the HIV-1 bNAbs are poly-/autoreactive (Haynes 
et al., 2005; Verkoczy and Diaz, 2014; Wu et al., 2010; Wu et al., 2011) (Table 
1). This property is not necessarily linked to the presence of long CDR-H3s, but 
it may be acquired during B-cell development due to the bypass of tolerance 
checkpoints (Mouquet and Nussenzweig, 2012; Wardemann et al., 2003). 
Correlation between polyreactivity and neutralization (Liu et al., 2015) has led to 
categorize polyreactivity as a mechanism to increased binding affinity by 
heteroligation (Mouquet et al., 2010) (Klein et al., 2013b).  
 
1.3. BROADLY NEUTRALIZING ANTI-MPER ANTIBODIES: 
THE AIM OF THIS STUDY 
 
MPER constitutes a conserved tryptophan-rich domain on the Env 
glycoprotein (FIG 8A) that represents a site of vulnerability targeted by 
neutralizing antibodies with remarkably high (4E10 and 10E8) (Huang et al., 
2012; Muster et al., 1993; Stiegler et al., 2001) and moderate (2F5, Z13e1 and 
m66.6) (Nelson et al., 2007; Zhu et al., 2011) breadth. The crystal structures of 
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4E10 and 10E8 antibodies in complex with peptides harboring their epitopes 
reveal a highly unusual helical conformation of the peptides (Cardoso et al., 
2007; Huang et al., 2012) in contrast to the more common extended 
conformations observed in other antibodies including 2F5 bNAb (Julien et al., 
2008; Ofek et al., 2004) (FIG 8A). 
 
 
FIG 8. Sequence and three-dimensional structure of MPER. A) WebLogo representation of 
MPER sequence conservation of all HIV/SIVcpz subtype genomes (filtered web, 5132 
sequences) available at the LANL HIV Sequence Database 
(http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html). Cartoon representation of 
the structures adopted by shorter versions of MPER in complex with the bNAbs 2F5 (PDB code 
1TJI), 10E8 (4G6F) and 4E10 (2FX7) are shown. The critical residues for antibody binding are 
displayed as sticks. B) Helical structures adopted by MPER ligand free peptides. Two flexible 
segments at the regions targeted by the anti-MPER bNAbs can be distinguished within the 
overall helical conformation of the peptide. C) Structure of the HIV-1 TMD displaying a hinge at 
position G690. 
 
NMR structures of several peptides embodying (i) the 2F5 epitope, (ii) 
the 4E10/10E8 epitope or (iii) peptides combining both epitopes reveal the 
overall helical conformation of MPER (Apellaniz et al., 2015; Mirassou et al., 
2009; Reardon et al., 2014; Schibli et al., 2001; Serrano et al., 2014; Sun et al., 
2008). However, segments 664DKW666 and 671NWFD674 harboring critical 
residues targeted by 2F5 and 4E10/10E8 antibodies, respectively, show a high 
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degree of conformational variability among the different structures (FIG 8B). 
This conformational flexibility is likely related to the critical role of gp41 in 
mediating viral entry by triggering membrane fusion. These two elements, 
together with the recently described flexible element 690GGLV693 within the TMD 
(Apellaniz et al., 2015), might function as articulated joints that enable the 
formation of structural intermediates emerging along the fusion pathway (FIG 
8C). Interestingly, the helical segment formed between 671NWFD674 and 
690GGLV693 joints (MPER671-693) has been reported to act as an active domain in 
membrane fusion by inducing viral envelope phospholipid acyl chain splay 
(Apellaniz et al., 2014b) (FIG 9).  
 
 
FIG 9. Fusogenicity of MPER671-693. MPER671-693 (black) fusion activity in lipid membranes of 
POPC (blue) and Chol (red) relies on phospholipid extraction as shown by molecular dynamic 
simulations (MDS). Taken from (Apellaniz et al., 2014b). 
 
MPER is embedded into the membrane interface hindering recognition 
and, thus, engagement by antibodies (Nieva et al., 2011). However, bNAbs 
targeting this conserved region have evolved to incorporate structural elements 
to both recognize and engage the epitope in a membrane environment. The 
hydrophobic residues at the apex of the CDR-H3 of anti-MPER antibodies (FIG 
10) are involved in mediating epitope recognition in biological membranes and, 
therefore, they are required for viral blocking (Alam et al., 2007; Cardoso et al., 
2005; Huang et al., 2012; Sanchez-Martinez et al., 2006a; Scherer et al., 2010). 
In addition, several studies have shown the capacity of 2F5 and 4E10 
antibodies to directly bind lipids (Alam et al., 2009; Julien et al., 2010; Maeso et 
al., 2011; Ofek et al., 2004). However, despite multiple similarities encountered 
Acyl chains 
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between 4E10 and 10E8 antibodies such as binding overlapping epitopes within 
MPER, 10E8 lacks the overall membrane binding tendency of 4E10 (Huang et 
al., 2012; Kwon et al., 2016a), although some authors have reported 10E8-lipid 
interactions in the context of cholesterol-containing vesicles (Chen et al., 2014).  
 
Lipid interaction has been proposed as a strategy employed by anti-
MPER antibodies to increase their neutralization potency either by acquisition of 
a second binding site and thus, increasing antibody avidity (heteroligation) 
(Klein et al., 2013b) and/or by providing an opportunity window to capture gp41 
fusion intermediates from a membrane pre-concentrated state (Alam et al., 
2009). Heteroligation (i.e., to combine strong binding to gp41 and weak binding 
to viral membrane) might be of special importance for HIV blocking due to its 
low spike density (Zanetti et al., 2006). Interestingly, although 10E8 antibody 
does not display strong interactions with membranes, it exhibits higher potency 
than any anti-MPER reported to date with an IC50 mean value of 0.35 µg/mL 
(Huang et al., 2012) (FIG 6B). 
 
 
FIG 10. Structure of the CDR-H3 of anti-MPER bNAbs. Depiction of the contacts between 
CDR-H3 (red) of anti-MPER bNAbs and epitope peptides (gray). Residues critical for 
neutralization are shown in stick representation. 
 
Due to the critical role in HIV infection exerted by the region targeted by 
the 4E10 and 10E8 antibodies, a phenomenon at the origin of their exceptional 
neutralization breadth, these antibodies serve as models of broad protection 
against HIV infection, particularly for the purpose of vaccine design. This 
warrants an extensive structural and functional characterization, which is the 
main objective of this thesis work. 
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Main goals  
 
1- To generate a platform for the fast and massive production of recombinant 
anti-MPER antibodies 4E10 and 10E8 in bacteria, and to validate them 
structurally and functionally. 
 
2- To use the above mentioned expression platform for the production of the 
following genetically modified recombinant antibodies: 
- CDR(H) mutants. 
- Cys mutants for labeling with fluorescent probes, and 
- pBPA mutants for photo-cross-linking assays. 
 
3- To use the above specimens to define the requirements for engaging MPER 
helix at the membrane interface with the aim of: 
- designing effective anti-MPER vaccines. 
- optimizing the functional performance of anti-MPER antibodies. 
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This chapter gathers a theoretical overview of the main techniques used 
during the thesis. A more detailed description of these and additional 
experimental approaches can be found in the Materials and Methods sections 
of the following Chapters 3-7. 
 
2.1. RECOMBINANT PROTEIN EXPRESSION 
 
To study the function and/or structure of a protein, recombinant 
overexpression is generally required due to the low levels present in natural 
sources. Nowadays, overexpression of many proteins remains a big challenge 
and therefore, a lot of effort is made to overcome this problem (Makrides, 1996) 
(Sorensen and Mortensen, 2005). The bacterium E. coli is the host of choice in 
many instances for this purpose due to its low cost, high production yields, easy 
transformation and the ability to grow to high culture density in fermenters. 
However, the use of E. coli for protein overexpression has certain limitations, 
including the formation of disulfide bonds. 
 
The cytoplasm of E. coli is a reducing environment and therefore proteins 
with disulfide bonds will generally not fold properly when overexpressed in this 
compartment. The cytosolic proteins thioredoxins (TrxA, TrxC) and 
glutaredoxins (GrxA, GrxB, GrxC) catalyze the reduction of proteins by cysteine 
thiol-disulfide exchange (Aslund and Beckwith, 1999). Consequently, the 
formation of stable disulfide bonds in the cytoplasm is strongly disfavored. The 
reductive state of both thioredoxins and glutaredoxins is maintained by the 
action of thioredoxin (trxB gene product) and glutathione reductase (gor gene 
product), respectively (FIG 11). 
 
In the periplasm of E. coli, disulfide bond formation can occur and it is 
actively catalyzed by the Dsb-system in a two-step process (Nakamoto and 
Bardwell, 2004) (FIG 11). The Dsb-system consists of a set of thiol disulfide 
oxidoreductases that share the sequence motif Cys-X-X-Cys. It consists of the 
components DsbA, DsbB, DsbC and DsbD. These proteins not only are able to 
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catalyze disulfide bond formation, but also to rearrange those that are not 
present in the native three-dimensional structure of the protein.  
 
Specifically, catalysis of disulfide bond formation is accomplished by the 
periplasmic protein DsbA (Inaba et al., 2006). This process occurs between 
consecutive cysteines while the primary structure of the protein emerges into 
the periplasm. Hence, a proofreading mechanism (Ito, 2010) is required for 
proteins that have more than two cysteines with nonlinear connectivity in their 
native conformation. The inner membrane protein DsbC is responsible for the 
sensing and subsequent isomerization of non-physiological disulfide bonds 
(McCarthy et al., 2000). The inner membrane proteins DsbB and DsbD catalyze 
the re-oxidation of DsbA and DsbC, respectively, in order to keep them in their 
active state (Kimball et al., 2003). 
 
Owing to the crucial role of disulfide bonds in physiological folding and 
function of various proteins, E. coli strains such as Origami or T7 Shuffle 
(Lobstein et al., 2012) have been engineered. The cytoplasm of these strains is 
turned into a more oxidizing environment by constructing trxB and gor null 
mutants. However, double mutants missing parts of both systems show an 
impaired growth. This growth defect can be alleviated by the presence of an 
extragenic suppressor mutation in the ahpC gene (Bessette et al., 1999). 
Suppression of thioredoxin and glutathione reductase reverses the normal role 
of thioredoxins and glutaredoxins, respectively. Thus, they act as catalysts for 
the formation of disulfide bonds in the cytoplasm, i.e, they act as oxidases. The 
E. coli T7 Shuffle strain has been further engineered to incorporate the gene of 
the DsbC isomerase into the genome of the bacteria, which results in its 
constitutive expression. The activity of this disulfide bond isomerase shuffles 
incorrect disulfide bonds into their native correct pairing and, therefore, sustains 
higher yields of the overexpressed recombinant protein. 
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FIG 11. Oxidative protein folding in E. coli. The reducing environment derived from the 
activity of E. coli cytoplasmic glutaredoxins and thioredoxins impairs the covalent bond 
formation of two thiol groups. Hence, proteins containing structural disulfide bonds have to be 
translocated to the periplasm of E. coli where the Dsb-system catalyzes the formation (DsbA) 
and isomerization (DsbC) of disulfide bridges. Reactivation of DsbA and DsbC is performed by 
DsbB and DsbD, respectively. 
 
The E.coli T7 Shuffle strain has been used in the present doctoral thesis 
for the overexpression of different neutralizing and non-neutralizing versions of 
two anti-MPER antigen-binding fragments (Fab), the anti-HIV 4E10 and 10E8 
Fab-s.  
 
Fab fragments consist of the region of an antibody that binds the antigen. 
This region is formed by the entire light chain (LC) of the antibody (VL and CL 
domains) paired with the amino-terminal half of the heavy chain (HC; VH and 
CH1 domains) (FIG 12A). Folding of the variable domains (VL and VH) leads to 
paratope formation that is comprised of a set of complementarity determining 
regions (CDR) responsible for the specificity of the Fab. 
S
 
S
 S
 
S
 
S
H
 
S
H
 
S
H
 
S
H
 
S 
S DsbA 
SH 
SH DsbA 
Reduction 
Oxidation 
Oxidation Isomerization 
S 
S DsbC 
SH 
SH DsbC Reduction 
Oxidation 
S S
S S
Outer membrane 
Cytoplasmic membrane 
DsbB DsbD 
Glutaredoxin 
(grxA, grxB, grxC) 
Thioredoxin 
(trxA, trxC) 
Glutathione 
Oxido-reductase 
(gor) 
Thioredoxin 
reductase 
(trxB) 
C
yt
op
la
sm
 
P
er
ip
la
sm
 
 32 
 
FIG 12. Fab (Fragment, antigen binding) expression system. A) Schematic representation 
of the HC and LC that constitute the Fab region of an IgG. Each chain consists of different 
subdomains: VH (variable heavy domain), CH (constant heavy domain), VL (variable light 
domain) and CL (constant light domain). Intermolecular and intramolecular disulfide bonds are 
shown. Pairing of the VH and VL give rise to the paratope of the antibody. B) Map 
representation of the pColaDuet vector employed for the simultaneous expression of two genes 
from a single plasmid. This vector encodes two separate multiple cloning sites (MCS), each 
preceded by its own T7 promoter, lac operator, and ribosome binding site (rbs). Besides, the 
vector contains the low copy ColA replicon and the kanamycin (Kn) resistance gene. 
 
The HC of the Fab was N-terminally fused to a hexahistidine tag followed 
by a Tobacco Etch Virus (TEV) cleavage site to remove the tag during protein 
purification. Both chains were cloned into the low copy number plasmid termed 
pColaDuet (20-40 copies) (FIG 12B). The presence of two multiple cloning sites 
(MCS) in the plasmid each preceded by the same promoter (T7 promoter) 
enables coexpression of both chains at the same rate. This strategy favors the 
correct folding of the Fab leading to the formation of a fully active soluble 
protein. 
 
2.2. X-RAY CRYSTALOGRAPHY 
 
X-ray crystallography is the premier technique to determine the three-
dimensional structure of proteins. This method provides detailed information on 
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the spatial position of atoms within a protein, which is crucial for determining 
protein functionality. 
2.2.1. Protein crystallization principle 
 
Protein crystallization constitutes the first and generally the limiting step 
in the process of determining protein structure. Crystallization occurs when the 
concentration of the protein in a solution is greater than its limit of solubility and 
therefore, the protein starts to precipitate. In order to obtain high-quality 
diffraction data, protein precipitation has to evolve in a controlled manner that 
leads to the formation of ordered crystals with a well-defined internal order 
(Rupp, 2009).  
 
The common strategy to induce protein crystallization is based on the 
addition of the so-called “precipitation agents” such as salts that increase the 
ionic strength of the solution, organic solvents that decrease solvent polarity or 
organic polymers that promote the exclude-volume effect. Moreover, physical 
and chemical properties of the system such as temperature or pH can be 
altered to optimize crystal growth. 
 
The thermodynamic principle that operates in protein crystallization is the 
minimization of the free energy of the system. In a clear solution, the protein 
molecules are fully solvated by the water and therefore, thermodynamically 
stable. However, when the system is brought into a state of limited solubility by 
the addition of different precipitants, these molecules become no longer 
solvated. Consequently, the system becomes thermodynamically unstable and 
undergoes internal changes that lead to the formation of new non-covalent 
bonds between the molecules that ultimately result in the formation of a solid 
phase (supersaturation state). A phase diagram represents the 
physicochemical state of a protein as a function of protein and precipitant 
concentrations. The solubility curve in a phase diagram represents such 
equilibrium between solution and solid states (FIG 13A). The supersaturated 
state can be divided into three separate stages, as schematically illustrated in 
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the phase diagram (FIG 13A). These zones are governed by a kinetic 
phenomenon responsible for the spontaneous formation of small microscopic 
clusters of proteins (nuclei) from which crystals will further grow. Such process 
requires a large supersaturation in order to overcome the activation energy 
barrier. This nucleation range takes place in the “labile zone”. Once the solution 
reaches this zone and the first nuclei are formed, it must enter the “metastable 
zone”. In this zone, the supersaturation level is not high enough to overcome 
the energy barrier required for nucleation. However, it allows nuclei growth so 
that they can evolve towards an ordered solid material. If supersaturation 
occurs too fast, the solution enters the “precipitation zone” where the protein 
aggregates in the form of amorphous precipitates. 
 
Vapor diffusion constitutes the most common method used in protein 
crystallization. This technique is based on water vaporization from a protein 
droplet to a reservoir solution. Generally, a concentrated solution of a highly 
purified protein is mixed with an equal amount of precipitant and placed in a 
tightly closed well that contains a reservoir solution consisting of the 
precipitating agent(s). The concentration of the precipitants in the reservoir is 
higher than in the protein droplet, and consequently, the system will tend to 
reach equilibrium between both solutions. At the beginning, the system is 
undersaturated, but during equilibration, water molecules will be transferred 
from the protein droplet to the reservoir. As a consequence, the concentration 
of the protein and precipitant in the droplet will steadily increase during the 
equilibration, reaching the supersaturated zone spontaneously. There are two 
variants of the vapor diffusion technique that essentially differ in the 
experimental set-up and geometry of the protein droplet relative to the reservoir. 
In the sitting drop method, the protein is placed horizontally to the reservoir, 
whereas in the hanging drop method the protein is located above the reservoir 
in a vertical position (FIG 13B).  
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Unfortunately, conditions that promote protein crystallization are not 
predictable and therefore, the process to obtain a new crystal always requires 
the screening of numerous crystallization solutions.  
 
  
FIG 13 Protein crystallization. A) Phase diagram illustrating the solubility of a protein as a 
function of the concentration of protein and precipitant. The red dot represents the initial state 
of a mixture of protein and precipitant. As a result of the diffusion of water molecules from the 
less concentrated solution (protein droplet) to the more concentrated solution (reservoir), the 
concentration in the protein drop increases and the solution enters the labile zone where nuclei 
are formed. Nucleation reduces the amount of protein remaining in the solution and 
consequently the solution enters the metastable zone were the formed nuclei steadily start to 
grow resulting in ordered crystals. B) Schematic representation of the two most popular vapor 
diffusion techniques. The arrows indicate the movement of water molecules in the vapor phase. 
 
2.2.2. Crystal diffraction 
 
X-rays are electromagnetic waves that have a wavelength in the order of 
the size of an atom (≈1 Å) suitable to obtain structural information at the atomic 
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level. When a beam of X-rays hits an atom, it sets the electrons into oscillation 
generating new waves of the same energy as the incident one (Thomson 
scattering) (FIG 14B). The three dimensional organization of proteins within a 
crystal can be described by the crystal lattice (FIG 14A). This arrangement 
places the molecules in atomic planes that enable the interaction of scattered 
waves when a beam of X-rays hits these ordered structures. The physical 
phenomenon of positive interaction between waves is called constructive 
interference. Consequently, the resulting wave presents a greater magnitude 
and due to this amplification, its intensity can be recorded in a detector device 
(FIG 14B).  In order to record information of all the existing atomic planes, the 
crystal is repeatedly rotated and exposed to the X-rays beam. 
 
 
FIG 14 Crystal diffraction. A) Schematic representation of the molecular arrangement inside a 
crystal (crystal lattice). The planes depicted in red and blue represent two of the multiple atomic 
planes that coexist inside a crystal. The orange box illustrates a cell unit that constitutes a 
repeating element that by simple translation can generate the entire crystal. B) X-ray diffraction. 
The internal organization of the crystal scatters the X-rays in a way that the waves that meet 
Bragg’s law interact with each other (constructive interference). This effect occurs when the 
difference in the distance travelled between two waves (2a) equals the distance between two 
atomic planes (d). This effect is translated into a diffraction spot on the detector. The sum of the 
diffraction spots of numerous planes constitutes the diffraction pattern. The symbol λ 
corresponds to the wavelength of the incident X-rays, n to an integral number, and Θ to the 
angle of incidence of the X-rays beam. 
 
The entire set of scattered waves that reach the detector defines the 
diffraction pattern of a protein crystal. The diffraction pattern is formed by 
discrete spots, since diffraction will only occur if the waves are in phase when 
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they emerge from the crystal. This event only occurs when i) the distance 
between the atomic planes (d-spacing) and ii) the angle of the incident ray meet 
Bragg’s law (FIG 14B). Hence, the diffraction pattern depends on the geometry 
of the crystal lattice and therefore represents the protein’s fingerprint. The 
mathematical method used to derive a protein structure from the diffraction 
pattern is called Fourier transform. This function uses the phase, position and 
intensity of each spot from the diffraction pattern to calculate a electron density 
map of a cell unit (repeating unit that by simple translation, can generate the 
entire crystal) to further determine the three dimensional arrangement of the 
atoms in a protein. 
 
In the present work protein crystallography has been used to determine 
the atomic structure of different neutralizing and non-neutralizing versions of 
two anti MPER Fab-s termed 4E10 and 10E8. 
 
2.3. CALORIMETRIC TECHNIQUES  
 
Structural studies constitute a key tool for the elucidation of the functional 
groups on interacting molecules. Hence, this technique has extended our 
knowledge of the interacting surfaces between proteins. However, in order to 
fully understand the energetic forces that drive complex formation, this 
structural information should be combined with the thermodynamic and kinetic 
information of the underlying processes. Differential Scanning Calorimetry 
(DSC) (Doyle, 2004) and Isothermal Titration Calorimetry (ITC) (Damian, 2013; 
Doyle, 2004) are among the most frequently employed techniques to elucidate 
thermodynamic information of biological systems. DSC is used for determining 
the order-disorder transitions (protein folding/unfolding) of proteins, whereas 
ITC is employed for the characterization of protein-protein interactions. 
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2.3.1. Principles of Isothermal Titration Calorimetry 
 
ITC is a biophysical technique employed to measure the thermal energy 
(enthalpy) associated with bimolecular complex formation. The stepwise 
addition of one of the reactants in a solution containing the other reactant, 
results in a titration curve from which the binding affinity (Ka), stoichiometry (n), 
and enthalpy change (ΔH) can be simultaneously determined from a single 
experiment. Consequently, the free energy change (ΔG) and the entropy 
change (ΔS) associated with the reaction can be calculated.  
 
Interaction of a protein with its ligand involves disruption and formation of 
non-covalent bonds. This process is associated with an overall heat change 
termed enthalpy. Generally, protein-protein interactions are enthalpy driven and 
therefore they generate exothermic reactions (ΔH < 0). ITC uses the power 
compensation method for the detection of the enthalpy change upon ligand 
binding. The calorimeter assembly consists of a reference cell filled with buffer, 
a sample cell where the protein is placed and a syringe device that holds the 
ligand (FIG 15A). Both compartments (reference cell and sample cell) are 
continuously and slowly heated by injecting a small and known amount of 
energy, necessary to keep both cells at a constant temperature. Injection of the 
ligand to the sample cell will shift the temperature of that chamber. In the case 
of a positive increment of temperature, the reaction is termed exothermic. In 
exothermic reactions, a greater amount of power has to be supplied by the 
instrument to the reference cell in order to bring the calorimeter back to its 
steady state. It can be demonstrated that, the applied power administered by 
the instrument to equalize the temperature between both compartments is 
directly proportional to the enthalpy of the binding reaction (ΔH).  
 
Elucidation of the binding affinity (Ka) requires the stepwise injection of 
the ligand in order to generate a titration curve. In the first injection, most, if not 
all, the ligand will react with the protein in the cell generating a peak of 
maximum magnitude. As the course of the experiment progresses, the amount 
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of unbound (free) protein will progressively decrease and consequently, the 
fraction of ligand injected in the cell that reacts with the protein will also 
decrease except when very high-affinity complexes are formed. Therefore, the 
magnitude of the peaks will become smaller until the cell is mostly devoid of 
free protein (FIG 15B). At this point, saturation is achieved and the small peaks 
recorded correspond to dilution heat from the injection of the ligand into the 
sample cell. The heat released/absorbed in each ligand injection is proportional 
to the area under each peak. Experimental heat can be normalized per mol of 
injectant and plotted vs the molar ratio [L] / [P] generating a curve called binding 
isotherm (FIG 15C). A fitting procedure is then employed to determine several 
thermodynamic parameters of the reaction: 
 
• Stoichiometry (n); determines the number of binding sites of the titrated 
protein. 
 
• Binding constant (Ka); the slope of the straight portion of the sigmoidal 
function that defines the isotherm corresponds to the affinity constant of 
the binding reaction.  
 
• Enthalphy change (ΔH); this parameter can be determined by 
subtraction of the heat generated by ligand dilution and buffer mismatch 
(upper plateau) to the maximum amplitude of the sigmoid (lower 
plateau). 
 
Besides, based on the experimentally determined Ka, the Gibb’s free 
energy change (ΔG) can be calculated from Eq (1) and the entropy change of 
the system (ΔS) from Eq (2).  
 
 ΔG! = −RTln!!  (1) 
   
 ΔG! = ΔH! − TΔS! (2) 
where R corresponds to the gas constant and T to the temperature in Kelvin. 
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FIG 15 Schematic overview of an ITC experiment. (A) Configuration of an ITC reactor where 
the reference cell, the sample cell and the syringe are shown (B) Raw ITC data showing a 
series of consecutive exothermic peaks. After each injection, the total heat released due to 
protein-ligand interaction is recorded. Excess amount of protein in the cell (in the first half of the 
experiment) gives rise to peaks with the greatest magnitude. In an average experiment, the 
successive addition of ligand causes protein saturation and, consequently, a reduction of the 
size of the peak until only the heat corresponding to dilution is detected. C) The integration of 
the exothermic peaks give rise to a classical sigmoidal binding isotherm. The solid line 
corresponds to the fitting of a one-site-model to the experimental data yielding three key 
thermodynamic parameters; binding constant (Ka), stoichiometry (n) and enthalpy change 
(ΔH). 
 
Contribution of the enthalpic and entropic components to the overall 
affinity of a reaction (binding signature) can provide insight into the interaction 
mechanism. A favorable binding enthalpy (ΔH < 0) is often associated with 
formation of hydrogen bonds and van der Waals interactions whereas reactions 
driven by a favorable entropy change (ΔS > 0) indicate conformational changes 
that involve the release of water molecules from a binding interface 
(hydrophobic effect) (Holdgate and Ward, 2005). 
 
2.3.2. Principles of Differential Scanning Calorimetry 
 
In differential scanning calorimetry (DSC) the heat induced during the 
phase transition of a sample is continuously monitored as a function of the 
temperature. Similarly to ITC, the DSC instrument is equipped with a reference 
and a sample cell but unlike in ITC, the temperature of both compartments is 
increased vigorously at a constant rate. In general, high temperature induces a 
conformational change in the protein that ultimately causes its denaturalization 
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in the sample cell. This thermal transition consumes additional energy from the 
electrical supply that is continuously feeding the chamber. Compensation of 
such temperature drop is recorded, normalized and plotted against the 
temperature. Integration of the experimental heat curve yields the calorimetric 
transition enthalpy (ΔH) of the system (FIG 16B). 
 
 
FIG 16 Schematic overview of a DSC experiment. A) Configuration of a DSC reactor where 
the reference cell and the sample cell are shown (B) Heat flux curve as a function of 
temperature (black) and fitting of the experimental data to a two-state thermal transition model 
(red). The thermodynamic parameters Tm (melting temperature) and ΔH (transition enthalpy) 
can be determined from the temperature at which the maximum heat is recorded and from the 
integration of the area under the peak, respectively. 
 
In the present work ITC and DSC have been employed to determine the 
binding thermodynamics and thermal stability, respectively, of different 
neutralizing and non-neutralizing versions of 4E10 and 10E8 Fab-s to MPER 
peptides with different lengths.  
 
2.4. SURFACE PLASMON RESONANCE  
 
Optical methods based on the Surface plasmon resonance (SPR) 
technology (Homola, 2003) are increasingly employed to characterize the 
binding kinetics of ligands to macromolecules in real time. 
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Plasmons consist of waves produced by the resonance of free electron 
clouds on a conductor surface (FIG 17A) (Daghestani and Day, 2010). When a 
light beam hits the surface of a metallic element, part of that light is used to 
induce the electron resonance effect, causing a reduction in the intensity of the 
reflected light. Gold constitutes the preferred metal to induce the formation of 
surface plasma waves due to its high chemical stability and mass extinction 
coefficient (σext) resulting from its large atomic number. The latest determines 
the amount of light absorbed and scattered by the metal particle. Hence, metals 
with large values of σext such as gold generate higher contrasts in the signal 
detected (greater changes between the intensity of the incident and the 
detected light). The maximum fall of intensity is recorded at a specific 
combination of the incident light angle θ (known as the resonance angle) and 
wavelength λ (FIG 17A). The electron resonance is very sensitive to the 
surrounding environment and therefore, small changes on the surface affecting 
its physical properties will result in a change in the angle at which the minimum 
intensity is recorded.  
 
In a SPR experiment a sensor chip made of a thin film of gold supported 
on a glass surface is employed. The chip is then prepared by immobilization of 
one of the molecules involved in the interaction. As noted above, when light hits 
the functionalized gold film, surface plasmons will be generated at critical 
angles (FIG 17B). In order to monitor the interaction with the immobilized 
molecule, the analyte is continuously flowed in an aqueous solution through the 
chip surface (Besenicar et al., 2006; Patching, 2014; Salamon et al., 1997). As 
the binding event takes place, molecule absorption changes the environment of 
the chip surface and consequently, the angle, at which the minimum of the 
intensity of the emerged light its recorded, changes (FIG 17B). The shift of the 
resonance angle is proportional to the mass of the material bound. Hence, 
binding will be recorded as response units (RU). Because the amount of free 
binding sites available at the beginning is very high, a large biomass of 
molecules will bind to the chip. This event will be registered as a rapid increase 
of the RUs. The ligand is continuously delivered until the binding equilibrium is 
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reached and a maximum RU value is obtained. When the solution that passes 
through the chip is devoid of the analyte, the bound molecules start to 
dissociate and consequently, a decrease of the RUs is recorded. The curve 
resulting from plotting RU values against time is called a sensogram and can be 
used to extract key kinetic and thermodynamic parameters of the binding 
reaction.  
 
 
FIG 17. The principle behind SPR and its use in detecting biochemical interactions is 
illustrated. A) At a certain incident angle, known as the resonance angle, the light hits the 
electron cloud of a thin film of gold causing the plasmon resonance effect. The resulting wave 
is called plasmon and its generation constitutes the key principle of the SPR technology. B) 
SPR detection scheme. The analyte solution is flowed through a sensor chip previously coated 
with the biomolecule of interest. The binding of analyte molecules to the immobilized molecule 
changes the angle at which the reflexive intensity is at its minimum [(i) → (ii)]. The change of 
angle can be monitored as response units (RU), which is proportional to the amount of mass 
absorbed in the sensor chip. The resulting curve is called sensorgram and the repeated 
addition of analytes at different concentrations and at different temperatures renders key kinetic 
and thermodynamic parameters of the reaction.  
 
2.4.1. Calculation of the kinetic and thermodynamic parameters  
 
A SPR sensorgram gives essential information about the kinetics of the 
interaction. The two key kinetic parameters association rate constant (kon) and 
dissociation rate constant (koff), are extracted from the behaviour of the binding 
and unbinding process, respectively. The rate between both constants yields 
the binding affinity of the system (KD) Eq (3). 
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 !! = !!"" !!" (3) 
Determination of these parameters gives information of the system in the 
equilibrium (the state of minimum energy or ground state). In order to gain 
insight into the molecular mechanism that drives the interaction process, 
thermodynamic information of the ground and transition states is also required.  
 
The transition state is considered a high energy state formed in the 
reaction pathway from reactants to products that, when overcome, equilibrium 
can be subsequently reached. This structure contains partial bonds and 
therefore it is characterized by a very short lifetime. The thermodynamic 
signature of the transition and ground states can be obtained from linear fits of 
experimental binding (KD) and rate (kon or koff) constants measured at several 
temperatures employing the van’t Hoff and Eyring plots, respectively. 
 
The thermodynamic information relating to the ground state can be 
extracted from the fitting to the logarithm of KD values vs the inverse of the 
temperature at which such constants have been measured. This straight line is 
defined by van’t Hoff’s equation (4) and the slope and the intercept on the Y-
axis determine ΔH0 and ΔS0, respectively (FIG 18). Similarly, representation of 
the logarithm of either kon or koff divided by the temperature at which each 
measurement has been performed against the inverse of temperature, results in 
a plot that can be fitted to the Eyring’s equation                          (5). The slope 
and Y-axis intercept of the resulting straight line corresponds to the transition 
state`s parameters; ∆!!∓and ∆!!∓, respectively (FIG 18).   
 
 !"!! = Δ!! !" − (ΔS! !) (4) 
 
 ! = !!! ℏ !"#(−Δ!!∓ !")                          (5) 
 
where R corresponds to the gas constant, T to the temperature in Kelvin, KB to 
Boltzmann constant and ℏ to Planck’s constant. 
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Following Eq (2), the Gibb’s free energy value associated with each state 
can be determined. ∆!!∓  corresponds to the energy barrier known as the  
activation free energy and consists of the minimum energy needed by the 
reaction to reach equilibrium.  
 
 
FIG 18. Free energy profile of a reaction. The energy barrier is depicted as ∆!!∓ . 
Thermodynamic signature of the ground and transition state can be extracted from the Van’t 
Hoff and Eyring equations, respectively (see text above). 
 
In the present work SPR was employed to shed light on the binding 
mechanism of the 4E10 Fab to a MPER peptide. For that, a comparative study 
of i) the binding kinetics and ii) the thermodynamic binding parameters of MPER 
binding at the transition state by a neutralizing and by two non-neutralizing 
versions of the antibody was performed.  
 
2.5. FLUORESCENCE SPECTROSCOPY  
2.5.1. Basis of fluorescence spectroscopy  
 
The electrons within an atom are localized in orbitals that describe the 
region of probability where they can be found. Formation of covalent bonds 
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within a molecule implies overlapping of such atomic orbitals leading to the 
formation of molecular orbitals that predict the location of the electrons shared 
by the atoms. The number of orbitals must be conserved and therefore when 
two atomic orbitals are combined, two molecular orbitals with different energy 
will be formed (FIG 19A). The different energy levels of these molecular orbitals 
define the electronic transitions allowed in a molecule. The electrons in a 
covalent bond will occupy the lower energy level called ground state (S0) 
leaving the remaining high energy level called exited state (S1) empty for further 
occupation if the molecule is exited by an external light source. Hence, if the 
molecule is exposed to light with an energy that matches the energy difference 
between two transition states, the energy will be absorbed and the electron 
from the highest occupied molecular orbital (HOMO) will jump to the lowest 
unoccupied molecular orbital (LUMO). 
 
 
FIG 19. Schematic representation of an electronic transition resulting in fluorescence 
emission. A) π-bond representation due to overlapping of two p-molecular orbitals. The 
electrons occupy the orbital of lower energy (bonding orbital) leaving the molecule with higher 
energy (anti-bonding orbital) empty for further occupation upon molecule excitation B) Energy 
diagram showing the events that take place when the frequency of the photon that hits a 
molecule matches the energy difference between two electronic states. (i) The photon is 
absorbed (blue arrow) and the molecule is excited (its electrons will jump to a higher energy 
level). Then, (ii) it losses part of the energy by thermal relaxation (curved black line) and the 
remaining energy is emitted (red arrow) when the molecule goes back to the ground state. In a 
polar environment, the dipole moment of the fluorophore rearranges the orientation of the 
solvent molecules resulting in the stabilization of the exited state. Consequently, the photon 
emitted contains lower energy (iii) and therefore, longer wavelength (green arrow), than the 
incident photon. 
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Once the absorption takes place, the exited electron will tend to return to 
the ground state releasing energy. If the energy is lost in a radiative form 
(photon emission), the fluorescence phenomenon occurs. The space in 
between each electronic transition is filled with discrete (quantized) energy 
levels corresponding to the vibrational motion of the molecule. When energy is 
applied to the system, the electron can be excited from any of the vibrational 
levels of S0 to any of the vibrational energy levels of S1. The energy difference 
between those levels is very small leading to a rapid thermal relaxation (10-13 
sec) of the molecule due to collisions with the solvent. As a consequence, the 
electron reaches the lowest vibrational level of S1 from where photon emission 
will occur (fluorescence emission) (FIG 19B). The loss of vibrational energy in 
the form of heat will result in the emission of a photon with longer wavelength 
than the photon absorbed. This shift towards longer wavelengths is called 
Stokes shift (Lakowicz, 2006). 
 
2.5.2. Fluorophores and its use in tracking protein-lipid interactions 
 
In order to use fluorescence spectroscopy for biological applications, 
non-destructive wavelengths (preferably within the visible region of the 
electromagnetic spectrum) that induce electron transitions are required. σ-
bonds constitute strong bonds due to the high overlap of the atomic orbitals that 
result from the covalent bond formation between two s-type orbitals. 
Consequently, the negatively charged electron density is placed in close 
proximity to the positively charged nucleus implying that the excitation of an 
electron within that bond will require photons of high energy. On the contrary, 
the electron density in a p-type orbital is farther away from the nucleus due to 
its parallel orientation (FIG 19A). Hence, orbital overlapping occurs at a lower 
extent and the resulting π-bond is weaker. Electrons within π-bonds are 
therefore delocalized and its excitation can be accomplished with photons of 
lower energy. Further electron delocalization can be obtained by double bond 
conjugation that consists on double bonds (formed by the combination of π and 
σ–bonds) separated by a single bond. The energy of the π → π* transition 
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decreases as the number of conjugated double bond increases and, therefore, 
fluorophores with high absorption in the visible part of the spectrum generally 
present several conjugated double bonds. 
 
Proteins contain aromatic residues with conjugated double bonds 
responsible for the intrinsic fluorescence of the protein. Tryptophan (Trp) is the 
strongest contributor since it has the highest quantum yield (ratio between 
photons emitted and photons absorbed). Trp fluorescence is sensitive to the 
local environment due to interactions with the surrounding media during the 
excited state lifetime. In a polar environment, excitation of π-electrons to a 
higher energy level produces a magnification of the dipole moment of the Trp 
compared to that in the ground state. As a consequence, polar solvent 
molecules interact more tightly with the Trp, lowering the energy of the excited 
state. This stabilization results in a lower separation between the ground and 
excited states, which in turns results in a red shift (towards longer wavelengths) 
of the fluorescence emission (FIG 19B). Hence, Trp can be used as a probe to 
monitor the change between a hydrophilic and a hydrophobic environment. It 
constitutes a powerful tool for examining the interactions of proteins with lipids 
(Ladokhin et al., 2000) based on the intensity change and the displacement of 
the emission spectra of Trp. 
 
This phenomenon is also found in fluorophores and therefore, other 
molecules can be used with the same purpose. The natural abundance of this 
aromatic residue in a protein (generally two or more Trp residues per protein) 
limits its practical use since interpretation of the overall fluoresce change 
becomes challenging. Hence, a molecule of 7-nitro-1,2,3-benzoxadiazole (NBD) 
can be introduced in a protein by site-directed mutagenesis and chemical 
modification and used as a reporter of the environment surrounding a selected 
region of the protein under study. In this work, the fluorescence of NBD has 
been employed to monitor the polar environment of the CDR-H3 of the 
antibodies 4E10 and 10E8, in particular during their interaction with lipids.  
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To shed light on the interactions between lipids and proteins a lipid 
membrane model called liposomes is normally used. A liposome consists of a 
lipid structure in a bilayer configuration enclosing an aqueous solution. 
Liposomes of several bilayers (Multilamellar Vesicles, MLV) are spontaneously 
generated when diluting cylindrical-shaped amphipathic lipid molecules in 
aqueous solutions. After cycles of i) freezing and thawing and ii) extrusion 
through membranes with fixed-size nanopores, MLV become vesicles of a 
certain size that ranges from 100 to 500 nm and with only one bilayer (Large 
unilamellar vesicles, LUV). Due to this diameter, the local curvature on the 
bilayer is almost zero, with 49 % of the lipids localized in the inner monolayer 
and 51 % in the outer monolayer (Mayer et al., 1986) almost resembling the 
non-existent curvature of the plasma membrane. 
 
2.6. CELL INFECTIVITY AND VIRAL NEUTRALIZATION 
 
The HIV-1 envelope protein induces in some instances an antibody 
response able to inhibit virus infection. In the present work, the molecular 
mechanism underlying the activity of two of these HIV-1 neutralizing antibodies 
has been studied. Aiming to identify the elements of the antibody involved in 
virus neutralization, different antibody mutants have been generated. The ability 
to block virus infectivity of these antibody variants was tested in standard 
neutralization assays reviewed in (Montefiori, 2009) or in our in-house cell entry 
inhibition assays (FIG 20, see below). In both experiments, the degree of 
infection was monitored after incubation of pseudovirus with antibodies. 
 
Production of molecularly cloned Env-pseudotyped viruses was carried 
out in 293T cells. 293T cells are derived from human embryonic kidney 293 
cells that express the SV40 Large T-antigen, which allows episomal replication 
of transfected plasmids containing the SV40 origin of replication. To produce 
pseudovirus, these cells are co-transfected with an Env-expressing plasmid 
(pIII-Env or JRCSF) plus an env-deficient HIV-1 genome backbone plasmid 
(pCMV8.91) and a plasmid encoding the reporter green fluorescent protein 
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(GFP) (pWPXL-GFP). LTR and Ψ sequences are only present in this latter 
plasmid. Consequently, generated pseudovirus particles packing the GFP-
encoding gene are able to infect cells but unable to produce infectious progeny 
virions. Upon infection, GFP expression allows detection of a single round of 
viral infection. As a host cells line TZM-bl cells are employed which are based 
on a HeLa cell line derived from the cell line JC.53. TZM-bls cells have been 
genetically modified for the stable expression of the viral receptor/coreceptor 
(CD4/CCR5). Infectivity of the pseudotyped viruses and therefore, neutralization 
efficiency of the antibodies, was determined from the reduction in the number of 
GFP-positive cells (infected cells) in samples incubated with increasing 
amounts of antibody as compared to a control sample without antibody. The 
quantitative measurement of GFP-expressing cells was accomplished by using 
flow cytometry. The IC50 value, at which 50 % inhibition is obtained, was used to 
compare antibody potency. This value was derived from plots of inhibitor 
concentration versus percentage inhibition. 
 
 
FIG 20. GFP fluorescence-based cell entry inhibition assay. Env-pseudotyped viruses were 
produced by co-transfection with an Env-deficient HIV-1 genome plasmid, an Env-expressing 
plasmid and a plasmid encoding the reporter fluorescence protein GFP. Pseudovirus infection 
was monitored by the amount of GFP expressing TZM cells (cells in green). Antibody-
pseudovirus binding hampers cell infection. The rate between infected (green) and non-infected 
cells in the presence of a Fab variant was measured by flow cytometry and determines the 
neutralization activity of the antibody. The virus particle was taken from (Freed, 2015). 
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3.1. INTRODUCTION 
 
The aromatic-rich MPER peptide connects the ectodomain of the HIV-1 
gp41 with the TMD anchor (FIG 21A). The remarkable high hydrophobicity-at-
interface of MPER predicts its stable association with the external leaflet of the 
viral membrane (Huarte et al., 2008; Saez-Cirion et al., 2003; Suarez et al., 
2000). This implies that orientation and accessibility of this vulnerable Env site 
may mainly depend on interactions of MPER residues with the membrane 
interface, in addition to motional restrictions imposed by the TMD anchor 
(Montero et al., 2012). In the current model, the MPER helix is predicted to 
associate with the membrane interface with its axis approximately parallel to the 
plane of the membrane up to residue Lys683, where the peptide would bend by 
90º to allow insertion of the TMD in a perpendicular orientation. However, 
experimental data supporting a kink at the MPER-TMD connection have not 
been reported (FIG 21B). 
 
Recent NMR characterization of the gp41 MPER-TMD region by using 
three overlapping synthetic peptides (Apellaniz et al., 2015), confirmed the 
adoption of main α-helical conformations by MPER and TMD in a membrane 
environment, but ruled out the existence of the kink at position Lys-683 
predicted to mark the initiation of the TMD (FIG 21B). The data also revealed 
that the MPER-TMD connection, spanning residues 671NWFDITNWLWYIK683-
684LFIMIVGGLV693, embodies a continuous helix (MPER-N-TMD helix) delimited 
by two hinge segments (underlined) (FIG 21B). To evaluate the contribution of 
the MPER-N-TMD helix (ITNWLWYIK) to binding energy, we have produced 
4E10 Fab in bacteria (Fab4E10r), and then performed binding experiments by 
ITC in which we compared the MPER(671-693) peptide with the canonical MPER-
representing MPER(656-683) peptide. The data indicated higher affinity of the 
MPER(671-693) peptide for Fab410r, which also comprised a neutralization-
relevant ligand when incorporated into liposome-based vaccines. Together, 
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these results suggest that preserving an intact MPER-N-TMD helix is required 
for a vaccine to effectively elicit anti-MPER antibodies. 
 
 
FIG 21. Organization of the HIV-1 gp41 MPER-TMD region. A) Diagram underlining the most 
important structural constituents of the membrane-anchored gp41 ectodomain. The same color 
code has been used to depict the gp41 ectodomain pre-fusion structure below (PDB code 
4TVP). B) Membrane topology predicted for the MPER-TMD region attending to its 
hydrophobicity distribution (left) and to the recent NMR characterization of the MPER-TMD 
region (Apellaniz et al., 2015) (right). 
 
3.2. MATERIALS AND METHODS 
 
3.2.1. Materials 
 
The peptides used in the structural and affinity studies were synthesized 
in C-terminal carboxamide form by solid-phase methods using Fmoc chemistry, 
purified by reverse phase high pressure liquid chromatography (HPLC), and 
characterized by matrix-assisted time-of-flight (MALDI-TOF) mass spectrometry 
4E10 4E10 K683 G690 
A 
B 
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(purity > 95 %). Peptides were routinely dissolved in dimethylsulfoxide (DMSO, 
spectroscopy grade) and their concentration determined by the bicinchoninic 
acid microassay (BCA) (Pierce, Rockford, IL, USA) or using absorbance at 
280nm. Goat anti-human IgG-Fab antibody was purchased from Sigma (St. 
Louis, MO). Secondary antibodies conjugated to horseradish peroxidase (HRP), 
goat (anti-human kappa light-chain)-HRP, goat (anti-human IgG)-HRP, and goat 
(anti-murine IgG)-HRP, were purchased from Life Technologies (Carlsbad, CA).  
 
3.2.2. Expression and purification of 4E10 Fab.  
 
4E10 Fab-s were cloned in pColaDuet and produced in E. coli T7-shuffle 
strain (see section 2.1). Protein expression was induced with 0.4 mM isopropyl-
D-thiogalactopyranoside (IPTG) when the culture reached an optical density 
(OD) of 0.8. Cells were harvested at 8,000 × g after over-night (o/n) expression 
at 18 ºC. Cells were resuspended in a buffer containing 50 mM HEPES pH 7.5, 
500 mM NaCl, 35 mM imidazole, DNase (Sigma-Aldrich) and an EDTA-free 
protease inhibitor mixture (Roche, Madrid Spain). Cell lysis was performed 
using an Avestin Emulsiflex C5 homogenizer. Cell debris were removed by 
centrifugation, and the supernatant from each culture was purified following 
various chromatography principles. First, Fab-s were purified using a nickel-
nitrilotriacetic acid (Ni-NTA) resin (GE Healthcare). Elution was performed with 
500 mM imidazole, and the fractions containing the his-tagged proteins were 
pooled, concentrated and dialyzed against 50mM sodium phosphate pH 8.0, 
300mM NaCl, 1mM DTT, 0.3mM EDTA in the presence of the protease TEV. 
His tag-free Fab-s were then further purified thought an additional Ni-NTA 
column step. The flow through was dialyzed o/n at 4 ºC against sodium acetate 
pH 5.6 10 % glycerol and loaded into a MonoS ion exchange chromatography 
(IEC) column (GE Healthcare). Elution was carried out with a potassium 
chloride gradient and the fractions containing the purified Fab concentrated and 
dialyzed against a buffer containing 10 mM sodium phosphate, pH 7.5 120 mM 
NaCl and 10 % glycerol. 
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3.2.3. Isothermal titration calorimetry  
 
Calorimetric titration experiments were performed with a VP-ITC 
microcalorimeter instrument (MicroCal, Northampton, MA) at 25 oC. Prior to the 
experiment, proteins were dialyzed o/n at 4 ºC against 10 mM sodium 
phosphate, 150 mM NaCl and 10 % glycerol at pH 7.5, and degassed just 
before the measurement. The buffer was supplemented with 5 mM dodecyl-
phosphocholine (DPC). Fab4E10r (3 µM) was titrated with 40 µM of peptide 
(dissolved in dialysis buffer supplemented with 5mM DPC). The volume of each 
injection was 10 µL. Peptide dilution heat was subtracted from the experimental 
and final data. The binding isotherms were fitted to a one-site binding model 
using the program ORIGIN 7.0. The fitting yields the stoichiometry (n), the 
binding constant (KD) and the enthalpy (ΔH°) of the binding reaction. 
 
3.2.4. Membrane binding assays 
 
Vesicle flotation experiments in sucrose gradients were performed 
following a method described earlier (Yethon et al., 2003). In brief, 100 µl of a 
sample containing rhodamine (Rho)-labeled liposomes (1.5 mM lipid 
concentration) was adjusted to a sucrose concentration of 1.4 M in a final 
volume of 300 µl, and subsequently overlaid with 400 and 300 µl-layers of 0.8 
and 0.5 M sucrose, respectively. The gradient was centrifuged at 436,000 × g 
for 3 h in a TLA 120.2 rotor (Beckman Coulter, Brea CA, USA). After 
centrifugation, four 250 µl-fractions were collected. Material adhered to tubes 
was collected into a 5th fraction by washing the tubes with 250 µl of hot (100º C) 
1 % (w/v) Sodium dodecyl sulfate (SDS) after the other fractions had been 
taken from the tube. 
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3.2.5. Crystallization of 4E10 Fab-peptide complex 
 
Co-crystals of Fab 4E10 in complex with the peptide MPER(671-683) were 
prepared by the hanging drop method. The Fab-peptide complex in the 
presence of detergent dihexanoyl-phosphocholine (DHPC) at 3 mM was 
concentrated to 2.5 mg/ml and mixed with a reservoir solution composed of 
200 mM  sodium acetate, 30 % PEG 8,000, and 100 mM  sodium cacodylate 
(pH 6.5). Suitable crystals grew to full size within a few days at 20 °C, after 
which they were transferred to mother liquor supplemented with 20 % glycerol, 
and subsequently frozen and stored in a vessel containing liquid N2 . 
 
3.2.6. Data collection and structure refinement 
 
Diffraction data from a single crystal was collected on beamline BL5A of 
the Photon Factory (Tsukuba, Japan) under cryogenic conditions (100 K). 
Diffraction images were processed with the program MOSFLM and merged and 
scaled with the program SCALA of the CCP4 suite (Evans, 2006). The three-
dimensional structure was determined by molecular replacement using the 
coordinates of 4E10 (PDB entry 2FX7) with the program PHASER (McCoy et 
al., 2007). The initial model was further refined with the programs REFMAC5 
(Murshudov et al., 1997) and COOT (Emsley et al., 2010). Validation was 
carried out with PROCHECK (Laskowski et al., 1993). Data collection and 
refinement statistics are given in Table 2. 
 
3.3. RESULTS 
 
3.3.1. Energetics of 4E10 binding to MPER(656-683) and MPER(671-693) 
and structural model 
 
Conservation of a continuous helical connection between MPER and 
TMD is likely to affect antibody binding to this region. Supporting this idea, it 
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has been demonstrated that the gp41 TMD plays a pivotal role in orienting the 
epitope recognized by the 4E10 antibody (Montero et al., 2012). Therefore, we 
selected the 4E10 antibody and the peptides MPER(656-683) (truncated at Lys-
683) and MPER(671-693) (containing the full MPER-N-TMD helix) to determine the 
importance of this element on the energetics of antibody binding.   
 
ITC experiments were carried out using the 4E10 Fab expressed in 
bacteria. To validate this recombinant Fab4E10r, it was crystallized in complex 
with the peptide NWFDITNWLWYIK-KKK (MPER(671-683)) (FIG 22 and Table 2). 
The crystal structure of the recombinant 4E10 Fab-peptide complex solved at 
2.10 Å was essentially indistinguishable from that of the Fab obtained by papain 
digestion of the recombinant IgG (rmsd = 0.20 Å) (Cardoso et al., 2007). The 
ITC experiments were conducted in the presence of the detergent DPC to 
mimic the composition of the buffer employed in the NMR experiments. The 
fitting of the binding isotherm to a one-site binding model yielded three key 
thermodynamic parameters in a single experiment (binding constant, KD, 
change of enthalpy, ΔH°, and stoichiometry of the reaction, n) (FIG 23A).  
 
The titration experiments demonstrated that both peptides engage with 
the Fab with high affinity (nM range) driven by favorable non-covalent 
interactions (ΔH° < 0).  Notably, the Fab4E10r exhibited 6-fold higher affinity for 
MPER(671-693) than for MPER(656-683). Comparison of the thermodynamic 
parameters for the binding equilibria revealed significant differences in the 
relative contribution of the entropy (-TΔSº) and enthalpy (ΔHº) terms for the 
binding of each peptide to the Fab. Specifically, the entropy loss of the peptide 
MPER(671-693) upon binding to the antibody (–TΔSº = 1.8 kcal mol-1) is greatly 
reduced in comparison with that of the short version MPER(656-683) (–TΔSº = 9.8 
kcal mol-1). Thus, these observations suggest that MPER(671-693) is a better 
ligand than MPER(656-683) due to an optimization of the hydrophobic surfaces in 
contact with Fab, and/or to lower levels of conformational and roto-translational 
restrictions upon binding. The thermodynamic signature of MPER(671-693) (high 
affinity and pre-organization in a membrane-mimetic environment) could be a 
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desirable property for the design of better vaccines, as previously discussed for 
the case of epitope-scaffolds (Correia et al., 2010). 
Table 2. X-ray data collection and refinement statisticsa 
 4E10 + peptide 
Data collection  
Space group C2 
Cell dimensions    
    a, b, c (Å) 157.3, 44.6, 85.4 
    α, β, γ  (°)  90.0, 113.8, 90.0 
Resolution (Å) 44.7–2.1 (2.21–2.10) 
No. reflections (total) 166,559 (18,803) 
No. reflections (unique) 30,114 (3,540) 
Rmerge (%)b 10.3 (37.1) 
I / σI 14.0 (4.3) 
Completeness (%) 94.2 (76.6) 
Redundancy 5.5 (5.3) 
  
Refinement  
Resolution (Å) 44.7–2.10 
Rwork / Rfree (%)c 16.2 / 20.6 
No. atoms  
    Protein 1,641 
    Peptide 159 
    Other (not solvent)d 12 
    Solvent 309 
B-factors  
    Protein 30.9 
    Peptide 41.8 
    Other (not solvent)d 34.6 
    Solvent 33.4 
Ramachandran plot  
    No. Preferred regions, % 344, 91.2% 
    No. Allowed regions, % 32, 8.5% 
    No. Outliers, % 1, 0.3 % 
R.M.S. deviations  
    Bond lengths (Å) 0.013 
    Bond angles (°) 1.52 
a Values in parentheses are for highest-resolution shell. 
b Rmerge = ΣhklΣi|I(hkl)i − [I(hkl)]| / Σhkl Σi I(hkl). 
c Rwork = Σhkl |F(hkl)o − [F(hkl)c]| / Σhkl F(hkl)o; Rfree was calculated exactly as Rwork, 
where F(hkl)o values were taken from 4 % of data not included in the refinement. 
dData corresponds to two glycerol molecules. 
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FIG 22. X-ray diffraction of recombinant Fab 4E10. A) Comparison of the crystal structures 
of recombinant Fab (this work, 2.10 Å) and Fab obtained upon cleavage of IgG (PDB entry 
2FX7). The overall rmds of the main chain atoms between the two structures is 0.20 Å. The 
orange and light green ribbons depict the heavy and light chain of the recombinant Fab, 
whereas the gray ribbons correspond to the 2FX7 structure (barely discernible due to 
superposition of the ribbons of the recombinant Fab). The peptide bound to the Fab is shown in 
the cartoon representation, where magenta and cyan correspond to recombinant and IgG-
derived Fab-s, respectively. B) Sigma-A weighted electron density of the peptide bound to 
recombinant Fab contoured at 1.0 σ.  The location of the residue Trp100HC at the tip of the 
CDR-H3 of the Fab is indicated. C) Comparison of coordinates of five different peptides 
superposed between residues 674 and 683.  The peptides correspond to recombinant Fab 
(magenta), 2FX7 structure (cyan, rmsd = 0.26 Å), MPER(656-683) (yellow, rmsd = 0.56 Å), 
MPER(671-693) (green rmsd = 0.82), and that of peptide bound to Fab 10E8 (orange, PDB entry 
4G6F, rmsd = 0.32 Å). 
 
To obtain molecular models of the peptides bound to the Fab, the 
constant helical region (residues 674-683) was employed to superpose the 
NMR coordinates of the peptides in DPC with those of the peptide-epitope 
obtained in the crystal structure with Fab (FIG 23B). The structure of MPER(656-
683) in DPC superimposes well with the short peptide epitope in the crystal 
structure, including the orientation of the side chains of the residues buried in 
the paratope (671NWF--T--LW680) (FIG 23B, left). In contrast, the coordinates of 
the MPER(671-693) in DPC show a disorganized hinge segment at its N-terminal 
region (FIG 23B, right). Hence, this superposition suggests that the segment 
671NWF673 must reorient for binding adequately to the antibody. Conversely, the 
other residues (674-683) superpose with those of the Fab-bound peptide with 
remarkable exactitude. 
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FIG 23. Binding to Fab4E10r by ITC and structural comparison. A) Binding isotherms of 
MPER(656-683) and MPER(671-693) to Fab4E10r. The upper panels indicate the heat released upon 
consecutive injections of peptide into Fab4E10r in the calorimeter cell. Lower panels: integrated 
heats (symbols) and non-linear least-squares fit (line) of the data to a one site binding model. 
The thermodynamic parameters of binding for MPER(656-683) were KD = 119 ± 10 nM, ΔHº = 
−19.2 kcal mol-1, −TΔSº = 9.8 kcal mol-1 and stoichiometry n = 0.90. The thermodynamic 
parameters for MPER(671-693) were KD = 18 ± 2 nM, ΔHº = −12.4 kcal mol-1, −TΔSº = 1.8 kcal 
mol-1 and stoichiometry n = 1.4. B) Fitting of MPER(656-683) and MPER(671-693) DPC structures into 
the Fab-bound peptide. Indicated side chains correspond to residues with highest buried 
surface area upon interaction. C) Modeled orientation of MPER(656-683) and MPER(671-693) in the 
recombinant Fab. Fab-bound peptide is depicted as a magenta ribbon. The modeled peptides 
MPER(656-683) and MPER(671-693) are depicted in yellow and green, respectively. The light and 
dark surface corresponds to the HC and LC chains, respectively. 
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The superposition of these two peptides on the Fab (FIG 23C) suggests 
the molecular basis of the higher affinity of a peptide extended at the C-terminal 
but not at the N-terminal end. Elongation of the peptide at the N-terminus 
(MPER(656-683)) must force the peptide to adopt a conformation different from 
that observed in solution to avoid steric clashes with the Fab (FIG 23C, left). On 
the contrary, the additional residues at the C-terminus of MPER(671-693) do not 
clash with the antibody, reducing the conformation penalty upon binding 
compared with MPER(656-683). Moreover, the orientation of the C-terminal 
residues of MPER(671-693) with respect to the long CDR-H3 loop of the antibody 
habilitates the peptide to engage in additional non-covalent interactions with the 
antibody (FIG 23C, right). 
 
3.3.2. Binding to peptide-liposome vaccines 
 
As put forward by the previous antigenicity results, peptide structuring in 
a membrane environment may influence 4E10 antibody binding, and hence, 
modulate interactions with cognate B-cell receptors. It has been argued that 
interactions with the membrane surface may be key for the selection of MPER 
conformations that induce specific antibodies (Alving et al., 2012; Montero et 
al., 2012), while lipid binding by anti-MPER antibodies has been hypothesized 
to increase avidity (Klein et al., 2013b; West et al., 2014). Thus, we formulated 
the MPER(656-683) and MPER(671-693) peptides with truncated or conserved MPER-
N-TMD helix, respectively, as potential liposomal vaccines. Vaccine antigenicity 
was assessed using a strategy similar to that described in a preceding study 
(Serrano et al., 2014). Those experiments based on Fab flotation experiments 
(FIG 24A) included a Fab mutant with the CDR-H3 loop tip ablated as a 
negative control. The Fab4E10r-Δloop mutant binds peptide epitopes in solution 
with comparable affinity but it is not neutralizing (Apellaniz et al., 2014b), which 
allows discriminating functional vs. non-functional binding.  
 
Both, Fab4E10r-WT and Fab4E10r-ΔLoop co-floated with the liposomes 
that contained MPER(656-683) peptide (FIG 24B). Fab4E10r-WT was also 
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recovered from floating fractions that contained liposomes decorated with the 
MPER(671-693) peptide. In contrast, practically all Fab4E10r-Δloop was recovered 
from pellets under these conditions (FIG 24B). Finally, none of the Fab-s co-
floated appreciably with control liposomes devoid of peptide under otherwise 
similar experimental conditions. In conclusion, the neutralizing function and the 
binding to MPER(671-693) inserted into liposomes were both dependent on the 
4E10 CDR-H3 loop, a correlation not observed for the MPER(656-683) peptide. 
The existence of a binding-function correlation in the case of the liposome- 
MPER(671-693) vaccine suggests that this formulation could be relevant to target 
4E10-like B-cell receptors. 
 
 
FIG 24. Correlation between 4E10 antibody function and binding to liposomal vaccines. 
A) Schematic representation of a flotation experiment to assess antibody binding to liposomes 
and liposomes-peptide complexes. Lipid vesicles in the absence or presence of peptide were 
pre-incubated with the antibody fragments and subjected to a sucrose gradient. Upon 
separation of the species based on their different densities, the sample is divided into 4 
different fractions. An additional sample was obtained from the material attached to the surface 
of the tube upon addition of SDS for its removal. The liposomes are located in the upper floated 
(light) fractions 3 and 4 and detected from the fluorescence emission of the fluorescently 
labeled lipid Rho-PE. Fractions 1, 2 and SDS contained the non-floated (dense) material. 
Location of the antibody was detected by western blot (WB). B) Membrane partitioning of 
Fab4E10r-WT or Fab4E10r-ΔLoop to liposomes devoid of peptide and MPER(656-683) or 
MPER(671-693)-containing liposomes.  
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3.4. DISCUSSION 
 
The existence of a continuous MPER-N-TMD helix motif may have 
implications for the definition of the neutralization-competent MPER structure 
(Montero et al., 2012) and, consequently, for the design of surrogates with the 
capacity to generate humoral responses against the MPER C-terminal region 
(Burton et al., 2012). Recreating this structure has been the aim of many 
studies employing representative MPER peptides truncated at position Lys-683 
and liposomes. As previously shown by us and other groups (Alving et al., 
2012; Dennison et al., 2011; Kim et al., 2013; Maeso et al., 2011; Serrano et al., 
2014; Venditto et al., 2013), formulations of this kind are usually poorly 
immunogenic and raise cross-reactive antibodies targeting the MPER N-
terminal region, i.e., directed to sites overlapping 2F5/M66.6 epitope residues. 
However, they seemingly fail to direct responses to the C-terminal epitopes 
recognized by 4E10 and 10E8 antibodies.  
 
Structural data and MDS of MPER(656-683) (Serrano et al., 2014) suggest 
two different causes for this phenomenon. On the one hand, modeling of the 
MPER(656-683) DPC structure into the 4E10 paratope reveals that the N-terminal 
side must reorient to avoid steric clashes. Thus, the presence of a well-defined 
helix preceding the 671NWFD674 segment reduces 4E10 affinity for MPER(656-
683). On the other hand, MDS studies put forward that the C-terminal 4E10/10E8 
key epitope residues can orient towards the lipid bilayer hydrocarbon core 
(Serrano et al., 2014). In combination, these two effects would hamper 
interaction of the membrane-inserted MPER(656-683) with B-cell receptors. ITC 
results indicate that peptide binding is limited by the entropic cost. Therefore, 
pre-formation of the MPER-N-TMD helix in a membrane mimetic medium 
appeared to elicit tighter binding to the 4E10 antibody. In addition, membrane-
inserted MPER(671-693) peptide, which mostly exhibited insertion orthogonal to 
the lipid bilayer plane in previous MDS studies (Apellaniz et al., 2014b), 
efficiently bound to functional 4E10, while binding to the neutralization-deficient 
mutant was severely affected. Thus, preservation of the MPER-N-TMD helix 
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motif might be important for functional antibody and B-cell receptor binding. 
Consistently, MPER-N-TMD-specific IgG was recovered from rabbit sera upon 
immunization with CpreTM but not from rabbits immunized with the NpreTM 
peptide-based formulations (Apellaniz et al., 2015).  
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4.1. INTRODUCTION 
 
The conserved MPER domain has been proposed to function in gp41-
mediated HIV-1 membrane fusion by perturbing the lipid packing of the viral 
envelope (Apellaniz et al., 2011; Apellaniz et al., 2014b; Salzwedel et al., 1999). 
This region is critical for viral entry and is highly conserved, as evidenced by the 
MAb 4E10, which binds to the MPER C-terminal helix and neutralizes up to 
98 % of global HIV-1 strains (Binley et al., 2004; Huang et al., 2012; Kwong and 
Mascola, 2012). Due to its exceptional neutralization breath, 4E10 has served 
as a model of broad protection against HIV infection, and consequently has 
been the subject of extensive structural and functional characterization, 
particularly for the purpose of vaccine design (Burton et al., 2004; Kwong and 
Mascola, 2012; Montero et al., 2008; Zwick, 2005). 
 
The first crystal structure of the 4E10 Fab in complex with a 13-residue-
long peptide containing the gp41 core epitope 671NWFDIT676 revealed the 
critical binding interactions (Cardoso et al., 2005). The residues of this peptide 
in contact with the Fab (Trp672, Phe673, Ile675, and Thr676) all gathered at 
one face of the helix. A second crystal structure of Fab 4E10 bound to an 
extended peptide epitope 671NWFDITNWLWYIK683-KKK was subsequently 
reported (Cardoso et al., 2007). This peptide (MPER671-683) displays an affinity 
three orders of magnitude higher than that of the shorter version (Brunel et al., 
2006). The enhanced affinity of the longer peptide is due to additional 
interactions between the extra helical turn of MPER671-683 (Leu679 and Trp680) 
and the antibody. Based on the structural data available, the 4E10 epitope was 
lengthened to comprise the motif 672WFX(I/L)(T/S)XX(L/I)W680 with residues at 
Env positions 672, 673, 675, 676, 679 and 680, located on the hydrophobic 
face of the amphipathic helix comprising the “neutralizing face” of the epitope. 
These conclusions were reinforced when stabilization of the helical structure at 
the non-binding face by covalently “stapling” residues 678 and 681, was shown 
to further enhance peptide affinity (Bird et al., 2014). 
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It has been proposed that the hydrophobic CDR-H3 loop of 4E10 
interacts with lipids of the viral envelope (Cardoso et al., 2005). This hypothesis 
was further elaborated after observing that binding of Fab and single-chain 
variable fragment (scFv) of 4E10 to liposomes composed of viral lipids is 
governed by the hydrophobicity of its unusually long and highly flexible CDR-H3 
loop (Alam et al., 2009; Apellaniz et al., 2014b; Scherer et al., 2010). In 
particular, Scherer et al. (Scherer et al., 2010) found a direct correlation 
between lipid binding and neutralizing activity for 4E10 IgGs bearing substituted 
Trp residues at the apex of the CDR-H3. For example, the double mutation 
WH100D/WH100BD (termed WDWD) exhibits poor affinity for lipids and 
undetectable activity in standardized viral neutralization assays. These authors 
concluded that hydrophobic residues of the apex region of CDR-H3 are 
required for MPER recognition through favorable lipid interactions in the context 
of the viral envelope. 
 
In crystal structures of 4E10 Fab-peptide complexes, the long CDR-H3 
loop required for neutralization extends beyond the bound helical peptide in an 
orientation that suggests its apex could contact the viral membrane and 
contribute to neutralization (Cardoso et al., 2007; Cardoso et al., 2005). Using a 
recombinant variable fragment (Fv) fragment (composed of VH + VL) it was 
shown that mutating a Trp residue of the apex does not change the binding 
mode of a scaffold-protein containing the sequence of the core epitope peptide 
(Xu et al., 2010). Later, studies employing the same Fv fragment suggested that 
the 4E10 paratope is flexible and undergoes a large restructuring process upon 
binding to peptide (Finton et al., 2014; Finton et al., 2013). Specifically, this 
conformational change would involve a shift of ca. 12 Å of the CDR-H3 loop, 
and especially of the apex segment (Finton et al., 2013). The possibility that the 
loop undergoes significant restructuring during peptide binding implies that 
mutations that abolish neutralization may alter the CDR-H3 conformational 
equilibrium, and through this mechanism, hamper peptide recognition. 
Opposing this data, co-crystals obtained in the presence of phosphatidic acid, 
phosphatidylglycerol, and glycerol phosphate reveal two binding sites involving 
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the CDR-H1 loop on the surface of 4E10 paratope facing the membrane (Bird et 
al., 2014; Irimia et al., 2016). This crystallographic analysis revealed the 
presence of these pockets in the unbound and complex-bound conformation of 
the 4E10 antibody consistent with the simultaneous accommodation of the 
phospholipid head-group moieties and peptide epitope within 4E10 paratope. 
Besides, the crystal structures reveal a 9 Å movement of the CHR-H3 inferring 
possible hydrophobic interactions between the residues of the loop and the lipid 
tails. Although this mode of interaction could account for the higher binding 
affinity of the antibody to its epitope in the context of lipid membranes, 
mutagenesis studies will be necessary to evaluate the functional role of these 
subsites during viral neutralization by 4E10.  
 
To determine the differences between neutralizing and non-neutralizing 
4E10 Fab-s at the molecular level, we have determined high-resolution crystal 
structures of two non-neutralizing Fab-s bearing mutations in the CDR-H3 
loops. The overall structure of the non-neutralizing antibodies and those of the 
WT Fab-peptide complexes previously reported (Apellaniz et al., 2015; Cardoso 
et al., 2007; Cardoso et al., 2005) are nearly indistinguishable, except for some 
differences in the conformation of the CDR-H3 apex. Following strategies 
delineated in our previous studies, the structural data were complemented with 
a detailed kinetic and thermodynamic analysis of the (MPER671-683) peptide 
binding mechanism, not only at equilibrium, but also at the transition state 
(Kiyoshi et al., 2014; Kiyoshi et al., 2015). We show that neutralizing and non-
neutralizing Fab-s recognize the helical (MPER671-683) peptide by means of 
nearly identical mechanisms at both the energetic and atomic levels. In 
particular, the novel crystal structure of the ligand-free Fab indicates that the 
CDR-H3 loop does not undergo significant conformational changes during 
recognition of the epitope. Comparison of the structures of Fab in the bound 
and free states revealed loss of flexibility in the CDR loops during peptide 
engagement, except for the apex region of the CDR-H3, which remained 
relatively flexible. In contrast to the common structural and energetic 
mechanism describing the binding of neutralizing and non-neutralizing Fab to 
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MPER(671-683) in solution, the non-neutralizing forms of 4E10 Fab were defective 
in binding to an MPER that was anchored to the plasma membrane via the 
gp41 TMD (Montero et al., 2012), which was otherwise efficiently recognized by 
the neutralizing WT Fab. Collectively, our data support the notion that the 
hydrophobic CDR-H3 apex governs recognition of the MPER epitope, 
constrained in a membrane context, a process required for efficient 
neutralization of the virus. 
 
4.2. MATERIALS AND METHODS 
 
4.2.1. Materials 
 
The peptides used in the structural and affinity studies were synthesized 
as described in 3.2.1. The following reagents were obtained through the NIH 
AIDS Reagent Program, Division of AIDS, DAIDS, NIAID, NIH: The IgG1 MAb, 
4E10, from H. Katinger (Polymun Scientific GmbH, Vienna, Austria), pNL4-
3.Luc.R-.E- from N. Landau (Aaron Diamond AIDS Research Center, The 
Rockefeller University), TZM-bl cells from J. C. Kappes, X. Wu and Tranzyme 
Inc., and plasmids encoding Env from the HIV-1 isolates: SS1196.1 clone 1 
(SVPB9) from D. Montefiori and F. Gao (Duke University Medical Center), 
Bal.26 from J. Mascola (Vaccine Research Center, NIH), and JR-CSF from I. 
Chen (David Geffen School of Medicine, University of California Los Angeles) 
and Y. Koyanagi (Institute for Virus Research, Kyoto University). A plasmid 
encoding the engineered HIV-1 Env, SF162.LS, was kindly provided by N. 
Haigwood (Oregon National Primate Center, Beaverton, OR), and a plasmid 
encoding the VSV-G Env was provided by Patricia Villace (CSIC, Madrid). A 
hybridoma cell line producing the murine MAb 17/9, which recognizes the HA-
tag sequence, DVPDYA, was kindly provided by R. Stanfield and I. A. Wilson 
(The Scripps Research Institute, La Jolla, CA); this IgG1 MAb was produced 
and purified from ascites fluid by Maine Biotechnology Services Inc. (Portland, 
ME). Recombinant gp41 (r-gp41; HIV-1MN isolate) was purchased from 
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ImmunoDiagnostics (Woburn, MA). A peptide bearing the MPER sequences 
residues 667-683 (MPER667-683; HXB2 numbering) from HIV strain JR-CSF 
gp41 (NH3+-ASLWNFDITKWLWYIK-SGK-(biotin)-CONH2) was purchased from 
United Biosystems (Herndon, VA) at > 95 % purity.  
 
4.2.2. Mutagenesis and production of 4E10 Fab-s. 
 
For the generation of the Fab 4E10-ΔLoop mutant, the hydrophobic 
CDR-H3 loop apex (residues Trp100HC-Gly100aHC-Trp100bHC-Leu100cHC) was 
deleted through site-directed mutagenesis. The resulting gap between residues 
Gly99HC and Gly100dHC was filled with a SG linker. In the case of the Fab 
WDWD, residues Trp100HC and Trp100bHC were substituted with Asp. Genetic 
modifications of the constructs were carried out with the KOD-Plus mutagenesis 
kit (Toyobo, Osaka, Japan) following the manufacturer’s instructions. 
Experimental procedures described in 3.2.2 were followed for the production 
and purification of Fab-s. 
 
4.2.3. Crystallization of ligand-free Fab and Fab-peptide complexes. 
 
Crystals of unbound WT 4E10 Fab, as well as crystals of WDWD or 
ΔLoop in complex with MPER(671-683), were prepared by the hanging drop 
method. The crystals of unbound WT Fab were obtained by mixing 0.5 µl of 
protein at 3 mg/ml with 0.5 µl of a solution containing 15 % (w/v) PEG 20,000 
and 100 mM MES (pH 6.5). To obtain crystals of non-neutralizing Fab-s in 
complex with peptide, first antibody and epitope were mixed at an approximate 
molar ratio of 1:1.3 (protein:peptide) and subsequently concentrated to 3 mg/ml. 
Suitable crystals of WDWD-MPER(671-683) were obtained by mixing 2 µl of the 
solution containing protein and peptide with 2 µl of a solution composed of 200 
mM ammonium acetate, 34 % PEG 8,000, and 100 mM Tris-HCl (pH 8.4). 
Similarly, co-crystals of ΔLoop Fab with epitope bound were obtained by mixing 
the complex with a solution composed of 200 mM ammonium acetate, 30 % 
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PEG 8,000, and 100 mM Tris-HCl (pH 8.5). In both cases crystals grew to full 
size within a few days at 20 °C. Suitable crystals were identified, harvested and 
briefly transferred to mother liquor supplemented with 25 % (v/v) ethyleneglycol 
(unbound Fab) or 15 % (v/v) glycerol (WDWD and ΔLoop Fab-s in complex with 
MPER(671-683)), and frozen and stored in a vessel containing liquid N2.  
 
4.2.4. Data collection and structure refinement 
 
Diffraction data from a single crystal of the unbound Fab were collected at 
beamline I02 of the Diamond Light Source (Oxfordshire, UK) under cryogenic 
conditions (100 K). Diffraction data of the WDWD and ΔLoop Fab-s in complex 
with MPER(671-683) were collected in beamline BL5A of the Photon Factory 
(Tsukuba, Japan) also under cryogenic conditions (100 K). Diffraction images 
were further processed as described in 3.2.6 using the coordinates of 
recombinant WT Fab described in chapter 3. The crystal of unbound WT Fab 
was partially twinned (ratio 70/30) as determined with the program REFMAC5 
during the refinement stage. Data collection and structure refinement statistics 
are given in Table 4. 
 
4.2.5. Differential scanning calorimetry (DSC) 
 
The heat capacity of individual Fab-s was measured using a VP-DSC 
system (MicroCal, Northampton, MA). All calorimetric scans were performed in a 
buffer composed of 10 mM NaH2PO4 (pH 7.5), 150 mM NaCl, and 10 % glycerol. 
Protein samples at 10 µM were heated from 30 to 90 ºC at a scanning rate of 
1 ºC min-1. The ORIGIN software package (MicroCal) was used for data 
collection and analysis. The buffer baseline was subtracted from the raw data, 
which were normalized by protein concentration to obtain thermodynamic 
parameters and then fitted to a to a non-two-state model. 
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4.2.6. Surface Plasmon Resonance (SPR) 
 
Temperature-dependence SPR experiments were performed on a 
Biacore T200 instrument (GE Healthcare). 4E10 Fab-s, WT, WDWD and ΔLoop, 
were dialysed against running buffer (10 mM HEPES-NaOH, pH 7.5, 150 mM 
NaCl, 3 mM EDTA, and 0.1 % (v/v) Tween-20). An antibody-capture method was 
used to obtain the binding response of the MPER(671-683)-Fab interaction. An anti-
human IgG-Fab secondary antibody was immobilized on a Biacore CM5 chip 
(GE Healthcare) to surface densities of ~15,000 response units (RU). For that 
purpose, the chip was first activated with N-hydroxysuccinimide and N-ethyl-N’-
(3-dimethylaminopropyl) carbodiimide hydrochloride as previously described 
(Kiyoshi et al., 2014; Kiyoshi et al., 2015; Sakamoto et al., 2009). After 
immobilizing the anti-human Fab antibody, the remaining active groups on the 
surface of the chip were blocked by flowing 100 ml of 1 M ethanolamine. The 
Fab variants were subsequently captured to surface densities of ~1400 RU. For 
these experiments, the lysine residues of the standard MPER(671-683) were 
substituted for Arg as previously described (MPER(671-683)R) (Huang et al., 2012). 
This peptide was flowed over the immobilized Fab-s at 30 µl/min in increasing 
concentrations from 7.8 to 500 nM. The association and dissociation phases 
were 120 and 200 s, respectively. Regeneration was achieved after completion 
of each sensorgram by injecting a solution of 10 mM glycine-HCl, pH 1.5, for 
30 s at a flow rate of 30 µl/min. Association (kon) and dissociation (koff) rate 
constants were determined with the Biacore T200 evaluation software (GE 
Healthcare). The dissociation constant (KD) was calculated from the ratio of the 
rate constants (KD = koff / kon). Changes in enthalpy (ΔHvH) and entropy (ΔSvH) 
were calculated from the slope and intercept, respectively, of the temperature 
dependence of the dissociation constant using the van’t Hoff approximation 
(Sakamoto et al., 2009) (see section 2.4.1). The activation energy parameters 
were obtained from the temperature dependence of each kinetic rate constant 
according to the Eyring equation (Cleland and Northrop, 1999) (see 
section 2.4.1). 
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4.2.7. Dot-blot PsV binding assay 
 
Decreasing amounts of the HIV-1 isolate JR-CSF PsV were spotted 
(1 µL) onto Hybond C nitrocellulose (GE Healthcare). The membrane was then 
blocked with 5 % fat-free milk in PBS (Blocking Buffer) o/n, and incubated for 
1 hour with Fab antibodies (0.2 µg/ml) in Blocking Buffer at RT. The 
membranes were washed 3 times, 10 min each with PBS, and soaked with 
primary antibody (goat anti- Human Fab specific (Santa Cruz) at a 1:2,000 
dilution. The membranes were washed again, and then incubated 1h with HRP-
conjugated secondary antibodies (GE Healthcare) at a 1∶2,000 dilution. After 
washing with PBS, binding was detected using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific). 
 
4.2.8. Cell lysate production 
 
Cell lysate production was carried out as previously described (Montero 
et al., 2012). 293T cells were transiently transfected with 1 µg plasmid DNA 
encoding recombinant MPER proteins, MPER-TM1 and MPER-PGDFR, using 
the XtremeGENE 9 transfection reagent (Roche, Basel, Switzerland), according 
to the manufacturer’s instructions, at a ratio of 1:6 (i.e., µg DNA to µL 
transfection reagent). Cells were cultured in 6-well plates (Sarstedt, Numbrecht, 
Germany) in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, 
location) supplemented with 10 % (v/v) fetal calf serum (FCS; Life 
Technologies) and 1 mM L-glutamine (Life Technologies) at 37 °C and 5 % 
CO2. After 48 hours, the cells were washed four times in phosphate-buffered 
saline (Life Technologies), and recovered from the plate with 1 mM Na2EDTA-
NaOH, pH 8.0 (Bioshop, Burlington, Canada). Cells were pelleted by 
centrifugation for 5 min at 350 × g, resuspended in 200 µL lysis buffer 
comprising a protease-inhibitor cocktail (complete ULTRA Tablets, mini, EDTA-
Free; Roche) diluted 1:12 in (250 mM sucrose and 0.5 mM Na2EDTA-NaOH, 
pH 8.0). Cell lysates were produced by 30 passages through a 22-gauge 
needle followed by two 15-s pulses with a Virsonic sonicator (VirTis, Gardiner, 
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NY). Total protein content was quantified using the Bradford reagent (Bio-Rad 
Protein Assay, BioRad, Mississauga, Canada) following the manufacturer’s 
instructions; lysates were stored at -80 °C. 
 
4.2.9. Enzyme-linked immunosorbent assays (ELISAs) 
 
Wells of high-binding microtiter plates (Corning Inc., Corning, NY) were 
coated o/n at 4 °C with 35 µL/well of one of the following diluted in Tris-buffered 
saline (TBS; 50 mM Tris-HCl, pH 7.5, 150 mM NaCl): (i) cell lysate (the 
equivalent of 10 µg protein), (ii) r-gp41 (50 ng), (iii) biotinylated MPER667-683 
peptide (400 ng), or (iv) TBS containing 2 % (w/v) bovine serum albumin (TBS-
BSA; Sigma-Aldrich). Wells were blocked for 1 h at room temperature (RT) with 
TBS-BSA, then washed twice with TBS containing 0.1 % (v/v) Tween-20 (TBS-
T), once with TBS, then incubated for 2 h at RT with the indicated dilutions of 
4E10 IgG1, 17/9 IgG1 or one of the 4E10 Fab-s (WT, WDWD, ∆Loop) diluted in 
TBS-T containing 5 % (w/v) non-fat dried milk (5 % NFDM; Bio-Rad). After five 
washes with TBS-T followed by one with TBS, bound 4E10 IgG or 4E10 Fab-s 
were detected with goat (anti-human kappa light chain IgG)-HRP, and bound 
17/9 IgG1 with goat (anti-murine IgG)-HRP, diluted 1:500 and 1:1,000, 
respectively, in 5 % NFDM. After 1 h incubation at RT, plates were washed five 
times in TBS-T and once in TBS. Bound HRP was detected using 400 ng/ml 
2’2’-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Sigma-Aldrich, St. 
Louis, MO) in developer solution comprising a 1:1.5 ratio of citrate (0.1 M, 
pH 2.4) and phosphate (0.2 M, pH 9.2) buffers, along with 0.03 % (v/v) H2O2. 
Absorbance was measured at 405 – 490 nm, using a Tecan Infinite M200 Pro 
microplate reader (Tecan, Mannedorf, Switzerland). 
 
4.2.10. HIV-1 envelope neutralization assays 
 
Neutralization assays were performed using a single-round infection 
assay with envelope (Env)-pseudotyped virus (PsV) as described previously 
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(Seaman et al., 2010). Briefly, PsVs were produced by co-transfection of 293T 
cells with (i) an Env-negative HIV genomic vector that carries a firefly luciferase 
reporter gene  (pNL4.3.Luc.R.E-), and (ii) a plasmid carrying an HIV envelope 
gene expression cassette. 293T cells (2 x 106 cells) were co-transfected with 
plasmid DNA at ratios of 1:3 to 1:20 µg pNL4.3.Luc.R.E- plasmid DNA to µg 
HIV Env+ plasmid DNA and 54 µg polyethylenimine (PEI; Polysciences, 
Warrington, PA). Plasmids encoding Env from HIV-1 isolates and controls 
include: SF162.LS, SS1196.1 clone 1 (SVPB9), or JR-CSF, or with a plasmid 
expressing the Env from vesicular stomatitis virus (VSV-G) (to produce a 
negative-control PsV). PsVs were harvested from cell-free supernatants 72 h 
post-transfection, passed through a 0.45 µm-filter, diluted 1:10 in 10X 
phosphate-buffered saline (Life Technologies), aliquoted, and stored at -80 °C. 
 
PsV infection is measured using a luciferase-based assay in TZM-bl 
cells, with neutralization being measured as a reduction in luciferase activity 
following single-round infection. TZM-bl cells were seeded o/n (10,000/well) in 
flat-bottom 96-well plates (Corning) in a total volume of 200 µL DMEM 
supplemented with 10 % heat-inactivated FCS and 1 mM L-glutamine (DMEM-
∆FCS). Three-fold serial dilutions of the appropriate MAb or Fab concentration 
were prepared in DMEM-∆FCS in a total volume of 150 µL, and added in 
triplicate to the wells of a separate round-bottom 96-well plate (Corning).  PsVs 
were added at 200 TCID50/well in a total volume of 50 µL DMEM-∆FCS 
supplemented with 25 µg/mL diethylaminoethyl-dextran hydrochloride (DEAE-
Dextran; Sigma-Aldrich), and plates were incubated for 1 h at 37 °C and 5 % 
CO2.  Following incubation, media was removed from wells of the TZM-bl-
seeded 96-well plates, and PsV-MAb/Fab samples were transferred to the 
plates. Control wells comprising TZM-bl cells only (cell control), and virus only 
(virus control) were also included. After a 72-h incubation, media was removed 
from wells, 50 µL Glo lysis buffer (Promega, Madison, WI) was added to each 
well, and lysis was allowed to proceed at RT with gentle rocking for 5 min. One-
Glo luciferase substrate (Promega) (50 µL/well) was added and incubated for 
five min at RT. Samples were transferred (50 µL/sample) to 96-well, white solid 
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plates (Thermo Fisher Scientific, Waltham, MA) and luciferase activity was 
measured using a Tecan Infinite M200 Pro multi-mode plate reader (Tecan). All 
values are reported as relative luminescence units (RLU), and neutralization 
was calculated with respect to cell- and virus-control wells using the following 
formula: 1 - [(RLUsample wells – RLUcells-only wells) / (RLUvirus-only wells – 
RLUcells-only wells)] x 100. The 50 % inhibitory concentration (IC50) 
concentration is calculated as the antibody/Fab concentration producing a 50 % 
reduction in RLU compared to the level in the virus-control wells after 
subtraction of cell-control RLU. 
 
4.3. RESULTS 
 
4.3.1. Crystal structures of non-neutralizing 4E10 Fab-s 
 
Modification of the flexible, hydrophobic CDR-H3 loop may result in 
impaired neutralizing 4E10 activity (Alam et al., 2009; Apellaniz et al., 2014b; 
Scherer et al., 2010; Xu et al., 2010). To investigate this phenomenon at the 
molecular level, we determined the crystal structure of two different non-
neutralizing 4E10 Fab-s mutated at the CDR-H3 loop, which were generated as 
follows: (i) truncating the hydrophobic apex by replacing the Trp100HC-
Gly100aHC-Trp100bHC-Leu100cHC sequence with a Ser-Gly dipeptide (termed 
ΔLoop); and (ii) substituting the aromatic Trp100HC and Trp100bHC residues for 
polar-charged Asp residues, hence reducing the hydrophobicity while 
preserving the length of the loop (termed WDWD and previously described by 
Scherer et al. (Scherer et al., 2010)). Recombinant Fab-s were expressed in E. 
coli without loss of performance or change of structure with respect to the Fab 
obtained by papain cleavage of IgG (Apellaniz et al., 2015). Compared with WT 
antibodies (IgG and its Fab fragment) the ΔLoop and WDWD Fab-s did not 
exhibited neutralizing activity in a standard assay (Table 3). The 4E10 IgG 
exhibits higher neutralization potency than that of the Fab fragment, (6.5-fold) in 
good agreement with observations reported in a previous study (4.4-fold) (Klein 
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et al., 2009). The molecular basis of this gap in neutralization potency is still 
unclear, although it might reflect the effect of avidity at the two available 4E10 
sites in the Env trimer (Leaman et al., 2015). 
 
Table 3. Neutralization of primary isolate viruses by 4E10 IgG, WT, and mutant Fab-s.a 
 Tier 1A Tier 1B Tier 2 Control 
Antibody SF162.LS SS1196.1 JRCSF VSV-G 
4E10 IgG 21b 21 20 > 200 
4E10 WT Fab 146 155 106 > 200 
4E10 WDWD Fab > 600 > 600 > 600 > 200 
4E10 ΔLoop Fab > 600 > 600 > 600 > 200 
a The data shown are from one of two experiments, both of which gave similar results. 
b IC50 values, nM. 
 
High-resolution crystal structures of WDWD or ΔLoop in complex with 
MPER(671-683) were determined at 1.81 and 1.70 Å, respectively (Table 4). The 
two complexes crystallized in the same space group as that reported for the WT 
Fab obtained either from papain-treated IgG or by heterologous expression in 
E. coli (Apellaniz et al., 2015; Cardoso et al., 2007). The superposition of the 
three crystal structures showed that they are nearly indistinguishable from each 
other (FIG 25). The root-mean square deviation (rmsd) values between the 
coordinates of WT and WDWD, and between WT and ΔLoop were 0.20 and 
0.29 Å, respectively. A significant difference was found in the conformation of 
the CDR-H3 apex of WT compared with that of ΔLoop because the latter 
construct is two residues shorter in this region. This conformational change 
brings the apex of the CDR-H3 of ΔLoop Fab closer to the peptide, generating 
an H-bond between residue Trp680 of the peptide and the backbone oxygen of 
the residue GlyH100A of ΔLoop (distance = 2.7 Å) (FIG 26 and Table S1). A 
similar H-bond was observed in one copy of the crystal structure of WT Fab in 
complex with a peptide containing α-aminoisobutyric acid at position Trp678 
(Cardoso et al., 2007). 
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FIG 25. Crystal structures of neutralizing and non-neutralizing 4E10 Fab-s. (A) 
Superposition of the backbone atoms of WT (gray), WDWD (white), and ΔLoop (black). The 
rmsd of the backbone coordinates of the HC of WT with those of WDWD was 0.20 Å, and with 
those of ΔLoop 0.29 Å. The arrows point at differences in the conformation of the apex region 
of the CDR-H3 loop. The MPER(671-683) peptide bound to WT, WDWD, and ΔLoop Fab is shown 
in orange, magenta, and blue, respectively. (B-D) Close-up view of the conformation of the 
CDR-H3 loop (residues 95-100J) of (B) WT, (C) WDWD, and (D) ΔLoop with respect to the 
peptide. Residues with side chains within the region 100-100D are depicted. 
 
Other polar and nonpolar interactions between the peptide and WT Fab 
were very well conserved in the WDWD and ΔLoop Fab-s (FIG 26). Key H-
bonds between peptide residues Asn671, Trp672, Asp674 and Thr676 and the 
Fab-s (Table S1), as well as the non-polar interaction surface involving the 
residues Asn671, Trp672, Phe673, Ile675, Thr676, Leu679 and Trp680 of the 
peptide, are well preserved in the three crystal structures (Table S2 and S3). 
Moreover, the values of buried surface area (BSA) calculated with PISA 
(Krissinel and Henrick, 2007) corresponding to the interaction surface between 
the peptide and the heavy or the light chain of the Fab remain essentially 
MPER(671-683) 
A B 
C 
D 
MPER(671-683) 
MPER(671-683) 
MPER(671-683) 
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unchanged in the three crystal structures (Table S2 and S3). The total BSA for 
WT, WDWD, and ΔLoop were within 2 % of each other; 1,487; 1,482; and 1,511 
Å2, respectively. 
 
 
FIG 26. Interaction network of MPER(671-683) peptide with neutralizing and non-neutralizing 
4E10 Fab-s. Diagram for WT (A), WDWD (B), and ΔLoop (C). Residues corresponding to the 
Fab (upper half) and the peptide (bottom half) are labeled in black and magenta, respectively. 
Water molecules are labeled in cyan. H-bonds and their distances are depicted with green 
lines. Residues engaging in direct or water-mediated H-bonds are shown in ball and stick 
representation. Residues displaying non-polar and van der Waals interactions are represented 
by spiked semi-circles. The red arrow in panel (C) points at the unique Fab-protein interaction 
observed in the complex with ΔLoop. The figure was generated with LIGPLOT+ (Wallace et al., 
1995). 
 
The shape complementarity coefficient (Sc), a parameter that quantifies 
the complementarity between protein/protein interfaces (Lawrence and Colman, 
1993) was also very similar among the three Fab-s. The Sc values calculated 
for the interface formed between the HC and MPER(671-683) in the three crystal 
structures were in the narrow range of 0.77-0.78, whereas those between the 
LC and the peptide were in the range 0.80-0.82. The potential lipid-binding site 
located in the CDR-H1 loop also remained unchanged in the three crystal 
structures. We note that a water molecule takes the position occupied by the 
A
B 
C 
MPER(671-683) 
MPER(671-683) 
MPER(671-683) 
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phosphate ion reported in the PDB structure with entry code 4NHC and (Bird et 
al., 2014) (data not shown). 
 
Table 4. Data collection and refinement statistics. Statistical values given in parenthesis 
refer to the highest resolution bin. 
Data Collection ΔLoop + MPER(671-683) WDWD + MPER(671-683) WT unbound 
     Space Group C 2  C 2 P 21 
     Unit cell    
        a, b, c (Å) 157.5, 44.7, 85.3 157.3, 44.9, 86.2 44.7, 134.2, 81.9 
        α, β, γ (°) 90.0, 113.6, 90.0 90.0, 114.6, 90.0 90.0, 90.0, 90.0 
     Resolution (Å) 36.1 – 1.70 44.5 – 1.81 44.7 – 2.48 
     Wavelength 1.000 1.000 1.000 
     Observations  313,934 (31,932) 265,738 (37,906) 79,271 (11,742) 
     Unique reflections 59,239 (7,703) 50,189 (7,203) 32,268 (4,692) 
     Rmerge. (%)a 8.8 (39.1) 9.9 (66.7) 7.2  (21.5) 
     Rp.i.m. (%) 4.2 (21.0) 4.6 (31.1) 5.6 (16.4) 
     CC1/2 
 
1.00 (0.87) 1.00 (0.78) 0.99 (0.93) 
     I / σ (I) 12.5 (3.3) 11.9 (2.8) 9.7 (4.2) 
     Multiplicity 5.3 (4.1) 5.3 (5.3) 2.5 (2.5) 
     Completeness (%) 98.3 (88.5) 99.7 (99.1) 98.4 (98.7) 
     B-factor (Wilson Plot) (Å2) 11.8 16.4 17.1 
Refinement Statistics    
     Resolution (Å) 36.1 – 1.70 44.5 – 1.81 44.7 – 2.48 
     Reflections Rwork/Rfree 56,860 / 2,379 48,180 / 2,007 30,609 / 1,632 
     Rwork / Rfree (%)b 14.7 / 17.8 16.3 / 18.8 18.3 / 23.1 
     No. atoms (protein) 3,336 3,346 6,541 
     No. atoms (peptide) 159 129 - 
     No. atoms (solvent) 590 412 135 
     No. atoms (other) 25 18 - 
     B-factor (protein) (Å2) 24.7 27.7 25.1 
     B-factor (peptide) (Å2) 31.9 44.8 - 
     B-factor (solvent) (Å2) 35.4 33.0 20.8 
     B-factor (other) (Å2) 34.9 36.7 - 
     Ramachandran Plot    
        Preferred (%) 89.9 91.2 88.7 
        Allowed (%) 9.8 8.5 11.0 
        Outliers (%) 0.3 0.3 0.3 
     RMSD Bond (Å) 0.013 0.015 0.008 
     RMSD Angle (°) 1.53 1.63 1.27 
     Coordinate error (Å) 0.08 0.10 0.13 
     PDB entry code 5CIN 5CIL 5CIP 
a Rmerge = Σhkl Σi |(I(hkl)i − [I(hkl)]| / Σhkl Σi I(hkl). 
b Rwork = Σhkl |F(hkl)o − [F(hkl)c]| / Σhkl F(hkl)o; Rfree was calculated as Rwork, where F(hkl)o values 
were taken from ~4-5 % of data not included in the refinement. 
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4.3.2. Mechanism of binding and stability of neutralizing and non-
neutralizing 4E10 Fab-s 
 
The structural data gathered so far has not satisfactorily explained the 
poor neutralization performance of the two CDR-H3 mutants, given the minimal 
structural differences among the Fab-s. To further characterize the molecular 
basis for these large differences in neutralization potency, we performed a 
comparative functional and thermodynamic analysis employing WT, ΔLoop and 
WDWD Fab-s. 
 
DSC measurements demonstrated that the CDR-H3 mutations did not 
affect the stability of the ligand-free forms of the Fab-s (FIG 27). The melting 
temperatures (TM) determined from the mid-point unfolding transition of WT 
Fab, WDWD, and ΔLoop were 70, 72, and 72 ºC, respectively. Therefore, 
decreasing the hydrophobicity of CDR-H3 at the apex translates into a modest 
increase in the thermostability of the Fab-s (ΔTM = 2 °C). 
 
 
FIG 27. Thermal stability by DSC. DSC thermograms for WT, WDWD and ΔLoop are shown 
as indicated in the panels. Unfolding of the three Fab-s shows a single thermal transition 
between 30 and 90 °C. The midpoint of the thermal unfolding (TM) and the associated enthalpy 
(ΔH) are also given.  
 
Kinetic and thermodynamic parameters governing MPER(671-683) peptide 
binding were next examined by SPR as previously described (Kiyoshi et al., 
2014; Kiyoshi et al., 2015). FIG 28 shows the sensorgrams corresponding to 
the binding of the MPER(671-683) peptide to immobilized WT, WDWD and ΔLoop 
Fab-s, illustrating the effect of mutations in the apex of the CDR-H3 loop on the 
-5 
5 
15 
25 
35 
60 70 80 90 
C
p 
(k
ca
l m
ol
-1
 K
-1
)
Temperature (ºC) 
-5 
5 
15 
25 
35 
60 70 80 90 
Temperature (ºC) 
-5 
5 
15 
25 
35 
45 
60 70 80 90 
Temperature (ºC) 
C
p 
(k
ca
l m
ol
-1
 K
-1
)
C
p 
(k
ca
l m
ol
-1
 K
-1
)
WT
TM = 69.8 ˚C
ΔH = -362 kcal mol-1
WDWD
TM = 72.4 ˚C
ΔH = -334 kcal mol-1
ΔLoop
TM = 72.3 ˚C
ΔH = -325 kcal mol-1
Results 
Chapter-4-  
 85 
association (kon) and dissociation (koff) rate constants. The values of kon and koff 
for WT Fab at room temperature were 5.2 × 104 M-1 s-1 and 1.1 × 10-3 s-1, 
respectively, corresponding to a dissociation constant (KD) of 21 nM (FIG 28A 
and Table 5). The small values of koff indicate slow dissociation of the peptide 
from the Fab, consistent with tight binding of the epitope-peptide to the antibody 
under these experimental conditions. The values of kon, koff, and KD were also 
determined for the WDWD and ΔLoop Fab-s (FIG 28A and Table 5). Ablation of 
the hydrophobic CDR-H3 tip did not appreciably affect peptide affinity (KD = 
18 nM). However, compared with the WT Fab, the slower kon in ΔLoop was 
compensated by a slower koff, suggesting that the intact loop establishes faster 
interactions with the peptide, but at the same time its release from the paratope 
is also accelerated. The slower dissociation rate observed for the ΔLoop Fab 
could be explained by the stronger H-bond between the GlyH100A(O) of the Fab 
and Trp680(Nξ) of the peptide (FIG 26 and Table S1). The double mutation 
introduced in WDWD Fab decreased the affinity slightly (KD = 41 nM) because 
of a faster koff with respect to the WT Fab, which was not compensated with a 
faster kon (Table 5). Although these differences are arguably small, the data 
suggest that the more hydrophobic loop of WT Fab facilitated binding of 
MPER(656-683) more effectively than the polar WDWD. 
 
The van’t Hoff thermodynamic parameters for the WT Fab and the 
mutated CDR-H3 Fab-s were obtained from the temperature dependence of KD 
(FIG 28B and Table 5). The change of enthalpy associated with the binding of 
WT Fab was negative (ΔHº < 0, exothermic reaction), whereas the contribution 
from the entropy energetic term (−TΔSº, calculated at 25 ºC) was small and 
positive. These values suggested that binding was essentially driven by 
favorable non-covalent interactions between Fab and peptide. The 
thermodynamic parameters obtained at equilibrium for the non-neutralizing 
WDWD and ΔLoop Fab-s exhibited the same thermodynamic signature (Table 
6), although the entropic cost in the case of the WDWD mutant was slightly 
higher (−TΔΔS° = 1.5 kcal mol-1), which could account for the decrease in 
affinity observed for this Fab. 
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FIG 28. Kinetic and thermodynamic characterization of Fab-peptide binding by SPR. (A) 
Sensorgrams corresponding to the binding of MPER(671-683) to a surface decorated with WT 
(left), WDWD (center), or ΔLoop (right) Fab-s (immobilization levels were ~1400 RU) at the 
temperatures indicated in each panel. The concentration of peptide injected in each run is 
indicated. Black and red curves correspond to the experimental data and best fit (using the 
Biacore T200 evaluation software), respectively. (B) Evolution of the thermodynamic 
parameters along the reaction coordinate. Thermodynamic parameters corresponding to the 
transition state and at equilibrium were obtained from the temperature dependence of kon and 
KD using the Eyring and van’t Hoff equations, respectively. The change of Gibbs energy (ΔG), 
change of enthalpy (ΔH), and change of entropy (−TΔS) are shown in blue, red and black, 
respectively. Values are given in Table 5. The double dagger symbol (‡) indicates the transition 
state. 
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Table 5. Kinetic parameters of binding of Fab 4E10 to MPER(671-683)R 
Fab kon (M−1s−1) koff (s−1) KD  (nM) 
WT 5.2 × 104 1.1 × 10-3 21 
ΔLoop 2.9 × 104 5.3 × 10-4 18 
WDWD 4.7 × 104 1.9 × 10-3 41 
 
Differences in the binding mechanism arising from fluctuating loop 
conformations could be more evident at the transition state, i.e. before reaching 
the final conformation of the complex. Hence, the activation free energy (ΔG‡, 
the double dagger symbol refers to the transition state) of each Fab-peptide 
complex was determined from the temperature dependence of kon (FIG 28B and 
Table 5). The transition state in the three Fab-s was governed by the 
unfavorable enthalpy term (ΔH‡ > 0), reflecting the destruction of non-covalent 
interactions during the rate-determining step. The unfavorable enthalpy term 
was partially counterbalanced by favorable entropic contributions (−TΔS‡ < 0). 
Due to the differences in mass and charge in the CDR-H3 loop of the mutated 
Fab-s with respect to WT, we expected to see dissimilar activation barriers for 
binding reactions requiring conformational changes of the loop. However, the 
resulting ΔG‡ values were strikingly similar for the three Fab-s (Table 5). 
Therefore, the shared thermodynamic signature at the transition state in the 
three constructs examined suggests that rearrangement of water molecules at 
the contact interface, rather than major alterations of CDR-H3 loop 
conformation, plays a key role on the activation of the binding process. 
 
Table 6. Thermodynamic parameters of binding of Fab 4E10 to MPER(671-683)R 
Fab ΔG 
(kcal mol−1) 
ΔH 
(kcal mol−1) 
-TΔS 
(kcal mol−1) 
ΔG‡ 
(kcal mol−1) 
ΔH‡ 
(kcal mol−1) 
−TΔS‡ 
(kcal mol−1) 
WT -10.5 -11.5 1.0 11.1 29.4   -18.3 
ΔLoop -10.6 -12.4 1.7 11.4 25.8  -14.5 
WDWD -10.1 -12.6 2.5 11.2 18.6 -7.4 
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4.3.3. Crystal structure of 4E10 Fab in the unbound state 
 
The thermodynamic data described above argue against major 
conformational changes occurring in the 4E10 paratope during MPER(671-683) 
peptide binding. This conclusion differs from that reported with the ligand-free 
Fv fragment (Finton et al., 2013). In that study it was shown that a large 
segment of the CDR-H3 loop (including the apex region) adopts a significantly 
different conformation in the unbound state, resulting in occlusion of the 
paratope. To solve this paradox, and to allow direct structural comparison 
between the Fab-peptide complex, and those previously reported in the 
literature (Bird et al., 2014; Cardoso et al., 2007; Cardoso et al., 2005), we 
determined the crystal structure of unbound 4E10 Fab (FIG 29). 
 
Single crystals of unbound WT 4E10 Fab were obtained in a solution 
containing 15 % PEG 20,000 and 100 mM MES at pH 6.5. The best diffracting 
crystal achieved a resolution of 2.48 Å in spacegroup P21, which was different 
from the spacegroup (C2) where the crystal of the Fab in complex with peptide 
was obtained (Table 4). Consequently, the packing forces experienced by 
protein chains of the unbound and the bound Fab-s were different. Despite this 
difference, the structures of unbound and bound Fab were essentially identical 
(rmsd = 0.32 Å) (FIG 29).  
 
The electron density corresponding to residues of the apex of CDR-H3 
(WH100−GH100D) was weak, indicative of dynamic disorder (FIG 29 and 30A). 
Importantly, the conformation of the CDR-H3 loop, in its entire length, is nearly 
identical to that of the bound form of WT but clearly different to that of the 
unbound form of the FV fragment (FIG 30B). We also note that the putative lipid-
binding site located in CDR-H1 also remains virtually unchanged with respect to 
the Fab with peptide bound (data not shown). 
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FIG 29. Comparison of the ligand-bound and ligand-free forms of 4E10 Fab. Sausage 
(tubular) representation of B-factors of ligand-free (A) and ligand-bound (B) 4E10 Fab. Higher 
B-factors are depicted by red and thick tubes. For the unbound form of 4E10, the blue-white-
red gradient corresponds to B-factor values of 12.6, 36.6 and 100.9 Å2, respectively. For the 
peptide-bound form, the blue-white-red gradient corresponds to B-factor values of 21.8, 40.0 
and 90.2 Å2, respectively. These values correspond to the minimum, a midpoint, and the 
maximum B-factor values of each crystal structure. Both molecules are oriented to display the 
paratope CDR loops at the front plane. In panel (B) the bound peptide is represented with a 
green ribbon. (C) Per-residue real-space correlation coefficient (RSCC, a measure of the fit 
between the model and the experimental electron density) of the six hypervariable loops of 
4E10 Fab in the unbound (red) and bound (black) state. Lower correlation values indicate less 
agreement between the model and the experimental electron density, suggesting the regions 
with lower RSCC are more dynamically disordered. The RSCC values were calculated using 
PHENIX (Adams et al., 2010). 
 
Crystallographic models contain dynamic information in the form of B-
factors and dynamic contact networks (van den Bedem et al., 2013), and thus 
the comparison of models of the same protein in the bound and unbound state 
may reveal regions of altered dynamics. The antibody employs the CDRs H1 
(25SGGSFSTYAL34), H2 (50GVIPLLTITNYA60), H3 
A B
MPER(671-683) 
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(95EGTTGWGWLGKPIGAFAH102), and L3 (89QQYGQSLST97) to engage 
MPER(671-683) (Cardoso et al., 2007). The CDR-L2 (50GASSRPS56) does not 
engage with the peptide, whereas CDR-L1 (24RASQSVGNNKLAW35) only 
makes minor contacts (Cardoso et al., 2007). Comparison of bound and 
unbound 4E10 Fab models revealed a reduction in the backbone dynamics (B-
factors) of several CDR loops in the bound state according to their involvement 
in peptide binding (FIG 29A,B and 31). 
 
 
FIG 30. Conformation of CDR-H3 in the unbound form. (A) Sigma-A weighted electron 
density map of the CDR-H3 of unbound WT Fab (σ = 1.0). Electron density for the residues of 
the apex (100WGWLG100D) is only visible at low contouring levels (σ ~ 0.5, not shown) but 
sufficient to allow modeling of the residues. (B) Comparison of conformations of the CDR-H3 in 
the unbound form of Fab (orange), in the reported Fab-peptide complex (PDB entry code 2FX7, 
black), and in the reported structure of the unliganded Fv fragment (PDB entry code 4LLV, 
blue). Sequence numbers are given. 
 
To strengthen the conclusions about the dynamic behavior of the CDR 
loops of Fab upon binding, we calculated the real-space correlation coefficient 
(RSCC, (Jones et al., 1991)) with PHENIX (Adams et al., 2010) (FIG 29C). The 
RSCC values for residues of the CDRs H1, H2, H3 and L3 are greater in the 
bound form than in the unbound form. This observation is explained by a better 
fitting of the electron density to the model, which can be qualitatively interpreted 
as a reduction in dynamic disorder. These differences cannot be attributed to 
the resolution of the crystal structures, since the average value of RSCC for the 
entire structure of bound (RSCC = 0.97) and unbound Fab (RSCC = 0.95) was 
comparable to each other. Although RSCC values for all residues of the CDR-
A B 
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H3 increased upon binding of the peptide, it is also certain that residues of the 
apex (99GWGWL100C) displayed a noticeable residual disorder as judged from 
the values of RSCC (< 0.90). In contrast to the CDR loops described above, 
CDRs L1 and L2 exhibited very little reduction of mobility, consistent with their 
minor role in binding. Similar results are observed in the average plots of six 
other crystal structures of 4E10 with various peptides bound (FIG 32). 
 
 
FIG 31. Crystallographic B-factors of Fab in the bound and unbound state. (A) HC. (B) 
LC. Relative B-factors are plotted to facilitate the comparison between crystal structures at 
different resolutions and quality. The relative B-factors were obtained by normalization with 
respect to the average B-factor of each structure. 
 
These results have proved that the binding process resulted in minor 
conformational adjustments mostly involving a change of mobility of the CDR 
loops after the antibody comes into contact with the epitope. Importantly, our 
results indicate that the hydrophobic cavity accommodating the peptide remains 
intact even in the absence of peptide. 
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FIG 32. Analysis of residues of the apex region of CDR-H3. Comparison of RSCC between 
unbound Fab (red lines, also shown in FIG 29C) and the arithmetic average RSCC of six 
crystal structures of 4E10 Fab with various types of peptide bound (black lines). The PDB entry 
codes of the crystal structures employed to prepare these plots were 1TZG (short peptide 
epitope), 2FX7 (MPER(671-683)), 2FX8 (peptide constrained with a α-amino isobutyric acid), 2FX9 
(peptide with a thioether intramolecular bond), 4NHC (stapled peptide), and 4NGH (stapled 
peptide with a phosphate tether). 
 
4.3.4. PsV neutralization and binding to the MPER in the context of 
the plasma membrane  
 
The above results describing the structure and energetics of peptide 
binding to the 4E10 Fab-s indicated that mutation of the CDR-H3 apex do not 
alter the ability of the antibody to interact with the peptide. Yet, a PsV-based 
neutralization assay (Table 3) showed that the Fab mutants had lost all 
neutralization activity compared to that of WT IgG and WT Fab. The results 
displayed on FIG 33 confirmed the inability of the non-neutralizing Fab to bind 
to PsV particles under the experimental conditions that otherwise sustain dose-
dependent binding of the WT-4E10 Fab and the anti-gp120 PG9 antibody, the 
latter being employed as a positive control of Env expression. Thus the 
dramatic differences in biological activity were mirrored by differences in binding 
of the Fab-s to the immobilized PdVs, further supporting that preservation of a 
solvent-exposed, flexible and hydrophobic CDR-H3 loop apex is required for 
binding and neutralization in the biological context. 
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FIG 33. JRCSF PsV recognition by dot-blot. Decreasing amounts of PsVs (from left to right) 
were spotted onto Hybond C nitrocellulose.  
 
The results in FIG 34 strengthen the conclusion that availability of the 
WT CDR-H3 apex contributes to additional interactions with membrane 
components as previously suggested (Cardoso et al., 2005; Huarte et al., 2008; 
Lorizate et al., 2006; Montero et al., 2012; Sanchez-Martinez et al., 2006b; 
Scherer et al., 2010; Sun et al., 2008). The DNA vaccine candidates, MPER-
TM1 and MPER-PDGFR (Montero et al., 2012), express fusion proteins 
comprising: (i) an N-terminal HA tag, (ii) the MPER, (iii) either the TMD of gp41 
followed by 27-AA of the cytoplasmic domain (TM1), or that of the platelet-
derived growth-factor receptor (PDGFR). These fusions are expressed in the 
context of the plasma membrane, however the PDGFR TMD has been shown 
to reduce exposure of the 4E10 epitope (Montero et al., 2012), and to a lesser 
extent, the 10E8 epitope (unpublished data, N.G.). The titrations shown in FIG 
34A indicate that IgG and Fab WT engaged effectively with the 4E10 epitope 
presented in the context of the plasma membrane (EC50 of ca. 0.1 and 1 nM, 
respectively). By comparison, in the range of measured concentrations, binding 
to MPER-TM1 was negligible for the WDWD and ΔLoop mutants (FIG 34A, 
bottom panels). None of the antibodies bound directly to the plasma membrane 
of cells devoid of an MPER construct (squares and dotted lines), demonstrating 
that the binding scored for the WT IgG and Fab under our experimental 
conditions was strictly dependent on the presence of the MPER epitope. 
4E10 WT
4E10 Δloop 
4E10 WDWD
PG9
(+) (–)
JRCSF PsV 
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FIG 34. Alterations in the CDR-H3 of 4E10 Fab impacts the binding of Fab-s to its 
cognate epitope in the context of the plasma membrane. (A) Cell vesicles displaying the 
MPER-TM1 protein product (solid line), and ‘empty’ control vesicles (dashed lines) were probed 
with 4E10 IgG and Fab-s (WT, WDWD, ∆Loop) at the indicated concentrations. (B) Cell 
vesicles bearing recombinant MPER proteins (MPER-TM1: black bars; MPER-PDGFR: grey 
bars) were probed with 20 nM 4E10 IgG and Fab-s, and 20 nM 17/9 IgG (binds to an HA tag 
located at N-terminus of the MPER constructs and is used to assess cell-surface expression). 
Absorbance values were normalized to the cell-surface expression of the constructs (i.e., 
Absorbance 4E10IgG or Fab-s/Absorbance 17/9IgG). (C) Binding of 20 nM 4E10 IgG and Fab-s to 
recombinant gp41, the MPER667-683-peptide, and assay controls (‘empty’ 293T cell lysates, BSA 
and ovalbumin). For all experiments, absorbance at 405 - 490 nm was recorded. Error bars 
represent standard error of the mean. The data shown are from one of two (FIG34C and D) or 
three (FIG34A) experiments, all of which gave similar results. 
 
A previous work (Montero et al., 2012) showed that, in comparison to the 
MPER-TM1 construct, binding of 4E10 IgG to the MPER-PDGFR construct was 
significantly reduced; this was also observed to a lesser extent for the bNAb, 
10E8, whose epitope overlaps with that of 4E10 (unpublished data; N.G. & 
J.K.S.), but not for bNAb 2F5 (Ofek et al., 2010), whose epitope is on the N-
terminal helix of the MPER (Montero et al., 2012) These results reflect the 
ability of the TMD to affect the positioning of bN epitopes in the C-terminal helix 
of the MPER, but not in its N-terminal helix. The binding of the WT and mutant 
Fab-s, particularly the ΔLoop Fab, to the MPER-TM1 and MPER-PDGFR 
constructs was assessed in relation to 4E10 IgG. FIG 34B shows that, as 
A B
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expected, binding to the MPER-PDGFR construct by the 4E10 IgG and WT Fab 
was significantly reduced, whereas the mutant WDWD and ΔLoop Fab-s bound 
negligibly to both constructs. The influence of membrane was finally inferred 
from control ELISAs performed using recombinant gp41 ectodomain or 
MPER667-683 peptide adsorbed to plates (FIG 34C). Experiments in the absence 
of membranes showed for the three Fab-s comparable levels of binding to 
these antigens, which do not correlate with their neutralizing capacities 
(Table 3). 
 
4.4. DISCUSSION 
 
The HIV-1 bNAbs isolated to date provide templates for rational vaccine 
design, facilitate the understanding of immune pathways and molecular 
processes that confer broad protection, and constitute the basis for 
immunotherapies with the potential to effectively prevent and treat HIV-1 
infection (Burton and Mascola, 2015; Klein et al., 2013b; Kwong and Mascola, 
2012). The 4E10 bNAb targets the conserved MPER C-terminal helix and 
displays near pan-neutralizing activity in standard panels of HIV strains and 
isolates (Binley et al., 2004; Huang et al., 2012; Kunert et al., 1998; Muster et 
al., 1994; Muster et al., 1993; Purtscher et al., 1994; Stiegler et al., 2001). Thus, 
4E10 constitutes a bNAb model particularly useful to study the molecular basis 
underlying HIV neutralization breath mediated through MPER recognition. 
 
The neutralizing activity of 4E10 is strictly dependent on aromatic 
residues of the CDR-H3 loop (Alam et al., 2009; Scherer et al., 2010). Here, we 
have studied the mechanistic basis of this requirement by characterizing 
structurally and functionally WDWD and ΔLoop, two Fab variants mutated at the 
critical apex region of the CDR-H3 loop. Thus, we have performed 
crystallographic, kinetic and thermodynamic studies on neutralization-active and 
neutralization-inactive Fab-s, and compared their 4E10-epitope binding 
mechanisms at the molecular level. The recombinant Fab-s were obtained by 
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heterologous expression in the cytoplasm of E. coli, avoiding aberrant forms 
that may occur upon refolding of inclusion bodies. 
 
The crystal structures of 4E10 Fab WT, WDWD and ΔLoop determined 
in complex with the epitope-peptide revealed combining sites and bound helical 
peptides essentially indistinguishable from each other (FIG 25). From these 
results, we have concluded that mutations in the CDR-H3 apex abolishing 
neutralization neither affect the collective set of interactions between Fab and 
the peptide (FIG 26 and Table S1-S3), nor change the configuration of the 
proposed lipid-binding subsite in significant ways (not shown). The only visible 
differences were restricted to the CDR-H3 loop apex, which remains exposed to 
solvent, i.e., does not contact the bound peptide (FIG 25). The mutated loop 
region in WDWD displays essentially the same conformation as that in WT Fab 
and very similar interactions (BSA and H-bond pattern) despite the large 
differences in the loop hydrophobicity (FIG 26 and Table S1-S3). In contrast, 
the backbone of the shorter loop of ΔLoop approaches the helical peptide as a 
result of the deletion of two residues of the CDR-H3 apex (FIG 25), thereby 
strengthening an H-bond between the Fab and Trp680 of the peptide (FIG 26 
and Table S1). Thus, the structural data demonstrate that an antibody bearing a 
short and non-hydrophobic CDR-H3 loop is capable of engaging with the helical 
MPER epitope as much or even more effectively than the WT Fab. These 
observations may have important implications for the design of anti-MPER 
vaccines. 
 
It has been proposed that the long CDR-H3 loop enhances paratope 
flexibility to effectively capture the membrane-inserted MPER (Montero et al., 
2012) by means of an induced-fit mechanism. Consistent with this idea, 
crystallographic studies on the unliganded 4E10 variable domain Fv revealed 
large conformational changes of CDR-H1 and, more prominently, of CDR-H3 
(FIG 30B). The position of CDR-H3 in the unliganted Fv shields the epitope-
binding pocket, creating an electropositive and unspecific lipid-binding subsite 
(Finton et al., 2014; Finton et al., 2013; Xu et al., 2010), but different from that 
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later proposed by Bird et al. (Bird et al., 2014; Irimia et al., 2016).  Based on the 
structural data obtained with the Fv fragment, it was proposed that a large 
portion of the CDR-H3 undergoes a large conformational change from the 
unbound to the bound state. If this was the case, mutations blocking the 
neutralizing activity could also impact the conformational equilibrium of the 
CDR-H3 in the unbound form, and thus alter the overall epitope-binding function 
of the paratope. 
 
In contrast to that prediction, the binding affinities of MPER(671-683) 
peptide at equilibrium for the three Fab-s were strikingly similar (FIG 28A and 
Table 5). Similarly, the free energy changes at the rate-determining step 
(transition state) of the three versions of the Fab were nearly identical to each 
other (FIG 28B and Table 5). Given the differences in size and polarity of CDR-
H3 in WT and mutated Fab-s, this result does not support a major restructuring 
of the loop during the activation stage of peptide binding. 
 
To tackle the disagreement between the reported unliganded structure of 
the Fv fragment (Finton et al., 2013), and our thermodynamic data obtained 
with a Fab construct, we determined the crystal structure of WT Fab in the 
absence of peptide. Consistent with the thermodynamic analysis, the crystal 
structure of the ligand-free 4E10 Fab displayed a paratope structurally similar to 
that found in the solved Fab-peptide complexes (FIG 29 and 30). 
Notwithstanding the overall similarity, higher degree of dynamic disorder was 
detected at the CDR loops implicated in peptide binding in the ligand-free Fab 
(FIG 29 and 31). Specifically, peptide engagement reduced the mobility of 
CDRs H1, H2, H3, and L3 to a noticeable extent. The flexibility of the CDR-H3 
loop, critical for neutralization, decreased markedly although we note that 
significant residual disorder remained in its apex region even in the presence of 
bound peptide. In contrast, the flexibility of CDRs L1 and L2 did not change 
significantly between bound and unbound forms of the Fab. These findings 
support the crystal structure of the peptide-free Fab described in our work and 
 98 
observed by Wilson et al (Irimia et al., 2016) as a relevant reference to describe 
the conformation of 4E10 Fab in the unliganded state. 
 
Thus, the kinetic, thermodynamic and structural data gathered herein 
indicated limited conformational changes of the Fab upon epitope binding 
(essentially the immobilization of certain CDR loops), suggesting a flexible lock-
and-key binding mechanism. The underlying reason explaining the 
conformational differences between the CDR-H3 (and CDR-H1) in the unbound 
forms of the short Fv and the longer Fab constructs (movement of backbone 
atoms of up to 14 Å in WH100 ((Finton et al., 2014; Finton et al., 2013), FIG 30B) 
was not clarified at this time. We suggest that the difference could be explained 
by the low pH required to crystallize the Fv construct (pH 4.6) and/or to different 
structural stabilities of these two specimens. In the unbound structure of Fv, the 
residues of the CDR-H3 move towards the empty pocket of the peptide-binding 
site, establishing numerous hydrophobic contacts with other CDR-H3 loops of 
other molecules of the asymmetric unit, and thus achieving maximum stability 
and minimizing their exposure to the low pH environment of the aqueous 
solution (Finton et al., 2013). In contrast, although the crystal structures of 
unbound and bound forms of Fab were obtained each in a different space group 
(thus experiencing different structural constraints and packing forces), the CDR-
H3 loop remains in a similar conformation. In addition, the thermal stability (as 
judged from the TM values) for the smaller 4E10 Fv fragments (TM = 52 ºC, 
(Finton et al., 2014)) is significantly lower than those of the Fab fragments (TM = 
~70 ºC, FIG 27). Therefore the combination of lower stability, extreme 
crystallization conditions, and crystal packing forces may all have induced a 
non-native conformation of the CDR-H3 loop in the crystal structure of the Fv 
fragment. 
 
It has been speculated that length, hydrophobicity and conformational 
flexibility of the 4E10 CDR-H3 loop apex may govern the interactions with the 
viral membrane (Cardoso et al., 2007; Cardoso et al., 2005). The structural and 
thermodynamic results obtained with WDWD formally demonstrate that length 
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and flexibility are not sufficient to elicit viral neutralization. Thus, maintaining an 
accessible hydrophobic patch at the apex of the flexible CDR-H3 emerges as a 
stringent requirement for the neutralizing activity of 4E10. Assuming that a 
common mechanism (i.e. conformational stabilization) applies to all CDR loops 
involved in binding, the high mobility of CDR-H3 indicates the existence of yet 
additional interactions with antigen that are not satisfied by contacts with 
MPER(671-683) peptide in solution. 
 
The Fab binding activity in dot-blot and cell-lysate ELISA supports the 
idea that additional CDR-H3 interactions can be fulfilled in the context of the 
membrane (FIG 33 and 34). In the cell lysate ELISA, the MPER-TM1 construct 
was employed to constrain the MPER and position it on the membrane surface. 
In contrast to what was observed for MPER(671-683) binding in solution, the 
capacity of the Fab-s to bind MPER-TM1 was correlated with their neutralization 
activity. Because the range of concentrations allowing for effective Fab-MPER-
TM1 binding was sufficiently low, direct association with membranes was 
negligible, as reflected by the lack of binding to “empty” cell lysates (FIG 34). 
Importantly, binding by WT 4E10 IgG and Fab to the MPER-PDGFR construct 
was weak relative to MPER-TM1 (FIG 34). As the PDGFR TM region has been 
shown to improperly constrain the MPER (Montero et al., 2012), this result 
supports the necessity of proper tethering by the TMD to optimally expose the 
MPER in the context of the plasma (or viral) membrane. Thus, overall, results 
from this and previous cell-lysate ELISAs (Montero et al., 2012) strongly 
suggest that the hydrophobic CDR-H3 loop enables direct binding to an MPER 
epitope that achieves its neutralization-competent antigenic structure through 
membrane insertion and tethering via an appropriate TMD (Huarte et al., 2008; 
Lorizate et al., 2006; Montero et al., 2012; Montero et al., 2008; Sun et al., 
2008). 
 
Together with the realization that antibodies bearing shorter and less 
hydrophobic CDR-H3 loops may display equal or even higher affinity towards 
peptides like MPER(671-683), these findings should have important implications 
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for anti-MPER vaccine development. Moreover, our results also suggest that a 
vaccine devoid of lipid might elicit high-affinity antibodies against the MPER C-
terminal helix. However, since antibodies with short-polar CDR-H3 loops are 
arguably easier to produce, the generated responses are likely to comprise 
non-neutralizing antibodies for the most part. On the other hand, accessibility to 
the MPER epitope inserted in membranes appears to correlate with the 
neutralization competence for 4E10-related antibodies. Taken together, the 
data presented here further support the vaccine-design strategy of replicating 
the neutralization-competent structure of the MPER on the viral membrane 
surface to elicit HIV-1 neutralizing antibodies. 
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4.5. SUPPLEMENTARY DATA 
 
Table S1. Hydrogen bonds between 4E10 and MPER(671-683. 
  WT ΔLoop WDWD 
Residue1 Residue 2 Distance (Å) 
H-Ile56 Pep-Trp672 3.21 3.32 3.23 
H-Glu95 Pep-Thr676 2.50 2.61 2.64 
H-
Leu100Ca 
Pep-Trp680 
3.30 2.73 3.31 
L-Tyr91 
Pep-
Asn671 2.93 2.97 2.93 
L-Ser94 Pep-Trp672 2.91 2.96 2.91 
L-Ser94 
Pep-
Asn671 3.30 3.39 3.33 
L-Lys32 
Pep-
Asp674 2.80 2.77 2.81 
aIn ΔLoop this residue corresponds to Gly100A. 
 
 
Table S2. Interaction surface between the LC of 4E10 Fab-s and MPER(671-683). 
 WT WDWD ΔLoop  
Residue BSA (Å2) 
L-Asn30 9.2 11.9 11.4 
L-Lys32 28.6 29.8 27.7 
L-Gln89 3.8 3.7 4.0 
L-Tyr91 38.2 38.6 38.9 
L-Gly92 13.5 13.2 14.1 
L-Gln93 12.5 14.8 14.7 
L-Ser94 58.5 57.4 56.7 
L-Ser96 12.5 12.4 12.8 
Subtotal 177 182 180 
Pep-Asn671 62.9 64.4 60.9 
Pep-Trp672 22.3 22.3 23.4 
Pep-Phe673 80.1 79.5 79.5 
Pep-Asp674 32.9 34.1 34.1 
Subtotal 198 200 201 
TOTAL 375 382 381 
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Table S3. Interaction surface between the HC of 4E10 Fab-s and MPER(671-683. 
 WT WDWD ΔLoop 
Residue BSA (Å2) 
H-Ser28 0 8.0 0 
H-Thr31 46.9 51.3 44.6 
H-Tyr32 6.2 7.1 2.9 
H-Ala33 25.5 24.2 25.7 
H-Leu34 0 0.2 0.2 
H-Ser35 7.5 7.8 7.6 
H-Trp47 17.9 18.6 17.3 
H-Gly50 6.7 7.2 7.3 
H-Val51 1.8 2.2 2.0 
H-Ile52 56.9 59.1 56.9 
H-Leu53 35.4 9.0 34.9 
H-Leu54 30.0 34.5 32.2 
H-Ile56 26.4 27.9 27.2 
H-Thr57 0.4 0.7 0.5 
H-Asn58 53.7 53.7 52.7 
H-Glu95 13.6 13.2 13.1 
H-Leu100Ca 12.5 12.2 23.6 
H-Gly100D 7.4 7.4 6.7 
H-Lys100E 59.4 61.0 56.9 
H-Pro100F 55.4 55.8 57.8 
H-Gly100H 27.7 27.8 28.0 
H-Phe100J 13.1 12.8 13.7 
Subtotal 504 501 512 
Pep-Trp672 160.1 160.9 161.1 
Pep-Phe673 78.3 79.9 79.3 
Pep-Ile675 38.7 35.5 41.8 
Pep-Thr676 97.5 94.7 94.9 
Pep-Asn677 44.8 48.9 45.3 
Pep-Trp678 9.4 0 11.9 
Pep-Leu679 54.7 66.3 56.7 
Pep-Trp680 89.0 85.8 95.9 
Pep-Lys683 35.8 31.0 31.5 
Subtotal 608 603 618 
Total 1,113 1,104 1,130 
aIn ΔLoop this residue corresponds to Gly100A. 
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5.1. INTRODUCTION 
 
The 10E8 antibody achieves potent and broad HIV-1 neutralization by 
targeting MPER within gp41 (Huang et al., 2012; Kim et al., 2014). It appears 
that this potency is developed after extensive somatic hypermutation of the 
heavy-chain complementarity determining regions 2 and 3 (CDR-H2 and CDR-
H3, respectively) (Soto et al., 2016). The exceptionally high degree of 
conservation of the MPER sequence (Montero et al., 2008; Zwick, 2005) 
justifies immunotherapeutic approaches based on the 10E8 antibody (Asokan 
et al., 2015; Barbian et al., 2015; Kwon et al., 2016a; Pegu et al., 2014; van Gils 
and Sanders, 2014). Supporting its functional activity in vivo, 10E8 confers 
complete protection to rhesus macaques against infection by a simian 
immunodeficiency virus–HIV chimera (Pegu et al., 2014). Remarkably, the 
10E8 antibody is less effective than many anti-gp120 antibodies in 
neutralization assays, but provides the strongest protection in vivo (van Gils and 
Sanders, 2014). Also, consistent with a higher degree of cross-reactivity, 10E8 
neutralizes SIVs that infect chimpanzees and gorillas with nanomolar potency 
(Barbian et al., 2015), surpassing the efficacy of other bNAbs directed against 
different vulnerability regions on Env. Engineered versions of the 10E8 with 
improved solubility have been recently reported (Kwon et al., 2016a), a finding 
that broadens the therapeutic potential of this bNAb (Asokan et al., 2015; Pegu 
et al., 2014). 
 
In addition, the advantageous properties of 10E8 could be employed for 
the development of anti-HIV-1 vaccines (Burton and Mascola, 2015; Kwong and 
Mascola, 2012; Montero et al., 2008; Zwick, 2005). However, an important 
hurdle in this research effort is the observation that the functional properties of 
10E8 are not adequately explained by its binding properties to MPER epitope 
peptides (Huang et al., 2012; Kim et al., 2014). In comparison to other MPER-
specific neutralizing antibodies, 10E8 exhibits greater potency (mean IC50 value 
below 1 µg/mL) and lacks the lipid binding and auto-reactivity properties 
previously thought to limit the usefulness of MPER in the conception of an 
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effective HIV-1 vaccine (Huang et al., 2012). However, 10E8 binding affinities 
have been reported to be lower than those of the less-potent neutralizing 
antibodies, 2F5 and 4E10 (Huang et al., 2012). Thus, the comparatively poor 
performance of 10E8 remains at odds with the expectation that tight binding 
between antibody and epitope underpins the potent biological activity of this 
antibody, either by stabilizing the MPER domain in a conformation that is 
incompatible with membrane fusion, or by ensuring the full occupancy required 
to completely inactivate Env trimers (Kim et al., 2014). 
 
Moreover, some mutations in 10E8’s CDR-H3 affect viral neutralization 
more strongly than binding to MPER (e.g. W100bHCA), whereas other mutations 
reduce binding significantly without markedly affecting the neutralizing activity of 
the antibody (e.g. Pro100fHCAla) (Huang et al., 2012). Inspection of the crystal 
structure of the 10E8 Fab in complex with MPER(656-683) peptide further reveals 
this incongruity (Huang et al., 2012). The quantification of the interaction 
surface at the apex of the CDR-H3 loop (Trp100bHC) performed with PISA 
indicated that only a small fraction of the surface of this residue (<15 %) directly 
contacts the peptide, whereas the majority of it remains exposed to the solvent. 
This observation could explain why substitutions of this residue do not abrogate 
engagement to MPER peptide; however they do not explain its critical role in 
neutralization. These puzzling observations have obscured the underlying 10E8 
mechanism of action, and have thwarted a faithful definition of the antigen 
structure mediating the biological activity of this important antibody. 
 
In this study, we have elucidated the structure of the 10E8 Fab in 
complex with a peptide antigen whose affinity has been optimized by the 
addition of native residues belonging to the gp41 TMD (MPER(664-690)) (Apellaniz 
et al., 2015). The dissection of the structural and energetic factors governing 
the recognition of the epitope in membrane environments explains the potent 
neutralization capabilities of the antibody. The full-length Env trimer in complex 
with 10E8 has been recently solved by cryo-EM (Lee et al., 2016). However, the 
limited resolution (8.8 Å) limited the atomistic understanding of the interactions 
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happening between antigen and antibody. Our structural, energetic and 
functional data clarifies critical aspects of the mechanism of recognition of the 
epitope of 10E8 in membranes in light of the cryo-EM structure reported (Lee et 
al., 2016), and also previous studies (Bird et al., 2014; Huang et al., 2012; Irimia 
et al., 2016; Kwon et al., 2016a). We propose that the helical scaffold of the 
MPER/TMD region of gp41, strengthened by nonpolar interactions with 
membrane lipids, is of biological relevance for the generation of potent anti-
MPER bNAbs. 
 
5.2. MATERIALS AND METHODS 
 
5.2.1. Materials 
 
The peptides used in the structural and affinity studies were synthesized 
as described in 3.2.1. Vector pEVOL, encoding a tRNA synthetase suitable for 
the incorporation of the photoreactive amino-acid, p-benzoylphenylalanine 
(pBPA), was a gift from Prof. P. G. Schultz (The Scripps Research Institute), 
and, pBPA was purchased from Bachem. 4-Chloro-7-Nitrobenz-2-Oxa-1,3-
Diazole (NBD) was from Molecular Probes. The rest of the plasmids and 
antibodies were obtained as indicated in 4.2.1. 
 
5.2.2. Fab-s production and characterization. 
 
Experimental procedures described in 3.2.2 and 4.2.2 were followed for 
the mutation, expression and purification of Fab-s. ITC and DSC measurements 
were carried out as described in 3.2.3 and 4.2.5, respectively. For thermal 
stability determination in the presence of the ligand, the complex was formed by 
the addition of the peptide at a molar ratio of ~1:1.5 (Fab:peptide). Antibody 
binding to PsVs and 293-T lysate cells expressing DNA constructs encoding the 
MPER-TM1 or the MPER-PDGFR (see section 4.2.8 for sample production) 
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was assessed as previously described in 4.2.7 and 4.2.9, respectively. PsV 
neutralization was performed as described in section 4.2.10. 
 
5.2.3. Crystallization of 10E8 Fab-peptide complex 
 
Crystals of the complex between 10E8 Fab (3 mg L-1) and the peptide 
MPER(664-690) added at a molar ratio of ~1:1.5 (Fab:peptide) in the presence of 
2.5 mM DPC were grown in a solution of 50 % (v/v) 2-methyl-2,4-pentanediol, 
200 mM phosphate, and 100 mM TRIS (pH 8.5) at 20 °C. A single protein 
crystal was harvested and stored in liquid nitrogen until data collection at the 
synchrotron. Data collection, processing and structure calculations are 
described in 3.2.5. The previous crystal structure of 10E8 (PDB entry code 
4G6F) was used as a model to determine the structure by the method of 
molecular replacement. The relative angle between 4E10 (PDB entry 4XBG) 
and 10E8, as well as other calculations were carried out with CHIMERA 
(Pettersen et al., 2004). Data collection and refinement statistics are 
summarized in Table S4. The phosphate groups were modeled based on five 
conditions: (i) The difference electron density fo-fc and 2fo-fc maps showed 
strong electron density features before the phosphate moiety was modeled. 
Typical σ values for the fo-fc map were 4.7-8.2. Typical σ values for the 2fo-fc 
map were 2.0-3.3. (ii) When modeled, the phosphate ions engaged in non-
covalent interactions with the neighboring residues. (iii) A water molecule could 
not properly account for the electron density (see below). (iv) A water molecule 
modeled at the position of the phosphorous atom could not engage in H-bonds 
with neighboring residues. (v) Other molecules present in the solution like TRIS, 
2-methyl-2,4-pentanediol, DPC, or glycerol did not seem to fit the electron 
density.  
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5.2.4. pBPA photo cross-linking assays 
 
For the photo cross-linking experiments, an amber codon specific for an 
engineered tRNA that translates the unnatural amino acid, p-
benzoylphenylalanine (pBPA), was genetically encoded in the DNA sequence 
of the 10E8 Fab. Procedures to express a 10E8 Fab mutein bearing pBPA 
instead of Trp at position 100bHC were adapted from previous reports (Abe et 
al., 2012; Young et al., 2010). Synthesis of Fab and the engineered tRNA was 
induced with 0.4 mM IPTG and 4 % (w/v) arabinose, respectively, in LB medium 
supplemented with 0.2 mg/L pBPA. For the photo-cross-linking experiment, 
samples containing Fab bearing the W100bHCpBPA substitution at 1.5 µM and 
peptides at 10 µM were irradiated with UV light at 365 nm for 20 min at 4 °C 
using a UVP B-100AP lamp. Peptide binding in solution and in lipid membranes 
was accomplished in the presence of 5 mM of DPC or 1.5 mM of large 
unilamelar vesicles (LUVs), respectively. The LUVs were composed of 1,2-
dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), 1,2-dioleoyl-sn-glycero-3 
phosphatidylethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3- 
phosphatidylserine (DOPS), and egg sphingomyelin (SM) (27:29:14:30, mole 
ratio), and were produced by extrusion through two stacked polycarbonate 
membranes with a nominal pore size of 0.1 µm (Nuclepore Inc.). Fab heavy-
chain-peptide adducts were separated by SDS-PAGE and stained with 
Coomassie blue. Alternatively, they were identified by WB using a sandwich 
comprising a goat (anti-human Fab) antibody (Sigma) and a mouse (anti-goat) 
antibody-HRP conjugate (Santa Cruz).  Photo-cross-linked products were 
monitored using an LAS-4000 image analyzer (GE Healthcare).  
 
5.2.5. NBD-Fab fluorescence measurements 
 
Labeling the Fab with the polarity-sensitive NBD probe was performed as 
described previously (Heuck et al., 2000; Shepard et al., 1998). In brief, a 
cysteine-substituted Fab mutant (W100bHCC) was first generated by site-
directed mutagenesis as described in 4.2.2, then the mutated Fab was 
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produced and modified with a sulfhydryl-specific iodoacetamide derivative of 
NBD. Fluorescence-emission spectra were recorded with the excitation 
wavelength fixed at 470 nm. An emission spectrum of a sample lacking the 
fluorophore was subtracted from the spectrum of the equivalent sample 
containing the fluorophore. Fluorescence spectra of NBD were obtained upon 
incubation of NBD-labeled Fab (0.5 µM) with liposomes composed of 
DOPC:DOPE:DOPS:SM (27:29:14:30 mole ratio, total lipid concentration 
250 µM) containing increasing amounts of peptide MPER(671-686) (1.7 and 
6.8 µM) or MPER(671-693)  (0.2, 0.65, 1.7, 3.4, and 6.8 µM) termed H(686) and 
H(693), respectively.  
 
5.3. RESULTS 
 
5.3.1. Design and characterization of an optimized peptide epitope 
for 10E8. 
 
The existence of the continuous H2 α-helix at the MPER/TMD junction 
(FIG 35A) (Apellaniz et al., 2015), forced to revise models which had assumed 
that the interfacial MPER helix bends at position Lys683 to promote the 
insertion of the TMD perpendicular to the plane of the membrane (Dennison et 
al., 2009; Huarte et al., 2008; Kim et al., 2013; Lorizate et al., 2006; Schibli et 
al., 2001; Sun et al., 2008). We hypothesize that peptides that conserve the 
continuous helical MPER/TMD domain might function as a helical scaffold to 
increase the affinity of antibodies targeting the C-terminal subregion of the 
MPER as shown in chapter 3. We therefore designed the MPER(664-690) peptide, 
KKKK-664DKWASLW-NW-FDITNWLWYIKLFIMIVG690-KKKKK, to cover the 
entire length of the H1-H2 helices (FIG 35B), and to include all the residues 
reported to establish contacts with the antibody (in bold, (Huang et al., 2012)). 
We postulated that, in the context of a membrane environment, this elongated 
peptide constitutes the bona fide antigenic structure recognized by the antibody 
at membrane interfaces. 
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FIG 35. MPER(664-690) peptide design and binding energetics to Fab 10E8 in membrane 
mimicking environments. A) Structural elements of gp41. The ectodomain pre-fusion 
structure of gp41 (PDB entry 4TVP) is depicted in a ribbon and tube representation above the 
diagram illustrating the relative positions of the most important constituents in the sequence. 
The ribbon structure below the diagram was modeled by superposing the NMR structures of 
MPER(656-683) and MPER(671-690) peptides solved in DPC micelles (PDB entries 2M8O and 
2MG3, respectively), and supports the existence of two distinct helical segments: H1 and H2. 
B) Env sequence covered by the MPER(664-690) peptide. C) Binding isotherm of the MPER(664-690) 
peptide to Fab 10E8 as measured by ITC. The thermodynamic parameters of binding are listed 
in Table 7. D) Thermal stability of the Fab-peptide complex by DSC. DSC thermograms (dotted 
lines) and curve fitting (solid lines) for 10E8 Fab before (black) and after titration with peptide 
(blue) are shown. Unfolding of the Fab shows a single thermal transition in both cases. The 
midpoints of the thermal unfolding (TM) and the associated enthalpies (ΔH) are given. 
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environment, high-resolution thermodynamic techniques in the presence of 
DPC micelles were employed (FIG 35C and D). Titration of 10E8 Fab with 
MPER(664-690) produced a high-affinity value of 9.6 ± 1.0 nM (FIG 35C and Table 
7). The binding free energy (ΔG° = −10.9 ± 0.1 kcal mol-1) resulted from 
favorable non-covalent interactions between peptide and antibody (ΔH° = −9.6 
± 0.1 kcal mol-1), and also from the entropic component, which contributed little 
but favorably to the affinity (−TΔS° = −1.3 ± 0.2 kcal mol-1). 
 
Table 7. Thermodynamic parameters of binding of Fab 10E8 to the peptide MPER(664-690) 
and peptides based on Helix 2. Peptides H2(683), H2(686), H2(690) and H2(693) 
corresponds to MPER(671-683), MPER(671-686), MPER(671-690), and MPER(671-693), respectively.  
Peptide KD 
(nM) 
ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
-TΔS° 
(kcal mol-1)a 
nb 
MPER(664-690) 9.6 ± 1.0 −10.9 ± 0.1 −9.6 ± 0.1 −1.3 ± 0.2 1.0 ± 0.1 
H2 (683) 746 ± 307 −8.3 ± 0.3 −3.3 ± 0.3 −5.0 ± 0.6 0.9 ± 0.1 
H2 (686) 369 ± 84 −8.7 ± 0.1 −9.6 ± 0.5 0.9 ± 0.6 0.9 ± 0.1 
H2 (690) 10 ± 1.6 −10.9 ± 0.1 −8.4 ± 0.1 −2.5 ± 0.2 0.8 ± 0.1 
H2 (693) 9.4 ± 2.0 −10.9 ± 0.1 −9.0 ± 0.1 −1.9 ± 0.2 1.3 ± 0.1 
a Temperature was 298 K. 
b n refers to the molar ratio peptide/protein. 
 
The thermal stability of the Fab in the presence and absence of 
MPER(664-690) was examined by differential scanning calorimetry (DSC) (FIG 
35D). The data clearly demonstrated that the antibody is greatly stabilized in the 
complex with peptide with respect to the unbound form. The melting 
temperature (TM, representing the unfolding mid-point) for the complex 
increases remarkably with respect to that for the unbound form of the Fab (ΔTM 
= 7.7 ± 1.0 ºC). In addition, the unfolding enthalpy (ΔH°DSC) of the Fab was 
significantly increased upon formation of the complex with the peptide (ΔΔH° = 
225 kcal mol-1). Thus, the thermodynamic analysis indicates that the MPER(664-
690) peptide binds with high-affinity and specificity to the Fab in the presence of 
DPC micelles. 
 
 
 
 
 Results 
Chapter-5- 
 113 
5.3.2. Crystal structure of MPER(664-690) peptide-10E8 Fab complex 
 
The X-ray crystal structure of the complex between peptide and Fab in 
the presence of DPC micelles was determined at 2.4 Å resolution (FIG 36A and 
Table S4). The model comprised residues 1-215 (HC) and 2-210 (LC) of the 
Fab, and residues 669-689 of MPER(664-690) peptide. Residues 664-668 of the 
peptide were not observed in the electron density because of dynamic disorder, 
consistent with the idea that the H1 helix is not essential for the recognition of 
Env by this antibody (FIG 36B-E and 37A) (Huang et al., 2012; Kwon et al., 
2016a; Lee et al., 2016). The region H2 adopted a helical conformation, which 
is very well conserved among all the structures available for 10E8 (Huang et al., 
2012; Kwon et al., 2016a) (FIG 37A). The last residue of the H2 region of 
MPER(664-690), Gly690, and the additional Lys residues flanking the sequence of 
the peptide were not observed in the electron density, reflecting dynamic 
disorder. Interestingly, with respect to the previous structure with MPER(656-663) 
epitope bound (Huang et al., 2012), the antibody exhibited an unusually large 
degree of flexibility at the elbow region between the variable and constant 
regions (FIG 37B) (Stanfield et al., 2006). The flexibility of the elbow region 
could facilitate the accessibility of the native gp41 epitope, being partially 
restricted by the gp120 component of Env and by the viral membrane (Huang et 
al., 2012; Lee et al., 2016). 
 
The bound peptide adopts a canonical α-helix throughout the sequence, 
except for residues at the N-terminal region 669LWN671 (FIG 36C and D). No 
evidence of a kink at position Lys683 was found, in agreement with previous 
NMR results (Apellaniz et al., 2015). The 10E8 Fab is perfectly adapted to 
recognize the α-helical structure of the peptide as evidenced by the high value 
of the shape-complementarity parameter (Sc = 0.79) (Lawrence and Colman, 
1993). The epitope is held tightly to the antibody by numerous contacts 
between a large patch of non-polar residues at both the CDR-H3 of the Fab and 
the peptide, and by H-bonds between main-chain atoms of the antibody and 
critical residues Trp672 and Lys683 of the peptide (Table S5 and S7). 
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FIG 36. Crystal structure of the complex between Fab 10E8 and MPER(664-690) peptide 
determined at 2.4 Å resolution in the presence of DPC. A) Overall structure of the complex. 
The surface of the heavy and light chains of the Fab are shown in light and dark gray, 
respectively. The MPER(664-690) peptide is depicted as a green helix. The hypothetical location of 
the viral membrane is shown (see FIG 40 for more details). B) Sigma-A weighted electron 
density map (blue mesh) of MPER(664-690) peptide bound to the Fab at a contouring level of σ = 
1.0. The peptide is depicted as green sticks. Numerous peptide hydrophobic residues (labeled) 
remain exposed even after engagement with the Fab. C) H-bond network between peptide and 
Fab. Bond distances are shown. The peptide and Fab are depicted in green and gray sticks, 
respectively. D) Interaction surface between peptide and Fab. The majority of interacting 
residues are non-polar. E) Comparison of the conformation of MPER(656-683) peptide (PDB entry 
4G6F) and the optimized peptide (this study) bound to 10E8. The Fab and peptide from the 
previously published structure are depicted in magenta and orange, respectively. The Fab and 
peptide from this study are shown in light gray and green, respectively. Side-chains of residues 
Phe100aHC and Trp100bHC of the Fab, and Ile686 and Met687 of the peptide are depicted to 
illustrate additional interactions. 
 
The interaction area between Fab and MPER(664-690) peptide covers only 
31 % of the surface of the peptide as calculated with the PISA server, leaving 
numerous aromatic and hydrophobic residues prone to interact with other 
A B
C D E
MPER(664-690) 
MPER(656-683) 
MPER(664-690) MPER(664-690) 
M
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peptide moieties in the crystal. The assembly of peptides at crystal-contact 
regions minimizes the degree of exposure of these hydrophobic residues, 
resembling the organization of a bilayer (FIG 38A). In particular, the two 
juxtaposing MPER-N-TMD helices share an overall organization similar to that 
observed in the recent 3-D reconstruction of Env-10E8 complex at 8.8 Å 
resolution (Lee et al., 2016) (FIG 38B). Consequently, an approximate 
orientation of the Fab-peptide complex with respect to the plane of the 
membrane in the crystal structure can be extrapolated (see also below). 
 
 
FIG 37. Binding properties of 10E8. A) Comparison of the conformation of the peptide bound 
to 10E8 Fab in multiple crystal structures. The peptide bound to the Fab in this study and in 
PDB entries 4G6F, 5IQ9 (two copies) and 5IQ7 are shown in green, orange, blue, yellow and 
magenta, respectively. Residues of the variable region (10-90) of the LC were employed for 
superposition of the structures, achieving RMSD values in the range of 0.19-0.34 Å. The region 
H1 appears in multiple conformations or it is not observed, whereas H2 remains essentially 
unchanged. The crystal structure of the Fab determined in this study is depicted with light (HC) 
and gray (LC) ribbons. B) Domain rotation (elbow angle). Comparison of two structures of 10E8 
Fab with peptide bound. Gray and magenta ribbons correspond to the structure determined in 
this study and with PDB entry 4G6F, respectively. The angle of the constant region with respect 
to the variable region shifts by 34° between the two structures, producing a conformational 
change (swinging-like movement) that is clearly visible in the figure. The elbow angles were 
calculated with the program RBOW. 
 
A C 
MPER(664-690) 
B 
MPER(664(690),
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The unprecedented detail of the structure of the extended region of 
MPER(664-690) peptide (TMD residues 684LFIMIVG690) visualized for the first time 
in the complex with 10E8 reveals that residues Ile686 and Met687 are located 
in the proximity of the crucial residues Phe100aHC and Trp100bHC of the Fab 
(FIG 36E). The combined buried surface area (BSA) of these four residues 
increased by 99 Å with respect to the complex between 10E8 and a peptide 
with a shortened C-terminal region (Table S7). The enlarged interaction surface 
in the complex with the longer peptide is expected to favorably contribute to the 
high-affinity between antibody and antigen. 
 
 
FIG 38. Intermolecular peptide-peptide interactions in the crystal. A) Close-up view of 
several peptides arranged in a micelle-like aggregate in the crystal structure of MPER(664-690) 
bound to Fab. The micelle-like aggregate is made of two pseudo-dimers, and stabilized by 
numerous hydrophobic residues of the peptide not interacting with the Fab. The micelle-like 
aggregate mimics the environment of a biological membrane, and is presumably surrounded by 
detergent molecules (DPC) from the crystallization buffer, although we note that no molecules 
of detergent were observed in the electron density. The approximate region occupied by the 
non-polar residues is indicated by the gray box. B) The X-ray structure of the variable region of 
10E8 in complex with the MPER(664-690) peptide was fitted into the electron density map of 
EnvΔCT-PGT151-10E8 (Entry code EMD-3312). 
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5.3.3. Relevance of the extended region of MPER(664-690) peptide for 
binding 
 
To establish the functional relevance of the interactions between 10E8 
and the helical epitope extending beyond residue Lys683, the peptide epitopes 
H2(683), H2(686), H2(690) and H2(693) lacking the H1 region of MPER were 
generated by progressively adding helical turns to their C-terminus (FIG 39A). 
Titration experiments with these peptides revealed different binding patterns 
depending on the extent of the elongation (FIG 39B and Table 7). The affinity of 
the peptides increased in the order H2(683) < H2(686) ≪ H2(690) ≈ H2(693). 
Importantly, the dissociation constant of the two longest H2 peptides H2(690) 
and H2(693) (10 ± 1.6 and 9.4 ± 2.0 nM, respectively) is comparable within 
error to that of the MPER(664-690) peptide (9.6 ± 1.0 nM), demonstrating that the 
H1 region of MPER does not contribute to high-affinity binding by this antibody. 
The thermodynamic signature is dominated by the large and favorable 
contribution of the enthalpy term, except for the shorter H2(683) peptide in 
which both entropy and enthalpy terms contribute similarly to binding. 
 
To obtain direct evidence about the non-polar contacts between the tip of 
the CDR-H3 and residues downstream position Lys683 of the peptide, we 
carried out photo-cross-linking experiments. The 10E8 Fab was modified with 
the UV-sensitive unnatural amino acid p-benzoylphenylalanine (pBPA) (Abe et 
al., 2012; Young et al., 2010), which was genetically encoded at position 
Trp100bHC of the antibody (FIG 39C). The Fab-peptide complexes were 
subjected to UV light and the formation of adducts analyzed by SDS-PAGE. An 
additional band corresponding to cross-linked peptide and Fab HC was 
observed in samples containing Fab and H2(690) or H2(693), but not with 
H2(683) or H2(686) (FIG 39C). The new band was absent in the Fab:peptide 
samples before irradiation (CTL lane) demonstrating it is specifically generated 
by UV-mediated cross-linking. Thus, inclusion of the full MPER-N-TMD helix 
(H2) sequence enabled additional interactions with the tip of the 10E8 CDR-H3, 
increasing significantly the affinity for the antibody.  
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FIG 39. Binding of peptides spanning Helix-2 to Fab 10E8 in the presence of DPC. A) 
Overview of the sequences of the H2 peptides displaying increasingly elongated C-termini. The 
four peptides differed in the number of consecutive helical turns following position 683. B) 
Binding isotherms of the H2 peptide epitopes to Fab 10E8 examined by ITC. The 
thermodynamic parameters of binding are displayed in Table 7. C) Photo cross-linking between 
Fab 10E8 and the peptides. Chemical structure and schematic mechanism for the formation of 
a covalent bond between Fab-pBPA and peptide upon irradiation with u.v. light (top panel). 
Protein bands were detected by Coomassie-blue staining or by WB using 4E10 antibody 
(center and bottom panels, respectively). The arrows point to the position of the photo-cross-
linked product. (CTL, control 10E8 Fab without peptide). Peptides H2(683), H2(686), H2(690) 
and H2(693) corresponds to MPER(671-683), MPER(671-686), MPER(671-690), and MPER(671-693), 
respectively. 
 
!
H2 (683) H2 (686)  H2 (690)  H2 (693)  b 
c 
a 671NWFDITNWLWYIK683_684LFI686_687MIV689_690GGLV693 
H2 (683) 
H2 (686) 
H2 (690) 
H2 (693) 
-KKK 
  -KKK 
-KKKKK 
-KK 
(CTL) (683) (686) (690) (693) 
(7)(1) (2) (3) (4) (5) (6)
(1) (2) (3)
(1) (2) (3) (4) (5)
1.Ͳ Fab 10E8
2.Ͳ +4E10ep(686)+LUVs
3.Ͳ +4E10ep(693)+LUVs
4.Ͳ +4E10ep(683)
5.Ͳ +4E10ep(686)
6.Ͳ +4E10ep(689)
7.Ͳ +4E10ep(693)
1.Ͳ Fab 10E8
2.Ͳ +4E10ep(686)+LUVs
3.Ͳ +4E10ep(693)+LUVs
1.Ͳ Fab 10E8
2.Ͳ +4E10ep(683)
3.Ͳ +4E10ep(686)
4.Ͳ +4E10ep(689)
5.Ͳ +4E10ep(693)
A 
B 
C 
- 
a 
b 
MPER R
C
10E8ep 
25- 
22- 
30- 
Fab 10E8    
NpreTM      
10E8ep 
+"
#"
+" +"
+"
+"
#" #"
#"
MPER H1-H2 R
UV light 
MPER H1-H2 
C
1. Photo-isomerization 
2. Cross-linking 
M
PE
R
 H
1-
H
2 
M
PE
R
 
25- 
22- 
30- 
0
20
40
60
80
100
120
0.001 0.01 0.1 1 10 100
0
20
40
60
80
100
120
N
eu
tra
liz
at
io
n 
(%
) 
µg/mL 
Fab 10E8    
MPER 
MPER H1-H2 
+"
#"
+" +"
+"
+"
#" #"
MPER H1-H2 R
UV light 
MPER H1-H2 
C
1. Photo-isomerization 
2. Cross-linking 
M
PE
R
 H
1-
H
2 
M
PE
R
 
25- 
22- 
30- 
0
20
40
60
80
100
120
0.001 0.01 0.1 1 10 100
0
20
40
60
80
100
120
N
eu
tra
liz
at
io
n 
(%
) 
µg/mL 
Fab 10E8    
MPER 
MPER H1-H2 
+"
#"
+" +"
+"
+"
#" #"
MPER H1-H2 R
UV light 
MPER H1-H2 
C
1. Photo-isomerization 
2. Cross-linking 
M
PE
R
 H
1-
H
2 
M
PE
R
 
25- 
22- 
30- 
0
20
40
60
80
100
120
0.001 0.01 0.1 1 10 100
0
20
40
60
80
100
120
N
eu
tra
liz
at
io
n 
(%
) 
µg/mL 
Fab 10E8    
MPER 
MPER H1-H2 
+"
#"
+" +"
+"
+"
#" #"
1. Photo-isomerization 2. Cross-linking 
UV light 
MPER H1-H2 R
UV light 
MPER H1-H2 
C
1. Photo-isomerization 
2. Cross-linking 
M
PE
R
 H
1-
H
2 
M
PE
R
 
25- 
22- 
30- 
0
20
40
60
80
100
120
0.001 0.01 0.1 1 10 100
0
20
40
60
80
100
120
N
eu
tra
liz
at
io
n 
(%
) 
µg/mL 
Fab 10E8    
MPER 
MPER H1-H2 
+"
#"
+" +"
+"
+"
#" #"
10 8ep 
10E8ep 
C 
!
H2 (683) H2 (686)  H2 (690)  H2 (693)  b 
c 
a 671NWFDITNWLWYIK683_684LFI686_687MIV689_690GGLV693 
H2 (683) 
H2 (686) 
H2 (690) 
H2 (693) 
-KKK 
  -KKK 
-KKKKK 
-KK 
(CTL) (6 3) (686) (690) (693) 
(7)(1) (2) (3) (4) (5) (6)
(1) (2) (3)
(1) (2) (3) (4) (5)
1.Ͳ Fab 10E8
2.Ͳ +4E10ep(686)+LUVs
3.Ͳ +4E10ep(693)+LUVs
4.Ͳ +4E10ep(683)
5.Ͳ +4E10ep(686)
6.Ͳ +4E10ep(689)
7.Ͳ +4E10ep(693)
1.Ͳ Fab 10E8
2.Ͳ +4E10ep(686)+LUVs
3.Ͳ +4E10ep(693)+LUVs
1.Ͳ Fab 10E8
2.Ͳ +4E10ep(683)
3.Ͳ +4E10ep(686)
4.Ͳ +4E10ep(689)
5.Ͳ +4E10ep(693)
 Results 
Chapter-5- 
 119 
5.3.4. Recognition of the MPER-N-TMD helix at the membrane 
interface 
 
A previous report employing short lipids revealed the orientation of 4E10 
Fab with respect to the plane of the membrane (Irimia et al., 2016). Because 
the bNAbs, 10E8 and 4E10, recognize approximately the same segment of 
MPER, we inferred the relative orientation between antibodies by simply 
superimposing the coordinates of the peptide in the crystal structures (RMSD = 
0.25 Å) (FIG 40A, left). The comparison revealed that the arrangement of 10E8 
Fab is different from that of the 4E10 Fab, with each antibody binding a 
somewhat different face of the peptide; consequently, they approach the helix 
from different orientations with an estimated difference of 30°. According to this 
simple model, 10E8 would approach the epitope from a direction parallel to the 
plane of the membrane.  
 
This model predicts that the variable and constant regions of the 10E8 
LC interact, at least weakly, with the surface of the viral membrane. This 
hypothesis was reinforced by two separate observations from the crystal 
structure (FIG 40A). First, a phosphate ion bound to the CDR-L2 of 10E8 
occupies a similar position to that of a lipid bound to 4E10 (PDB entry 4XBG). 
And second, three phosphate ions, scattered across the constant region of the 
LC, occupy positions consistent with the location of the headgroups of lipid 
molecules. This region of the antibody is expected to sit on the viral membrane 
when bound to Env (Lee et al., 2016). Collectively, the model in FIG 40A 
suggests that the Fab region of the 10E8 antibody approaches laterally to the 
MPER helix, the peptide being inserted obliquely into the lipid bilayer.  
 
 120 
 
FIG 40. Binding to the membrane-inserted epitope. A) Model of the recognition of the 
epitope by 10E8 and 4E10 Fab in membranes. Left: Relative orientation of 10E8 (gray) with 
respect to 4E10 (PDB entry 2FX7, cyan) after superimposing residues 673-678 of the peptide 
bound in both structures (RMSD = 0.25 Å). The lipid molecule bound to 4E10 was obtained 
from the PDB entry 4XCN. Carbon, oxygen and phosphate atoms of the lipid are depicted in 
blue, red and yellow, respectively. Several phosphate ions (red and yellow) bound to 10E8, 
suggesting a putative orientation of the antibody with respect to the surface of the viral 
membrane (dotted line). Inset: Close-up view of the residue Trp100bHC (magenta) of 10E8 
(gray) and the lipid molecule (blue) bound to 4E10 (cyan). Right: Difference electron density 
map at the location of each phosphate (a-d) shown as a green mesh. Difference fo-fc electron 
density map (magenta mesh) was obtained by placing a water molecule at the position of the 
phosphate ion and subsequently refined with REFMAC5. Maps are shown at a contouring level 
of σ = 3. C (see materials and methods). B) Photo-cross-linking of Fab 10E8 with peptides 
H(686) and H(693) inserted in membranes detected by WB. C) Membrane insertion of the 
10E8 CDR-H3 apex. Top panels: Spectra of NBD emission upon incubation of NBD-Fab in 
solution (red traces), with liposomes devoid of peptide (black solid traces) or with LUV-peptide 
complexes with increasing amounts of H2(686) or H2(693) (black dotted traces in left and right 
panels, respectively). Bottom panels: Fractional changes (top) and maximum shifts (bottom) of 
NBD emission deduced from the spectra. The initial fluorescence (F0) was determined from 
NBD-Fab in buffer samples (red traces). Final fluorescence values (F) were measured after the 
addition of LUV-peptide complexes (black traces). Lipid concentration was fixed at 250 µM. 
Means ± S.D. of three independent experiments are represented. The lines correspond to the 
best fit of the experimental values to a hyperbolic function. Peptides H2(686) and H2(693) 
correspond to MPER(671-686), and MPER(671-693), respectively. 
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The orientation of 10E8 Fab with respect to the membrane places the 
CDR-H3 tip immersed into the lipid bilayer. Hence, if the hydrophobic 
interactions with the C terminus of the peptide described above were relevant 
for the activity of the antibody they must occur inside the membrane (FIG 40). 
To test this prediction, we used Fab-s incorporating pBPA, or Fab-s labeled with 
the polarity-sensitive fluorescent probe NBD, and compared their interactions 
with the short H2(686) and long H2(693) peptides inserted in membranes (FIG 
40B and C). In this experiment, we first established conditions for the 
quantitative partitioning of the peptides into large unilamellar vesicles (LUVs) 
(FIG 41). Incubation of the LUV-peptide complexes with 10E8 W100bHCpBPA 
Fab, followed by irradiation with UV-light, generated Fab-peptide adducts in the 
presence of the long peptide H2(693) peptide, but not in the presence of the 
shorter H2(686) (FIG 40B). This experiment corroborated that the interactions 
observed in presence of DPC micelles (FIG 39C) are also reproduced in the 
environment of biological membranes. 
 
To determine the degree of penetration of the CDR-H3 apex of Fab 10E8 
into lipid membranes, Trp100bHC was replaced by Cys, and modified chemically 
by attaching an NBD dye to its sulfhydryl group (Heuck et al., 2000; Shepard et 
al., 1998). The fluorescence intensity of NBD increases and shifts to shorter 
wavelengths upon transferring from an aqueous solvent into the less polar 
environment of the bilayer (FIG S1). Thus, the extent of the interaction between 
the labeled NBD-Fab and the membrane was evaluated by comparing the 
emission of fluorescence of NBD before and after incubation with LUV-peptide 
complexes (FIG 40C). The fluorescence spectrum of NBD did not change 
appreciably upon incubation of the labeled Fab with bare vesicles, or with 
vesicles containing the short H2(686) peptide (FIG 40C). In contrast, incubation 
of Fab with vesicles containing the longer peptide H2(693) enhanced 
fluorescence emission, accompanied by a shift of the maximum towards lower 
wavelengths. Importantly, the changes described correlated with the density of 
H2(693) in the membrane (FIG 40C), and were not observed with vesicles 
decorated with a the H2(693) peptide bearing a double-Ala substitution for 
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residues Trp672 and Phe673 (FIG S1B); this result strengthens the conclusion 
that a change in polarity sensed by the Fab-probe is the consequence of 
specific binding to the H2(693) peptide. Collectively, the results in FIG 40 
suggest that recognition of the epitope in a membrane setting requires the 
interaction with the tip of the 10E8 CDR-H3, an idea that is further reinforced by 
the data from the crystal complex (FIG 36). 
 
 
FIG 41. Peptide-liposome complex formation. A) Incorporation of H2(686) or H2(693) into 
liposomes was determined after flotation of the complexes in a sucrose gradient. Rh-PE-
labeled liposomes and peptides were incubated at the same concentrations as in photo-cross-
linking assays (1.5 mM and 10 µM, respectively) (see section 3.2.4 for more details). B) 
Titration experiments following the changes in peptide Trp fluorescence intensity that occur 
upon membrane insertion. Changes in fractional intensity (top) and maximum emission 
wavelength (bottom) were measured upon incubation with increasing concentrations of lipid 
vesicles. Peptide concentration was 0.5 µM. The lines correspond to the best fit of the 
experimental values to a hyperbolic function. Saturation values indicate that quantitative 
incorporation of peptide can be attained with lipid concentrations higher than 50 µM. Peptides 
H2(686) and H2(693) correspond to MPER(671-686) and MPER(671-693), respectively. 
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5.3.5. Biological activity 
 
We next evaluated binding for 10E8 in membrane-like environments in 
relation to its biological activity by producing 10E8 Fab-s bearing substitutions 
in the critical CDR-H3 loop (Table 8, FIG 42 and 43). Two separated Ala 
substitutions, namely P100fHCA, and W100bHCA, were selected based on 
previous work indicating a lack of correlation between affinity for the peptide 
and neutralization potency (Huang et al., 2012). In addition, Fab 10E8 muteins 
bearing conservative W100bHCY and non-conservative W100bHCD substitutions 
were prepared to determine the role of the aromatic residue, Trp100bHC, in 
optimizing the Fab-antigen hydrophobic contact surface (Table S7). 
 
 
FIG 42. MPER(664-690) peptide binding to CDR-H3 10E8 Fab mutants by ITC. A) Binding of 
Fab mutants with Ala substitutions P100fHCA and W100bHCA, reflecting higher affinity of the 
former (Table 8), and correlating with its higher neutralization potency (FIG 43C). B) Effect of 
substitutions at position 100bHC critical for neutralization. The Fab containing the conservative 
W100bHCY substitution displayed the highest affinity (Table 8), which also correlated with its 
comparatively higher neutralizing activity (FIG 43C). 
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Titration of the muteins with peptide in solution (FIG 42 and Table 8) 
revealed diminished affinity for the MPER(664-690) peptide between 5- and 39-
fold. The experimental order of affinities was WT > W100bHCY > P100fHCA > 
W100bHCA ≈ W100bHCD. Examination of the thermodynamic parameters did not 
clarify the energetic mechanism behind the loss of affinity, although we note 
that in all cases the weaker binding was still governed by a favorable change of 
enthalpy (ΔH < 0 kcal mol-1). 
 
The ranking of affinities changed when the sequence encompasing 
MPER(664-690) was presented in the context of immobilized pseudovirus (PsV) 
particles (FIG 43A). The dose-dependent binding of the Fab-s to immobilized 
PsV particles diminished gradually for P100fHCA and W100bHCY variants, and 
was undetectable for W100bHCA or W100bHCD variants. Thus, in the context of 
the viral surface the P100fHCA variant bound more efficiently to the 10E8 
epitope than the conservative W100bHCY one. 
 
Table 8. Thermodynamic parameters of binding of Fab 10E8 CDR-H3 muteins to the 
peptide MPER(664-690). 
Antibody KD 
(nM) 
ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
-TΔS° 
(kcal mol-1)a 
nb 
WT 9.6 ± 1.0 −10.9 ± 0.1 −9.6 ± 0.1 −1.3 ± 0.2 1.0 ± 0.1 
P100fHCA 161 ± 22 −9.2 ± 0.1 −11.1 ± 0.2 1.9 ± 0.3 0.8 ± 0.1 
W100bHCY 52 ± 12 −9.9 ± 0.1 −8.9 ± 0.1 −1.0 ± 0.2 1.1 ± 0.1 
W100bHCA 361 ± 82 −8.8 ± 0.1 −10.0 ± 0.5 1.2 ± 0.6 1.0 ± 0.1 
W100bHCD 375 ± 66 −8.7 ± 0.1 −6.5 ± 0.3 −2.2 ± 0.4 1.0 ± 0.1 
a  Temperature was 298 K. 
b  n refers to the molar ratio peptide/protein. 
 
To determine if this effect was induced by membrane anchoring, the 
MPER(664-690) peptide was next presented in the plasma membranes of cells 
expressing the fusion polypeptide, MPER-TM1, which comprises (i) an N-
terminal HA tag, (ii) the MPER residues, and (iii) the TMD residues of gp41 
followed by 27-AA of the gp41 cytoplasmic domain (MPER-TM1; FIG 43B, left) 
(Montero et al., 2012). Previous studies of MPER-TM1 revealed that the 4E10 
epitope is well exposed for antibody binding when constrained by the gp41 
TMD; in contrast, 4E10 binds weakly to a construct in which the gp41 MPER-
 Results 
Chapter-5- 
 125 
TMD junction is disrupted by fusion to another receptor’s 20-AA membrane-
proximal external region and TMD (MPER-PDGFR) (see also chapter 4). In this 
previous work, the C-terminal helix of the MPER was envisioned as being 
continuous with the gp41 TMD helix; this arrangement was thought to fully 
expose the MPER for 4E10 docking (Montero et al., 2012). 
 
FIG 43B shows that both 4E10 and 10E8 IgGs bind tightly to the MPER-
TM1 in the context of the plasma membrane. These antibodies engaged with 
the MPER-TM1 construct as effectively as the 17/9 IgG, which binds to the 
solvent-exposed HA epitope and served to normalize expression levels 
(Montero et al., 2012). A comparable degree of binding was observed for the 
WT 10E8 Fab, thereby sustaining side-by-side comparative assessment of its 
CDR-H3 muteins. The binding pattern of substituted Fab-s to MPER-TM1 
coincided with that previously observed in PsVs. In contrast, the MPER-PDGFR 
construct was a poor ligand for both the 4E10 and 10E8 IgGs, and for the 10E8 
Fab and its muteins, whereas, 2F5, whose epitope is on the N-terminal sub-
region of the MPER, was marginally affected (FIG 43B, right). None of the 
mutant Fab-s bound to the MPER-PDGFR in the membrane context. These 
results reflect the ability of the gp41 TMD residues to affect the positioning of 
10E8 epitope at the membrane interface, and demonstrate the requirement of 
the hydrophobic CDR-H3 tip for the occurrence of the recognition process. 
 
The differences observed in binding of the 10E8 Fab and its muteins to 
PsVs or MPER-TM1 were mirrored by differences in their neutralization 
potencies (FIG 43C). The neutralization assays confirmed the previously 
reported detrimental effects induced by the P100fHCA and W100bHCA 
substitutions (Huang et al., 2012), which rendered a less potent, but still 
functional Fab, and an almost non-neutralizing variant, respectively. Moreover, 
in comparison to the W100bHCA mutein, the Fab bearing the conservative 
W100bHCY substitution gained neutralization potency. However, the activity of 
the W100bHCY variant was lower than that of the P100fHCA variant. Finally, the 
non-conservative W100bHCD substitution rendered a Fab devoid of all activity. 
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FIG 43. Effect of substitutions in CDR-H3 on Fab binding to MPER in the context of the 
plasma membrane and correlation with neutralizing activity. A) JRCSF PsV recognition by 
10E8 Fab and mutein Fab-s in a dot-blot assay. Decreasing amounts of PsV (from left to right) 
were spotted onto nitrocellulose membranes and probed with 10E8 Fab and its muteins. B) Cell 
lysates bearing recombinant MPER proteins (MPER-TM1: left; MPER-PDGFR: right) were 
probed with 20 nM IgG or Fab, as indicated, and binding signals were normalized to that of 20 
nM 17/9 IgG, which binds to N-terminal HA tags on both constructs. C) Neutralization profile of 
a panel of PsVs bearing HIV Env or that of vesicular stomatitis virus (negative control). IC50 and 
IC90 values for 2F5, 4E10 and 10E8 IgGs, 10E8 Fab and its muteins are shown. 
 
5.4. DISCUSSION 
 
In this work, we have provided new insights into the molecular 
mechanism linking the binding of the helical epitope at the membrane interface 
with the biological function of 10E8. The chemically heterogeneous membrane 
interface region allows multiple types of non-covalent lipid-peptide interactions 
(White et al., 2001; White and Wimley, 1999). Importantly, aromatic residues, 
and particularly Trp, have a tendency to preferentially locate within this region 
(McDonald and Fleming, 2016; Wimley and White, 1996). Thus, interactions 
with lipids and the spatial arrangement of favorably inserted aromatic residues 
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may influence the orientation of MPER epitopes at the membrane surface, the 
mechanism of antibody docking, or both. Our previous data (chapter 3) 
suggested that preservation of the continuous MPER-N-TMD helix observed by 
NMR studies (Apellaniz et al., 2015) could be critical for high affinity binding to 
epitopes of the C-terminal MPER sub-region when inserted into the membrane 
(FIG 35A). The peptide MPER(664-690) was designed to preserve this element 
while including all residues that were in contact with the 10E8 antibody in the 
first reported structure of the Fab-peptide complex (FIG 35B). This optimized 
peptide was bound with high affinity by the 10E8 Fab forming a stable complex 
in the presence of DPC micelles (FIG 35C and D).  
 
Recent crystallographic studies (Kwon et al., 2016a) and cryo-EM 
reconstructions (Lee et al., 2016) together with previous data regarding the 
binding of 10E8 to peptides systematically substituted with Ala (Huang et al., 
2012), indicated that 10E8 binding affinity is primarily mediated by its mode of 
recognition of the shorter 671NWFDITNWLWYIK683 sequence. However, 
structure resolution of the complete helix 671NWFDITNWLWYIKLFIMIVG690 in 
complex with Fab adds three important factors to our understanding of the 10E8 
epitope. 
 
First, we propose the absence of a kink interrupting the MPER helix at 
position Lys683 and the oblique insertion of the whole structural element into 
the membrane. A widely assumed model suggests that the MPER helix inserts 
in parallel to the membrane interface and kinks at position Lys683 to allow the 
perpendicular insertion of the TMD helix starting at position Leu684 (Huarte et 
al., 2008; Kim et al., 2013; Ofek et al., 2004; Schibli et al., 2001; Sun et al., 
2008).  Accordingly, it has been proposed that anti-MPER antibodies approach 
from above the membrane-inserted MPER epitopes (Cardoso et al., 2005; 
Lorizate et al., 2006; Ofek et al., 2004; Song et al., 2009; Sun et al., 2008). In 
contrast, our crystallographic data (FIG 36, 38 and 40) support more recent 
models suggesting that the main axis of the uninterrupted helix of the epitope 
forms an oblique angle with respect to the membrane plane (Apellaniz et al., 
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2015; Irimia et al., 2016), with some intermolecular contacts made by the anti-
MPER Fab-s occurring at the vertex, after engaging with the helix surface facing 
the membrane (Irimia et al., 2016; Lee et al., 2016). The absence of a kink at 
position Lys683 is also supported by the recent structural resolution of a trimeric 
TMD sequence embedded in lipid bicelles (Dev et al., 2016). 
 
Second, our data clearly suggest the active participation of residues 
beyond Lys683 in the interaction with Fab in the membrane environment. 
Titration, photo-cross-linking data, and structural analysis revealed the 
involvement of residues Ile686 and Met687 in establishing non-polar contacts 
with the CDR-H3 apex residue, Trp100bHC; the interaction surface of this 
residue is doubled in the presence of the long peptide (FIG 36E, 39 and Table 
S7). Collectively, the identification of several phosphate groups on the surface 
of the antibody in the crystal structure (FIG 40A), and the capacity of the Fab to 
recognize the membrane-anchored peptide (FIG 43B and C) suggest that key 
Fab-peptide interactions required for the effective neutralization occur within the 
membrane interface. It appears that the maximum binding potential of 10E8 
emerges from the simultaneous interactions of Trp100bHC with TMD residues 
Ile686 and Met687 and phospholipids (FIG 36E and 40A). 
 
And third, the mutational analysis of the 10E8 CDR-H3 region indicates 
that preservation of such interactions directly correlates with the neutralizing 
activity of the antibody (Table 8 and FIG 43). Thus, the binding of the 10E8 Fab 
and its muteins to Env-bearing PsVs or to the MPER-TM1 polypeptide in the 
context of the plasma membrane reflected with remarkable accuracy their 
neutralizing activity (FIG 43). The model displayed in FIG 44, which combines 
the high-resolution structural information described in this work, with that 
derived from cryo-EM reconstructions (Lee et al., 2016), provides a putative 
mechanism to explain that correlation. 
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FIG 44. Model for 10E8 epitope binding at the viral membrane interface. A silhouette 
model of the trimer of Env from Lee et al. (Lee et al., 2016) was employed to illustrate the 
figure. To facilitate the understanding of the model, only two MPER epitopes (green helices) 
are shown. The antibody is shown in blue, and the critical aromatic cluster depicted as 
magenta sticks. Orange boxes represent deeper segments of the TMD. Inset: close-up view of 
the aromatic residue cluster stabilizing the MPER-N-TMD helix at the membrane interface. 
Residues contributed by Fab and gp41 are depicted in magenta and green, respectively. 
 
We conclude that high-affinity binding to the 10E8 epitope at the 
membrane interface requires engagement with the N-terminal core-epitope 
residues, and establishment of a firm grip along the full MPER-N-TMD helix, 
including the interaction between Trp100bHC and TMD residues, Ile686 and 
Met687. Assuming that a recently reported trimeric structure might represent 
the organization of the TMD in the native Env (Dev et al., 2016), full 
achievement of that interaction implies that the 10E8 antibody engages the 
epitope after rotation and uplifting of the TMD helix. Thus, the stringent 
dependence on the aromatic nature of the Trp100bHC residue for biological 
activity might be due to the fact that, to establish an effective grip, the CDR-H3 
apex must submerge in the membrane interface (McDonald and Fleming, 
2016), and establish at the deepest level tight contacts with the C terminus of 
the MPER-N-TMD helix surrounded by membrane phospholipids. Holding the 
helices in the uplifted position observed in the 10E8-bound form of the Env 
trimer (Lee et al., 2016) would be energetically favored by the network of 
interfacial aromatic residues that are contributed upon binding by both the Fab 
and the MPER-N-TMD helix (FIG 44, inset). We speculate that the stabilization 
of monomeric helices in this state might be incompatible with the progression of 
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Env-mediated fusion explaining, at least in part, the mechanism by which 10E8 
blocks viral fusion. 
 
In summary, the model proposes that, for effective neutralization, the 
antibody must combine the specific binding to MPER residues transiently 
exposed to solvent at the membrane surface, with establishment of downstream 
interactions with the TMD at the deepest levels of the membrane interface. We 
propose that vaccines incorporating membrane-stabilized, MPER-N-TMD helix 
structures, bearing the range of (i) orientations, (ii) depths of penetration and (iii) 
angles suggested by the model, will more effectively elicit 10E8-like antibodies. 
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5.5. SUPLEMENTARY DATA 
 
 
FIG S1. Membrane penetration of NBD covalently attached to 10E8 Fab. A) Strategy of 
labeling and spectroscopic properties of the NBD-Fab in solution or upon membrane insertion. 
B) Emission spectra of the labeled 10E8 NBD-Fab (0.5 µM) obtained in presence of bare 
liposomes (left), liposomes containing H(693)-AA (center) or liposomes containing H(693) 
(right). Lipid and peptide concentrations were 250 and 6,8 µM respectively. In H(693)-AA 
sequence key epitope residues Trp672/Phe673 were substituted by Ala. Red traces 
correspond to spectra obtained in solution with maximum emission normalized to 1. Peptides 
H2(686) and H2(693) correspond to MPER(671-686) and MPER(671-693), respectively. 
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Table S4. Data collection and refinement statistics (molecular replacement)a,b 
 10E8 + MPER(664-690) 
Data collection  
Space group I 2 2 2 
Cell dimensions    
    a, b, c (Å) 66.6, 81.2, 254.2 
    a, b, g  (°)  90.0, 90.0, 90.0 
Resolution (Å) 52.4 - 2.40 (2.49 - 2.40) 
Rmerge 4.6 (20.2) 
I / sI 34.0 (8.0) 
Completeness (%) 90.0 (56.2) 
Redundancy 9.7 (7.0) 
Refinement  
Resolution (Å) 52.4 – 2.40 
No. reflections 24,462 
Rwork / Rfree 19.2 / 23.4 
No. atoms  
    Protein 3,360 
    Peptide 201 
    Ligand/ion 35 
    Water 132 
B-factors  
    Protein 40.0 
    Peptide 59.5 
    Ligand/ion 30.0 
    Water 48.2 
R.m.s. deviations  
    Bond lengths (Å) 0.011 
    Bond angles (°) 1.3 
aData obtained from a single crystal. 
bValues in parentheses are for highest-resolution shell. 
Table S5. Hydrogen-bond connectivity between 10E8 and two distinct peptides. 
  MPER(664-690) MPER(656-683) 
Peptide 10E8 Distance (Å) 
Trp670 H-Glu53 - 2.8 
Trp672 H-Glu53 3.0 3.1a 
Trp672 H-Pro100G 2.8 2.9 
Lys683b H-Phe100A 3.0 3.0 
Lys683b H-Gly100D 2.7 2.9 
Table S6. Interaction surface of the LC of 10E8 Fab with two distinct peptides. 
 MPER(664-690) MPER(656-683) 
Residue BSA (Å2) 
L-Arg91 15.7 16.3 
L-Arg95B 69.3 49.9 
Subtotal 85.0 66.3 
Pep-Asn671 1.5 - 
Pep-Trp672 10.4 10.9 
Pep-Phe673 63.7 54.6 
Pep-677 1.0 - 
Subtotal 76.6 65.4 
Total 161.6 131.7 
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Table S7. Interaction surface of the HC of 10E8 Fab with two distinct peptides. 
 MPER(664-690) MPER(656-683) 
Residue BSA (Å2) 
H-Asp28 - 14.4 
H-Asn31 16.6 33.2 
H-Trp33 27.3 29.2 
H-Arg50 7.9 5.9 
H-Thr52 4.9 4.6 
H-Pro52B 29.9 23.8 
H-Gly52C 52.8 58.5 
H-Glu53 59.0 59.7 
H-Ser56 9.5 7.1 
H-Asp58 3.6 6.9 
H-Lys97 53.2 46.1 
H-Tyr98 3.1 4.1 
H-Tyr99 80.1 81.4 
H-Phe100A 98.4 80.1 
H-Trp100B 63.2 32.2 
H-Ser100C 1.4 5.1 
H-Gly100D 16.7 16.2 
H-Tyr100E 32.0 25.3 
H-Pro100F 67.7 65.5 
H-Pro100G 63.6 62.1 
H-Gly100H - 0.1 
H-Glu100I 0.6 1.4 
H-Glu100J 4.5 5.3 
Subtotal 695.8 668.3 
Pep-Leu-661 - 1.8 
Pep-Asp664 - 0.2 
Pep-Lys665 - 22.0 
Pep-Ser668 - 53.9 
Pep-Leu669 67.4 28.2 
Pep-Trp670 41.4 11.7 
Pep-Asn671 27.8 34.3 
Pep-Trp672 129.3 134.2 
Pep-Phe673 84.4 94.1 
Pep-Thr676 49.2 48.4 
Pep-Asn677 17.0 19.6 
Pep-Leu679 51.0 46.2 
Pep-Trp680 66.1 64.3 
Pep-Ile682 6.0 15.0 
Pep-Lys683a 84.0 106.8 
Pep-Ile686 29.8 - 
Pep-Met687 19.6 - 
Subtotal 672.9 680.5 
Total 1368.7 1348.8 
aThis residue is a Arg in the structure of 10E8 with MPER(664-690). 
 
  
 
 
 
 
 
 
 
 
 
 
 
6.  DUAL ROLE OF THE APEX OF THE 
CDR-H3 OF 4E10 FAB IN BINDING TO 
MPER AT THE MEMBRANE INTERFACE 
 
 
 
 
  
 
C
ha
pt
er
 
6 
C
ha
pt
er
 

Results 
Chapter-6-  
 
 137 
6.1. INTRODUCTION 
 
The bNAb 4E10 antibody targets the highly conserved vulnerability 
MPER site on gp41 and it is classified among the HIV antibodies with the 
highest neutralization breadth described so far (Binley et al., 2004; Kwong and 
Mascola, 2012). Previous research has shown that hydrophobic and aromatic 
residues belonging to the apex of the CDR-H3 of 4E10 are essential for viral 
neutralization (Alam et al., 2009; Apellaniz et al., 2014b; Scherer et al., 2010). 
Despite the direct implication of the CDR-H3 apex in the neutralization potency 
exerted by the 4E10 antibody, the crystal structures of the peptide-Fab 
complexes revealed that the CDR-H3 apex remains solvent-exposed and 
oriented in a direction opposite to the location of the bound peptide (Bird et al., 
2014; Cardoso et al., 2007; Cardoso et al., 2005; Irimia et al., 2016). In 
contrast, the crystal structure of the functionally similar antibody 10E8 revealed 
that the apex of the CDR-H3 sits along the helical peptide placing the 
Trp100bHC at the apex, into close contact with the TMD (Huang et al., 2012). 
This conformation allows the establishment of the non-covalent interactions 
between the Trp100bHC at the apex of the CDR-H3 and the gp41 TMD N-
terminus described in the previous chapter. Interestingly, those interactions can 
explain the correlation that is observed between the binding strength of 10E8 to 
the epitope and the intensity of the neutralization response by the antibody.  
 
The unusual length and hydrophobicity of the CDR-H3s shared by both 
antibodies suggest however that a mechanism similar to the one described for 
10E8 could operate for 4E10. In the latter case, membrane insertion and 
subsequent interaction with gp41 TMD would imply the reorientation of the 
CDR-H3 apex with respect to the position observed in crystals of Fab-peptide 
complexes. Supporting this possibility a recent crystallographic study by the 
group of Wilson (Irimia et al., 2016) indicates that the presence of lipids might 
trigger a conformational change of the CDR-H3 of 4E10. Hence, the 4E10 CDR-
H3 could undergo a conformational change to insert into the viral membrane, 
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placing the apex in the vicinity of the gp41 TMD, and enabling the full 
engagement of the MPER/TMD epitope by the antibody.  
 
Herein we sought to (i) test the hypothesis that the CDR-H3 of 4E10 
reorients upon interaction with membranes, and (ii) to establish the importance 
of this conformation for the neutralization potency of the antibody. With that aim 
in mind, we monitored the position of the two Trp residues, at positions 100HC 
and 100bHC, upon membrane binding by replacing each of them with the polarity 
reporter probe NBD. In addition, proximity of each Trp to the TMD of gp41 was 
assessed using the photo-active amino acid pBPA. From these experiments, 
we inferred the relative position of the Trp residues at the apex of the CDR-H3 
with respect to the MPER/TMD region when inserted into the membrane.  
 
Our results demonstrate that both Trp residues immerse in the 
membrane when the Fab partitions into vesicles. Moreover, it is revealed that 
the CDR-H3 deploys Trp100bHC, but not Trp100HC, in the immediate vicinity of 
the TM region of gp41 suggesting that only one strand of the loop sits on the 
MPER/TMD helix. The specific roles of these hydrophobic residues were further 
supported by the absence of correlation between membrane binding and 
neutralization observed for a set of mutants that were designed to modify the 
hydrophobicity, the length, and the order of the residues of the apex of the 
CDR-H3. 
 
Collectively, the data suggest that the apex of the CDR-H3 loop plays a 
dual role during viral neutralization by (i) promoting association to the 
membrane and (ii) stabilizing the antibody-epitope complex in a membrane 
environment. The efficient antibody neutralization is dependent on both Trp 
residues. A stable 4E10-MPER/TMD interaction, occurring through one single 
strand of the CDR-H3 loop, requires simultaneous interactions with membrane 
lipids. This is in contrast to the 10E8 antibody whose CDR-H3 loop embraces 
the MPER/TMD helix using both strands of the CDR-H3 (see chapter 5). These 
findings suggest specificities for the mechanism of viral neutralization by 4E10, 
Results 
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inspiring the design of novel vaccines capable of inducing antibodies with a 
4E10-like neutralization breadth. 
 
6.2. MATERIALS AND METHODS 
 
6.2.1. Materials 
 
The peptides used in the structural and biophysical studies were 
synthesized as described in 3.2.1. Vector and antibodies were obtained as 
indicated in 5.2.1. 
 
6.2.2. Production and characterization of Fab-s. 
 
Experimental procedures described in 3.2.2 and 4.2.2 were followed for 
the mutation, expression and purification of Fab-s. ITC and DSC measurements 
were carried out as described in 3.2.3 and 4.2.5, respectively. Antibody binding 
to empty VL (DOPC:DOPE:DOPS:SM:Chol) (14:16:7:16:47 mole ratio) LUVs 
and to POPC: Chol (1:1) membrane embedded-MPER(671-693) was carried out as 
described in 3.2.4. Photo cross-linking and NBD fluorescence assays were 
performed as described in 5.2.4 and 5.2.5, respectively. LUVs used for 
fluorescence measurements in the presence of MPER(671-693) was carried out in 
the absence of Chol rendering to the following LUV composition; 
DOPC:DOPE:DOPS:SM (27:29:14:30 mole ratio) due to the fusogenic activity 
of the peptide in liposomes enriched in cholesterol (Apellaniz et al., 2014b).  
 
6.2.3. Crystallization and data collection of 4E10 Fab mutant Npro in 
complex with MPER(671-683) peptide. 
 
Crystals of the complex between Npro Fab (3 mg L-1) and the peptide 
MPER(671-683) added at a molar ratio of ~1:1.3 (Fab:peptide) were grown in a 
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solution of 100 mM NaAc pH 5, 34 % PEG 4000, 225 mM NH4Ac at 18 °C. A 
single protein crystal cryoprotected with 10 % glycerol was harvested and 
stored in liquid nitrogen until data collection at the synchrotron. Diffraction data 
from a single crystal was collected on beamline BL13-XALOC of the ALBA Cell 
Synchrotron (Barcelona, Spain) under cryogenic conditions (100 K). Diffraction 
images were further processed as described in 3.2.6 using the coordinates of 
recombinant WT Fab described in chapter 3. Data collection and refinement 
statistics are summarized in Table 10. 
 
6.2.4. Cell entry inhibition 
 
For the cell infection inhibition assays (Julien et al., 2010; Serrano et al., 
2014), HIV-1 pseudoviruses were produced by transfection of human kidney 
HEK293T cells with the full-length env clone JR-CSF (kindly provided by Jamie 
K. Scott and Naveed Gulzar, Simon Fraser University, BC, Canada) using 
calcium phosphate. Cells were co-transfected with vectors pWXLP-GFP and 
pCMV8.91, encoding a GFP and an env-deficient HIV-1 genome, respectively 
(provided by Patricia Villace, CSIC, Madrid). After 24 h, the medium was 
replaced with Optimem-Glutamax II (Invitrogen Ltd, Paisley, UK) without serum. 
Three days after transfection, the PsV particles were harvested, passed through 
0.45 µm pore sterile filters (Millex® HV, Millipore NV, Brussels, Belgium) and 
finally concentrated by ultracentrifugation in a sucrose gradient. Neutralization 
was determined using TZM-bl target cells (AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH, contributed by J. Kappes). 
Samples were set up in duplicate in 96-well plates, and incubated for 1.5 h at 
37 °C with a 10-15 % tissue culture infectious dose of PsV. After antibody-Psv 
co-incubation, 11,000 target cells were added in the presence of 30 µg/mL 
DEAE-dextran (Sigma-Aldrich, St-Louis, MO). Neutralization levels after 72 
hours were inferred from the reduction in the number of GFP-positive cells as 
determined by flow cytometry using a BD FACSCalibur Flow Cytometer (Becton 
Dickinson Immunocytometry Systems, Mountain View, CA). 
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6.3. RESULTS 
 
6.3.1. The two Trp residues of the apex of the CDR-H3 loop insert into 
membranes. 
 
Previous mutational studies have demonstrated the critical importance of 
the two Trp residues at the apex of the CDR-H3 of 4E10 for the neutralization of 
the virus (Alam et al., 2009; Scherer et al., 2010). It has been suggested, but 
not rigorously demonstrated, that these residues insert into membranes. 
Liposome flotation assays displayed in FIG 45A illustrate conditions for the 
membrane interaction of the 4E10 Fab with membranes. In those assays, 
liposome-Fab complexes formed both in the absence (top) and in the presence 
(bottom) of epitope peptide.  
 
A previous study had suggested that the apex undergoes a 
conformational change in the presence of lipids (FIG 45B), but it was unclear 
whether the apex would insert deeply into the membrane or not. We further 
employed a molecular sensor introduced at the position of each Trp (100HC and 
100bHC) to monitor the insertion of each residue into the membrane. Each Trp 
was mutated to a Cys residue and covalently linked to a NBD molecule by a 
disulfide bond. The resulting NBD-labeled Fab-s were used to determine their 
interaction with the membrane by monitoring changes in the fluorescence of the 
NBD moiety. In particular, a shift of the maximum of emission to a shorter 
wavelength is suggestive of transfer of the NBD moiety from a high to a low 
polarity environment such as that of the hydrophobic environment of the 
membrane. This change is generally accompanied by an increase of the 
intensity of fluorescence. Incubation of each of the NBD-Fab-s just described 
above with increasing concentrations of virus-like (VL) LUVs resulted in an 
increment of the NBD-fluorescence intensity and a displacement of the 
maximum of emission from 543 nm to 539 nm consistent with immersion of the 
NBD moiety of each construct in the bilayer (FIG 45C).  
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FIG 45. Membrane insertion of positions 100HC and 100bHC of the CDR-H3 of 4E10. A) 
Membrane partitioning of 4E10 Fab into LUVs in the absence (top) and presence (bottom) of 
MPER(671-693) in a sucrose gradient. Location of the LUVs in the third and fourth fractions (i.e., 
floated fractions) was detected from the Rho-PE emission (bottom panel) and the presence of 
Fab-s in the different fractions probed in WB. B) Cartoon representation of the putative CDR-
H3 movement resulting from the Fab interaction with membrane. Superimposed structures of 
the 4E10 Fab in complex with MPER(671-683) (PDB entry 2FX7) and in complex with the lipid PA 
(6:0) (PDB entry 4XBG) are depicted in gray and orange, respectively. Residues Trp100HC and 
Trp100bHC are shown in stick representation and the approximate position of the surface of the 
membrane indicated by the dotted line (inferred from the position of bound lipids, not shown). 
C) Fluorescence emission spectra of Fab-s labeled at positions 100HC or 100bHC with NBD. Top 
panels: Emission spectra of NBD were measured after incubation of NBD-Fab in solution (gray 
traces) or in the presence of increasing concentrations of VL vesicles (black traces). Bottom 
panels: Emission spectra of NBD-Fab labeled after incubation with liposomes devoid of peptide 
(gray traces) or containing increasing amounts of peptide MPER(671-693) (red traces). For each 
set of spectra the right-side plots display the relative changes of fluorescence (top) and the 
position of the wavelength at the maximum intensity (bottom). The initial fluorescence (F0) was 
determined from the maximum intensity of the spectrum of NBD-Fab in buffer (top panels, gray 
traces) or that of NBD-Fab in the presence of bare liposomes (lower panels, gray traces). The 
values of fluorescence (F) were obtained after the addition of LUV (top panels, black traces), or 
of LUV-peptide complexes (bottom panels, red traces), respectively. 
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The emission of fluorescence of the NBD moiety also increased upon 
incubation of the NBD-labeled Fab-s with liposomes containing increasing 
concentrations of the MPER(671-690) peptide. This is a clear evidence that the 
antibody is recognizing the liposome-embedded epitope at membrane 
interfaces (FIG 45C). Interestingly, the changes of fluorescence (wavelength 
and intensity) of the NBD moiety upon interaction with bare vesicles or with 
peptide-liposome complexes were remarkably similar in the two positions 
examined. This observation suggested that the two Trp residues occupying 
these positions in the WT antibody would insert in the membrane to a similar 
extent (FIG 45C). 
 
6.3.2. Estimation of the proximity of each Trp residue of the apex to MPER 
under different environments. 
 
In chapter 5 we have identified, for the first time, non-covalent 
interactions between the CDR-H3 tip of a broad neutralizing antibody and 
residues of gp41 fully embedded in the membrane (downstream of Lys683) 
resulting in the strengthening of the binding affinity for the peptide and 
increasing its neutralization potency. Taking into account that the Trp residues 
at the apex of the CDR-H3 of 4E10 penetrate into the lipid membrane, we 
hypothesized that the tip of the CDR-H3 may also interact with residues of 
MPER-TMD after the conformational change proposed in FIG 45B, optimizing 
the antibody interaction with the epitope in a membrane environment (FIG 46A).  
 
In order to verify this hypothesis, photo cross-linking experiments with a 
genetically encoded photoreactive non-natural amino acid were conducted (FIG 
46). Positions 100HC and 100bHC of the CDR-H3 were substituted with the 
photoreactive amino acid p-benzoylphenylalanine (pBPA). The resulting Fab 
mutants were irradiated with UV-light in the presence of peptides of various 
lengths including peptides that encompassed the MPER/TMD sequence. When 
the photoreactive amino acid pBPA occupied the position 100bHC of the Fab, an 
SDS-PAGE gel revealed an additional band of higher molecular weight 
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corresponding to the Fab-peptide adduct. This band resulted from the formation 
of a covalent bond between the pBPA moiety and residues of the peptide but 
was absent when pBPA was introduced in the position of Trp100HC (FIG 46B). 
Importantly, the same photo-crosslinking pattern (positive crosslinking when 
pBPA was introduced at position 100bHC, but not at position 100HC) was 
observed in the presence of lipid membranes (FIG 46B). This latter observation 
suggests that the Trp100bHC of the WT Fab locates in the immediate vicinity of 
the gp41 TMD in the viral membrane. 
 
 
FIG 46. Binding of 4E10 Fab to MPER(671-683) peptide. A) To illustrate the conformational 
change of the CDR-H3 loop, Fab structures in previous FIG 45A have been rotated. In addition 
the relative position of the bound peptide is shown. The long peptide was modeled by 
superposing the MPER(671-683) peptide co-crystallized with the 4E10 Fab (PDB entry 2FX7) and 
the MPER(664-690) peptide bound to 10E8 Fab (Chapter 5). B) Photo cross-linking between 4E10 
Fab labeled with pBPA at position 100HC or 100bHC, and MPER peptides spanning part of the 
TMD. The experiment was carried out in the presence of DPC (solution), or POPC:Chol LUVs. 
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6.3.3. Design of CDR-H3 apex mutants to evaluate interactions with 
MPER/TMD. 
 
In order to determine the functional relevance of the two Trp residues of 
the apex without mutating them, we elongated the CDR-H3 loop. Thus, with the 
idea of separately repositioning each Trp100bHC and Trp100HC, we constructed 
two different CDR-H3 mutants in which either the N-terminal side or the C-
terminal side of the apex was shifted by introducing two Pro residues (FIG 47A). 
Specifically two proline residues were inserted between Gly100cHC and 
Lys100dHC, or between Thr98HC and Gly99HC, to render two mutants termed 
Cpro or Npro, respectively (FIG 47A). Based on the recent crystal structure of 
4E10 in complex with micelles of PA (6:0) (Irimia et al., 2016), the Trp100bHC 
residue in the mutant Npro would remain in a similar position to that in WT Fab 
and therefore in close proximity to the peptide. In contrast, in Cpro the residue 
Trp100bHC is expected to shift its position with respect to the peptide (FIG 47A). 
In principle, the opposite behavior is expected for Trp100HC, i.e., shifted in Npro 
and unaltered in Cpro. 
 
We first verified that the mutations were not detrimental to the stability of 
the antibodies (Table 9). Second, we employed X-ray crystallography to 
determine the position of the CDR-H3 apex. Despite the high-resolution 
achieved (1.48 Å) the position of the Trp100bHC in Npro could not be confirmed 
because this region was disordered in the crystal (FIG 47B and Table 10). 
Except for this region, the structure of the Fab was essentially indistinguishable 
to that of WT Fab (rmsd = 0.13 Å). No crystal of Cpro was obtained. In principle, 
Npro and Cpro retained the same CDR-H3 loop hydrophobicity. Accordingly, 
both mutants interacted to the same extent with lipid vesicles (FIG 47C). In 
those experiments, the mutant Δloop resulting from the ablation of the CDR-H3 
apex (Apellaniz et al., 2014b) was used as negative control of membrane 
binding (bottom panel). Thus, Npro and Cpro displayed equal capacities for 
partitioning into membranes, which otherwise were comparable to that of the 
WT antibody (FIG 45A). 
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Table 9. Thermal stability, inhibition potency and thermodynamic parameters of binding 
of peptide MPER664-690 to 4E10_WT and mutants in the presence of DPC.  
4E10 
Antibody 
TM 
(ºC) 
ΔTM 
(ºC) 
HXB2  
IC50a 
JRCSF 
IC50a 
KD 
(nM) 
ΔH° 
(kcal mol-1) 
-TΔS° 
(kcal mol-1)b n
c 
WT 69.8 n.a. 0.21 ± 0.02 1.3±0.1 4.6 ± 1.5 -15.1 ± 0.2 3.7 1.0 ± 0.1 
Npro 68.6 1 0.30 ± 0.08 6.5 ± 1.6 6.2 ± 1.3 -12.8 ± 0.1 1.6 1.1 ± 0.1  
Cpro 67.5 2.3 6.4 ± 1.4 17 ± 4 6.9 ± 1.5 -15.2 ± 0.2 4.0 1.0 ± 0.1 
 
a (µg/mL) 
b Temperature was 25 °C. 
c n refers to the molar ratio peptide/protein. 
 
 
 
Table 10. Data collection and refinement statistics (molecular replacement)a,b 
 4E10 mutated 
Data collection  
Space group C2 
Cell dimensions    
    a, b, c (Å) 157.5, 44.5, 85.1 
    α, β, γ  (°)  90.0, 113.7, 90.0 
Resolution (Å) 22.3 – 1.49 (1.57 – 1.49) 
Rmerge (%) 8.1 (20.2) 
I / σI 11.9 (2.4) 
Completeness (%) 99.5 (99.5) 
Redundancy 6.0 (5.8) 
  
Refinement  
Resolution (Å) 22.3 – 1.49 
No. reflections 88,093 
Rwork / Rfree 17.6 / 20.3 
No. atoms  
    Protein 3,328 
    Peptide 138 
    Ligand/ion 13 
    Water 329 
B-factors  
    Protein 17.4 
    Peptide 25.2 
    Ligand/ion 22.5 
    Water 25.7 
R.m.s. deviations  
    Bond lengths (Å) 0.013 
    Bond angles (°) 1.5 
 
aData obtained from a single crystal. 
bValues in parentheses are for the highest-resolution shell. 
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FIG 47. Design and properties of 4E10 Fab-s with extended CDR-H3 loops. A) Schematic 
representation. Cpro was generated by the introduction of two prolines between Gly100cHC and 
Lys100dHC (in blue) resulting in the predictable displacement of Trp100bHC away from the 
peptide in WT Fab. The mutant Npro was prepared by introducing two prolines between 
residues Thr98HC and Gly99HC (also in blue). B) Superposition of the crystal structure of 
4E10_WT (gray) (PDB entry 2FX7) and Npro (green) bound to MPER(671-683) (dark pink). One of 
the proline residues introduced in the apex was  observed in the structure. Other residues of 
the apex (PGWGWL) were disordered. C) Flotation assay to assess membrane partitioning of 
Npro and Cpro mutants to VL vesicles. Location of the liposomes and Fab-s was detected from 
the Rho-PE emission (bottom panels) and by WB analysis, respectively. D) Photo cross-linking 
experiment of Npro and Cpro mutants, each modified with pBPA at position 100bHC, with MPER 
peptides of different lengths in the presence of DPC. Ablation of the CDR-H3 apex yielded a 
construct that we termed Δloop (Apellaniz et al., 2014b) that was used as a negative control of 
membrane binding.  
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Photo cross-linking experiments in which Trp100bHC was replaced by 
pBPA, confirmed the proximity of this position of the apex to MPER in the 
bound state of Npro, but not in that of Cpro (FIG 47D). The displacement of the 
photoreactive pBPA in the Cpro variant resulted in the inability of the Fab to 
form a covalent adduct with the peptide, indicating that pBPA does no longer 
remain near the peptide in this mutant (FIG 47D). On the contrary, the mutant 
Npro displayed the same photo-crosslinking pattern as that of WT Fab (FIG 46B 
and 47D). 
 
6.3.4. Functional characterization of 4E10 Fab-s with extended CDR-
H3 loops. 
 
The previous results are consistent with the design presented in FIG 
47A, thereby allowing the specific assessment of the importance of the 
Trp100bHC TMD interaction for the neutralizing activity of 4E10. Thus, the 
effects of Npro and Cpro mutations were subsequently tested in cell entry 
assays (FIG 48 and Table 9). The Npro mutant was almost indistinguishable 
from the WT in assays based on a sensitive HXB2 strain, while the IC50 of the 
Cpro mutant increased 20 fold. In the more resistant JRCSF strain the 
differences were not so marked, but Cpro was still deficient in viral inhibition. 
Thus, despite the similar capacities for interacting with membranes, the Cpro 
mutant did not interact with TMD through Trp100bHC and displayed weaker 
biological activity in comparison with Npro. 
 
To determine if weaker binding to epitope was at the origin of this 
phenomenon we carried out ITC experiments. Titration of WT, Npro and Cpro 
antibodies with MPER(664-690) in the presence of DPC revealed that the three 
Fab-s engaged the peptide with nearly identical affinity (KD values were 4.6, 6,2 
and 6.9 nM for WT, Npro and Cpro, respectively) (FIG 49A and Table 9). 
Moreover, no significant differences in the relative contribution of the enthalpy 
and entropy to the binding free energy to the peptide were observed (Table 9). 
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We next investigated the impact of these mutations (Npro and Cpro) in 
the binding to the epitope presented in an environment that better mimics the 
viral membrane (FIG 49B). To that purpose, and prior to each assay, the MPER 
was anchored to liposomes through the N terminus of the TMD. The binding of 
the Fab to the anchored MPER was estimated from the relative abundance of 
antibody co-floating with the vesicles (fractions 3 and 4) as detected by 
western-blot in a flotation assay. 
 
 
FIG 48. Functional characterization of 4E10 Fab-s with extended CDR-H3 loops. 
Neutralization potency of 4E10 WT (filled circles, red line) Npro (empty circles) and Cpro (filled 
triangles) against PsV HXB2 (top panel) and JRCSF (bottom panel). 
 
Efficient binding of the Fab to the peptide inserted into the membrane 
was achieved with WT 4E10 and with Npro Fab, as demonstrated by the high 
abundance of these two antibodies in the fractions co-floating with the 
liposomes. In contrast, a significant fraction of the Cpro mutant was observed in 
the dense fractions suggesting a defect in binding of this mutant to the 
membrane-inserted peptide (FIG 49B). Under these experimental conditions the 
position 100bHC of the pBPA-Npro mutant remains in close proximity to the 
peptide in a lipid membrane similarly to the WT 4E10 Fab. This conclusion is 
deduced from the additional band corresponding to cross-linked adduct in the 
SDS-PAGE of the sample containing the pBPA-Npro mutant pre-incubated with 
peptide-vesicles complexes (FIG 49C). In combination, these results suggest 
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that the assay carried out in solution did not capture all the complexity of the 
binding events that must occur in the environment of the viral membrane. 
 
In conclusion, results displayed in FIG 48 and 49 indicated that 
preserving the position of Trp100bHC in close proximity to the MPER/TMD 
region is not only critical for the neutralization potency of the antibody, but also 
for epitope binding in a membrane context. 
 
 
FIG 49. Epitope binding by 4E10 Fab-s with extended CDR-H3 loops. A) Binding isotherm 
of MPER(664-690) to 4E10 WT, Npro, and Cpro in the presence of DPC. B) Epitope recognition in 
the presence of lipid membranes. Flotation experiment was carried out to evaluate the binding 
of 4E10 WT and the CDR-H3 elongated mutants (Npro and Cpro) to VL membranes or to the 
epitope MPER(671-693) anchored to POPC:Chol LUVs. C) Photo cross-linking of Trp100bHC of 
Npro and Cpro mutant Fab-s with the MPER(671-693) peptide under the same conditions as the 
flotation assay in panel B. 
 
A 
B C 
580 600 620
0
20
40
60
80
100
580 600 620 580 600 620 580 600 620 580 600 620 580 600 620
WT 
Npro 
Cpro 
Input 1 2 3 4 SDS 
Floated 
Rho-PE 
λ(nm) 
In
te
ns
ity
 (a
.u
.) 
MPER(671-693) 
 
+ +
Npro Cpro 
Time (min) Time (min) 
Molar Ratio Molar Ratio 
µc
al
/m
ol
 o
f i
nj
ec
ta
nt
 
µc
al
/s
ec
 
Molar Ratio 
WT 
Time (min) 
Npro Cpro 
Results 
Chapter-6-  
 
 151 
6.3.5. Effect of the interfacial hydrophobicity of the CDR-H3 apex on 
membrane binding and neutralization potency of the 4E10 bNAb. 
 
The interaction of 4E10 with membranes through the CDR-H3 has been 
proposed as the element governing the neutralization potency of the antibody. 
However we have identified direct interactions between Trp100bHC and the 
peptide that strengthen their affinity when the epitope is embedded in the 
membrane, increasing viral inhibition. Hence, CDR-H3 hydrophobicity appears 
not to be the only property influencing the neutralization potency of the 
antibody. Specifically, the CDR-H3 apex hydrophobicity in Npro and Cpro 
mutants remains unchanged with respect to the WT, enabling them partitioning 
into membranes to comparable extents (FIG 47C), but only the former displays 
a comparable neutralizing activity (FIG 48).  
 
To obtain additional insights into the correlation between the 
hydrophobicity of the CDR-H3 apex, membrane binding and neutralization 
potency, we generated several versions of 4E10 Fab differing in the 
composition and sequence order of the residues comprising the apex of the 
CDR-H3 loop (i.e. WGWL) listed in FIG 50A. Thus, interfacial hydrophobicity of 
this region was altered by i) mutating one (W100HCC, or W100bHCC) or both 
(W100HCY/W100bHCY, or W100HCD/W100bHCD) Trp residues of the loop with 
residues of different hydrophobicity; ii) substitution of the residue L100cHC of the 
CDR-H3 apex with a Trp residue to render the 3W mutant that displays an 
increased interfacial hydrophobicity, and (iii) swapping the apex with the 
functional CDR-H3 apex (LFGV) of the anti-MPER antibody 2F5. The “LFGV” 
region of the antibody 2F5 has an active role in mediating lipid binding and 
antibody neutralization of 2F5 without binding to MPER (Julien et al., 2010) in a 
similar manner as that proposed for the 4E10 antibody. In addition, 4E10 Fab 
mutants that conserved the hydrophobicity but differed in other aspects of the 
CDR-H3 were also prepared. These included mutants with unchanged amino 
acid composition but scrambled sequences (Scr-1; Scr-2; Scr-3) and the 
previously analyzed Npro and Cpro mutants containing longer CDR-H3 loops. 
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The ability of the mutated Fab-s to bind to the membrane was assessed 
by vesicle flotation and WB, whereas the hydrophobicity of the resulting 
sequences were calculated using the Wimley and White (WW) hydrophobicity-
at-interface scale ( FIG 50B) (Wimley and White, 1996). When the value of the 
ΔGiwu (free energy of transfer from bilayer interface to water, also termed free 
energy of partitioning) of the CDR-H3 apex was decreased below the level of 
the WT antibody (<4.2 kcal/mol), it resulted in a severe defect of membrane 
binding for most of the mutations evaluated ( FIG 50B). Lower values of ΔGiwu 
also translated into a diminished capacity of the antibody to block the entry of 
the virus into the cell ( FIG 50B and C). Interestingly, although the mutants 
W100C and W100bC displayed the same hydrophobicity, they displayed a 
different membrane binding profile. Removal of the interfacial Trp amino acid at 
position 100bHC resulted in the loss of antibody partitioning into lipid membranes 
revealing that the magnitude of the hydrophobicity of the apex is not the only 
factor governing the binding of the antibody to the lipid membrane.  
 
As expected, we observed a broad spectrum of neutralization responses 
among antibodies sharing sequences of constant hydrophobicity ( FIG 50B and 
C). Fab 4E10 WT, Scr-1, Scr-2 and Scr3, sharing exactly the same residue 
composition but different sequence order at the CDR-H3 apex, displayed 
different neutralization capacities. This result suggested an important role for 
each residue of the apex in a sequence-dependent manner, in addition to their 
contribution to the overall hydrophobicity of the loop. Increasing the number of 
Trp residues in the apex enhanced the binding to the liposomes, as expected 
from the greater hydrophobicity, but did not increase the neutralization 
response ( FIG 50B and C). Based on these results, it is suggested that, 
although not sufficient, a minimum hydrophobicity in the CDR-H3 is required to 
exert some viral neutralization, since 4E10 Fab mutants with reduced 
hydrophobicity (ΔGiwu < 1 kcal/mol) are expected to have a very poor 
neutralization competence (IC50 > 100 µg/mL) (extracted from  FIG 50C). 
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6.4. DISCUSSION 
 
Mutational studies demonstrate that the hydrophobic and aromatic 
residues at the apex of the CDR-H3 of anti-MPER antibodies are essential for 
viral neutralization (Alam et al., 2009; Apellaniz et al., 2014b; Huang et al., 
2012; Julien et al., 2010; Scherer et al., 2010). Concretely, Trp residues at 
positions 100HC and 100bHC are required for the biological activity of the bNAb 
4E10. Despite their importance, the location of those residues when the 
antibody binds MPER in a membrane context is unknown. In this regard, 
knowledge on the neutralization-competent structure adopted by the CDR-H3 
apex could help elucidate the molecular mechanism by which 4E10 blocks the 
virus. 
 
Comparison of the crystal structures of the 4E10 antibody in the unbound 
and the bound forms reveals a reduction of the B-factors of the regions 
encompassing the CDRs H1 (25SGGSFSTYAL34), H2 (50GVIPLLTITNYA60), H3 
(95EGTTGWGWLGKPIGAFAH102), and L3 (89QQYGQSLST97) as a 
consequence of peptide binding (see chapter 4). Even though the residues at 
the apex Trp100HC−Leu100cHC slightly decrease their b-factors, they remain 
highly dynamic suggesting their predisposition to establish further interactions, 
for example, in the context of the viral membrane. However, the CDR-H3 apex 
projects away from the bound helical peptide and, therefore, establishment of 
membrane interactions imply the reorientation of that stretch of the loop. In 
agreement with this idea, we have formally shown that both Trp residues of the 
CDR-H3 apex interact with the lipid membrane (FIG 45). Hence, we propose 
that the affinity for the membrane interface of the two Trp residues provides the 
driving force for the structural reorientation of the CDR-H3 loop towards the 
lipid, as inferred from the recent crystallographic structure of 4E10 co-
crystallized with micelles of the lipid PA (6:0) (Irimia et al., 2016).  
 
We also demonstrate that the Trp residues at the apex of the CDR-H3 
play a role beyond promoting lipid membrane interaction. Thus, by incorporating 
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a genetically encoded photo-activable amino acid, we show that Trp100bHC 
efficiently engages with MPER/TMD and that such interaction is critical for the 
neutralization potency of the antibody (FIG 46-48). In contrast, direct interaction 
between Trp100HC and the peptide was not observed in the photo cross-linking 
assays. This difference suggests that both Trp residues do not contribute 
equally to the biological function of the antibody. Hence, Trp100HC must 
contribute to the overall activity of the antibody by stabilizing the antibody-
peptide complex in a more indirect manner. 
 
The biological relevance of the position of the Trp100bHC to mediate 
additional interactions with the TMD was further emphasized by results obtained 
using an engineered mutant where the position of Trp100bHC was shifted. The 
displacement of Trp100bHC had a deleterious effect on the ability of the antibody 
to interact with the MPER/TMD region, neutralize PsVs, and efficiently engage 
the epitope when embedded in the membrane. However, the value of the 
affinity constant (KD) of 4E10 to MPER peptide solubilized with the detergent 
DPC was unaltered. These results clearly indicate that binding in solution does 
not completely capture the complex process of neutralization occurring at the 
constrained environment of the viral membrane. To mimic that complexity, we 
employed a more elaborated assay in which the peptide is pre-immobilized in 
the surface of liposomes. Results of these experiments correlated with the 
biological activity more accurately. 
 
The discrepancy between the experiments performed in solution and in 
lipid membranes can be explained as follows. In solution, the highly flexible 
CDR-H3 undergoes a large oscillation from a closed (PDB entry 2FX7) to an 
open conformation (PDB entry 4XBG), transiently placing the Trp100bHC of the 
apex near the peptide. Hence, the otherwise weak Trp100bHC-MPER interaction 
in solution can be captured by the photo cross-linking assay without reflecting a 
gain of enthalpy and binding affinity. On the contrary, in the presence of the 
membrane, the hydrophobicity of the two Trp residues would shift this 
equilibrium towards the closed conformation, where the CDR-H3 is positioned 
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close to the TMD inside the lipid membrane. Rigidifying the conformation of the 
CDR-H3 inside the membrane would restrict the mobility of Trp100bHC thus 
intensifying the interaction with the N-terminus of the TMD. Consequently, 
specific interactions involving Trp100bHC with this region of gp41 might occur in 
a manner analogous to that of the 10E8 antibody (see chapter 5).  
 
The data presented herein further suggest that in the presence of a lipid 
membrane, Trp100bHC–MPER/TMD interactions are stabilized by the 
surrounding lipids, decreasing the dissociation rate constant (koff) of the peptide-
lipid-antibody complex. It is likely that full stabilization of such complex would 
require the presence of Trp100HC. Interaction of Trp100HC with surrounding 
lipids in a way previously suggested by Irimia et al (Irimia et al., 2016) with the 
simultaneous interaction of the Trp100bHC reported here with the TMD (FIG 51) 
could represent the neutralization competent conformation adopted by the apex 
of the CDR-H3. We speculate that the resulting gp41-antibody-lipid complex 
involving both CDR-H3 Trp residues would efficiently zip the contact surface 
between the antibody and gp41 interrupting MPER conformational changes 
during the fusion process and, ultimately, preventing viral infection. 
 
Supporting additional, more specific, roles for the CDR-H3 aromatic 
residues, we also show that, although necessary, hydrophobicity is not 
sufficient to trigger the neutralization levels of the parental antibody. In 
particular, shuffling the residues of the apex region of the CDR-H3 of 4E10, 
while keeping a constant hydrophobicity, (or even increasing the hydrophobicity 
by the incorporation of an additional Trp residue) resulted in lower neutralization 
potency. These observations highlight the importance of preserving the specific 
amino acid sequence of the apex to exert its biological function, a requirement 
most likely arising from the adoption of a particular neutralization competent 
conformation.  
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FIG 51. Model of the gp41-4E10 antibody-lipid complex. 4E10 antibody is shown in orange, 
the MPER/TMD region in gray and the lipid molecule in blue. Inset: close-up view of the gp41-
4E10 antibody-lipid complex showing interaction of Trp100bHC with residues M687 and I686 of 
the TMD. A lipid molecule located in between both Trp residues of the CDR-H3 acts as 
additional glue for enhancing the stability of the complex. PDB entry 4XBG and the MPER(664-
690) peptide bound to Fab 10E8 from chapter 5 was used to build the model.  
 
In summary, we report the dual role of the two Trp residues of the apex 
of the CDR-H3 of 4E10, and specially that of Trp100bHC, for the recognition of 
gp41 at the membrane interface, and for its neutralization potency. This work 
contributes to (i) clarify the molecular basis by which the 4E10 antibody exerts 
effective neutralization, and (ii) to guide future formulations to design and to 
develop an efficient vaccine against HIV infection based on anti-MPER 
antibodies. 
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7.1. INTRODUCTION  
 
The bNAb 4E10 displays an extreme breadth of HIV-1 neutralization 
(98 % of viruses blocked in standard infectivity tests (Binley et al., 2004; Huang 
et al., 2012; Zwick et al., 2001)) and thus constitutes a model system for 
structure-guided vaccine design and immunotherapeutics (Huang et al., 2012; 
Kim et al., 2014; Klein et al., 2013b; Montero et al., 2008). This bNAb targets an 
epitope on the gp41 subunit: the section at the base of the MPER helix in 
contact with the viral membrane interface. Since the viral membrane takes part 
in the stabilization of the MPER helix, it is amply assumed that antibodies 
targeting this MPER-membrane site are polyspecific, showing capacity to bind 
lipid moieties (Chen et al., 2014; Irimia et al., 2016; Matyas et al., 2009; 
Sanchez-Martinez et al., 2006a). In fact, some researchers consider these 
antibodies as generally auto-reactive, and postulate that their natural production 
is limited by B-cell tolerance mechanisms (Doyle-Cooper et al., 2013; Haynes et 
al., 2005; Verkoczy et al., 2014).  
 
Experimental evidence suggesting that 4E10 binds to phospholipids, 
particularly anionic species as phosphatidylserine (PS), cardiolipin (CL) or 
phosphatidylinositol (PI), has been obtained in several laboratories during the 
last decade (Finton et al., 2013; Haynes et al., 2005; Matyas et al., 2009; 
Sanchez-Martinez et al., 2006b). A binding pocket was proposed to exist within 
the 4E10 paratope to accommodate the polar head groups of PS or CL (Finton 
et al., 2013). According to this proposal, the 4E10 paratope with lipid bound 
would differ structurally from the paratope with peptide epitope bound. This 
concept has been challenged by us and by recent reports showing the crystal 
structures of the unbound Fab forms and Fab-lipid complexes (Bird et al., 2014; 
Irimia et al., 2016) (see also chapter 4). Co-crystals obtained in the presence of 
phosphatidic acid (PA), phosphatidylglycerol (PG), and glycerol phosphate 
reveal two binding sites on the surface of 4E10 paratope that approaches the 
membrane, which involve residues of the heavy-chain complementarity 
determining region 1 (CDR-H1) (Irimia et al., 2016). This crystallographic 
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analysis is also consistent with the simultaneous accommodation of the 
phospholipid head-group moieties and bound peptide epitope within the 4E10 
paratope, and underscores the role of the hydrophobic CDR-H3 in establishing 
interactions with the lipid tails. 
 
Here, we have attempted to discern the specific roles played by 
membrane lipids in the 4E10 neutralization mechanism. To that end, we have 
run liposome-flotation assays (physical separation), which have been 
subsequently complemented with spectroscopic titration assays using Fab-s 
labeled with the polarity-sensitive probe NBD. Direct partitioning of the 4E10 
antibody from the aqueous phase into membranes was driven by the favorable 
electrostatic interactions between the membrane and paratope surfaces. In 
contrast, electrostatic forces were not required to trigger the process of binding 
to peptide epitope when anchored to the membrane. However, it is worth noting 
that electrostatic forces, were in general beneficial for binding to the epitope-
anchored peptide, and that these favorable interactions correlated with the 
neutralizing activity of the 4E10 antibody. Collectively, our observations support 
the view that favorable, albeit unspecific, interactions between 4E10 and lipids 
play a central role in the neutralization mechanism by 4E10. The implications of 
these findings for the natural production and biological function of this antibody 
are discussed. 
 
7.2. MATERIALS AND METHODS 
 
7.2.1. Materials 
 
The peptides used in the structural and biophysical studies were 
synthesized as described in 3.2.1. Expression vector and antibodies were 
obtained as indicated in 5.2.1. 
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7.2.2. Fab-s production and characterization. 
 
Experimental procedures described in 3.2.2 and 4.2.2 were followed for 
the mutation, expression and purification of Fab-s. ITC, flotation, NBD 
fluorescence, photo cross-linking and cell entry inhibition measurements were 
carried out as described in section 3.2.3, 3.2.4, 5.2.5, 5.2.4 and 6.2.4, 
respectively.  
 
7.3. RESULTS 
 
7.3.1. Partitioning of 4E10 into membranes depends on anionic 
phospholipids. 
 
We first determined the partitioning of the 4E10 antibody into membranes 
using a vesicle flotation assay. Initial experiments were aimed at establishing 
the contribution of each lipid present in the VL mixture, mimicking the viral 
envelope composition (FIG 52A) (Huarte et al., 2016). A major fraction of the 
input antibody was recovered from the upper fractions, co-floating with the VL 
vesicles. Subtraction from the VL mixture of individual zwitterionic phospholipids 
(sphingomyelin (SM), or phosphatidylethanolamine (PE)), or cholesterol (Chol) 
did not abolish membrane binding. However, removal of the anionic 
phosphatidylserine (PS) prevented 4E10 to bind to the liposomes. To determine 
if binding is specific for PS, or is a more general electrostatic effect, we replaced 
PS with other anionic phospholipid species (i.e. PG, PI, PA or CL). The result 
shown in FIG 52B clearly shows that binding of 4E10 to liposomes is restored 
for all anionic compositions tested. 
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FIG 52. Partitioning of the anti-MPER 4E10 Fab into membranes. A) Effect of the 
constituent lipids of the VL mixture on 4E10 membrane partitioning in a sucrose gradient. Lipid 
vesicles pre-incubated with the Fab were subject to centrifugation. Based on their different 
densities, the sample was divided into four different fractions. An additional fraction employing 
SDS was collected, representing the material attached to the surface of the tube. Location of 
the liposomes in the third and fourth fractions (i.e., floating fractions) was detected from the 
Rho-PE emission (bottom panels). The presence of Fab was probed by WB. B) Effect of 
replacing PS by other anionic phospholipids; PG, PI, PA or CL.  
 
7.3.2. Basic residues of the paratope promote partitioning into the 
membrane. 
 
The previous flotation experiments suggest that electrostatic interactions 
with anionic phospholipids promote the partitioning of 4E10 into membranes. 
Inspection of the surface of the paratope in contact with the membrane interface 
reveals a positively charged region close to the binding site of the antibody 
(Irimia et al., 2016) (FIG 53A). Thus, we sought to elucidate the relevance of 
this region for the electrostatic interaction with the membrane. We designed two 
Fab mutants substituting separately the basic residues Arg73HC or Lys100eHC 
by Glu (R73E and K100eE mutants, respectively, FIG 53A). We assumed that 
such charge-reversing substitutions reduced the overall positive net charge at 
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the base of the antibody making it less prone to interact electrostatically with 
negatively charged membranes. In addition, the analysis included a negative 
control designated as BS, in which Ser-to-Ala mutations at positions 28 and 30 
of the CDR-H1 were prepared. These substitutions did not appreciably alter the 
surface charge of the paratope, even if involving residues located in a recently 
described lipid-binding site (Irimia et al., 2016).  
 
 
FIG 53. Design of 4E10 variants with exposed basic residues of the paratope mutated. A) 
Effect of R73E and K100eE substitutions on the surface charge of the paratope. B) Membrane 
partitioning as measured by flotation assays using vesicles containing 50 mol % of anionic lipid 
(PS). BS stands for a negative control with a double Ser-to-Ala substitution at positions 28 and 
30 of the heavy chain. 
 
FIG 53B illustrates the membrane-binding phenotypic traits resulting from 
the mutations. To make a more robust comparison, these assays employed 
membranes containing high levels of PS (PC:PS 1:1, mole ratio). As expected, 
intensifying the electrostatic interaction promoted association of all input WT 
antibody with LUVs (see below). In contrast, association of R73E to vesicles 
was reduced by approximately 50 %. Consistent with an even weaker 
partitioning in membranes, the K100eE mutant was barely recovered in the 
floating fractions containing the vesicles. The negative BS control reproduced 
the behavior of the WT antibody. We arrived at similar conclusions using VL 
vesicles (see below). 
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7.3.3. Functional characterization of the charge-reversing mutants. 
 
We next examined the role of electrostatic forces in the biological 
function of the 4E10 antibody (FIG 54, 55 and Table 11). First, ITC experiments 
were conducted to assess the effect of the above described mutations on the 
affinity of 4E10 for the peptide (FIG 54A). The calculated KD values were all in 
the nM range (Table 11). A significant reduction of affinity for the epitope 
peptide (≈20-fold) was only observed in the case of the K100eE mutant.  
 
To examine the effect of the mutations in a membrane context, flotation 
experiments were next carried out comparing bare VL vesicles with VL vesicles 
containing the peptide (FIG 54B). In the absence of peptide, the most 
conspicuous effect was observed for the K100eE mutant, which again did not 
appreciably associate with membranes in the VL system (left panel). As 
compared to WT or BS, a lower level of binding to LUVs was also evident for 
the R73E mutant. Addition of peptide resulted in the complete association of the 
WT and BS antibodies with VL vesicles (FIG 54B, right panel). By comparison, 
although a significant increase with respect to the bare vesicles was evident, 
association of R73E and K100eE variants with vesicles containing peptide was 
still not complete.  
 
Table 11. Thermodynamic parameters of binding of Fab 4E10 mutants to the MPER 
peptide and their neutralization potencies. 
Antibody 
(4E10) 
KD 
(nM) 
ΔG° 
(kcal mol-1) 
ΔH° 
(kcal mol-1) 
-TΔS° 
(kcal mol-1)a 
nb 
HXB2- IC50 
(µg/mL) 
JRCSF- IC50 
(µg/mL) 
4E10_WT 4.6 ± 1.5 -11.4 ± 0.2 -15.1 ± 0.2 3.7 1.0 ± 0.1 0.21 ± 0.02 1.26 ± 0.09 
BS 12.2 ± 2.5 -10.8 ± 0.1 -11.7 ± 0.1 0.9 1.3 ± 0.1 0.38 ± 0.03 1.59 ± 0.27 
R73E 12.8 ± 3.5 -10.8 ± 0.1 -14.7 ± 0.2 3.9 1.1 ± 0.1 5.3 ± 0.4 13.2 ± 3.5 
K100eE 91 ± 14 -9.6 ± 0.2 -10.4 ± 0.2 0.7 1.4 ± 0.1 3.3 ± 0.2 12.7 ± 4.0 
a Temperature was 298 K. 
b n refers to the molar ratio peptide/protein. 
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FIG 54. Functional characterization of 4E10 mutants. A) Binding isotherms of the MPER 
peptide epitope to Fab 4E10 examined by ITC. The upper panel indicates the heat released 
upon consecutive injections of 10 µL of peptide solution (40 µM) into Fab (3 µM) in the 
calorimeter cell, and the lower panel the integrated heats (symbols) and non-linear least-
squares fit (solid line) to the data using a one site binding model with the program ORIGIN 7.0. 
The thermodynamic parameters of binding are displayed in Table 11. B) Flotation experiments 
in the presence of VL LUVs (left) or VL LUVs containing MPER(671-693) peptide (right). C) 
Recognition of VL LUVs (left) or VL LUVs containing MPER(671-693) peptide (right) as determined 
by dot blot analysis. 
WT R73E K100eE BS 
JRCSF  
µg/mL 
N
eu
tra
liz
at
io
n 
!g/mL
0,01 0,1 1 10 100
%
N
eu
tra
liz
at
io
n
-20
0
20
40
60
80
100
!g/mL
0,01 0,1 1 10 100
%
N
eu
tra
liz
at
io
n
-20
0
20
40
60
80
100
!g/mL
0,01 0,1 1 10 100
%
N
eu
tra
liz
at
io
n
-20
0
20
40
60
80
100
!g/mL
0,01 0,1 1 10 100
%
N
eu
tra
liz
at
io
n
-20
0
20
40
60
80
100
Time (min) 
µc
al
/s
ec
 
µc
al
/m
ol
 o
f i
nj
ec
ta
nt
 
Molar Ratio Molar Ratio 
Time (min) 
Molar Ratio Molar Ratio 
Time (min) Time (min) 
A 
B 
C 
580 600 620
0
20
40
60
80
100
580 600 620 580 600 620 580 600 620 580 600 620 580 600 620
WT 
R73E 
K100eE 
BS 
Rho-PE 
VL  
Input 1 2 3 4 SDS 
Floated 
λ(nm) 
In
te
ns
ity
 (a
.u
.) 
Floated 
580 600 620
0
20
40
60
80
100
580 600 620 580 600 620 580 600 620 580 600 620 580 600 620
Input 1 2 3 4 SDS 
λ(nm) 
In
te
ns
ity
 (a
.u
.) 
VL (+peptide) 
WT 
R73E 
K100eE 
BS 
VL 
[LUVs]  
VL (+peptide) 
[Peptide-LUVs]  
  168 
The previous flotation results were obtained under conditions that 
promote membrane partitioning (i.e., high lipid concentration). In this regard, 
they allow discerning high-to-moderate from low range of membrane affinities. 
To establish further differences in affinity, and distinguish between high and 
moderate affinity conditions, membrane concentration was titrated down in dot-
blot assays (FIG 54C). In this approach, physical separation is attained after 
washing the nitrocellulose membranes, where the liposomes were previously 
spotted, several times to remove loosely bound Fab. For the matter of 
comparison, measuring conditions were initially set up to reproduce the relative 
binding observed in flotation assays (i.e., to match signals of the Fab-s 
recovered in the floating fractions). These experiments underscored the lower 
capacity of the charge-reversing R73E and K100eE mutants for partitioning into 
VL membranes, as well as their lower affinity for VL vesicles containing the 
epitope peptide.  
 
To establish a correlation between biological function, binding to 
membrane-embedded epitope and membrane partitioning, the mutants were 
tested in neutralization assays (FIG 55A). The increment of the IC50 values as 
compared to the WT antibody indicated that the capacity for inhibiting PsV cell 
entry of both polarity-reversed mutants, R73E and K100eE, was reduced 
approximately by an order of magnitude (FIG 55A and Table 11). As above, the 
negative BS control reproduced for the most part the behavior of the WT Fab. 
Finally, dot-blot assays indicated that the reduced levels of infection-inhibition 
appeared to correlate well with lower binding of the mutant antibodies to PsV 
immobilized on a solid substrate (FIG 55B). Overall, these results revealed a 
correlation between direct binding to immobilized PsVs (FIG 55B) and direct 
binding to immobilized vesicles containing the epitope peptide (FIG 54C). 
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FIG 55. Neutralization profiles of the 4E10 mutants (II). A) JRCSF PsV neutralization 
capacity of the different mutants. B) JRCSF PsV recognition as determined by dot blot analysis. 
Decreasing amounts of PsV (from left to right) were spotted onto nitrocellulose membranes and 
probed with 4E10 Fab and its mutants. 
 
7.3.4. Contribution of the electrostatic interactions to 4E10 
partitioning into membranes. 
 
The results displayed in FIG 52-55 and chapter 6 warrant the 
consideration of 4E10 interaction with membranes as a partitioning process 
contributed by electrostatic forces and the hydrophobic effect, respectively. 
Thus, this nonspecific association is more accurately described by a partition 
coefficient rather a binding constant which assumes the formation of Fab:lipid 
stoichiometric complexes. To gain insight into the relative contribution of 
electrostatic interactions we sought to analyze the partitioning process 
quantitatively by performing spectroscopic titration assays (FIG 56).  
 
In chapters 5 and 6 we have shown that the polarity-sensitive NBD probe 
replacing for Trp at the position 100b of the CDR-H3 can be used to monitor 
Fab insertion into the membrane. FIG 56A illustrates the changes in NBD 
fluorescence that occur upon incubation of the labeled NBD-Fab 4E10 with 
increasing concentrations of VL or PC:PS lipid vesicles. In the presence of VL 
vesicles NDB emission shifts toward shorter wavelengths and increases in 
intensity (FIG 56A, leftmost panel), indicating the movement of the dye (and 
therefore the apex of the CDR-H3) from its original location surrounded by 
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solvent molecules, to a more hydrophobic environment. In line with the absence 
of interactions deduced from the flotation assays (FIG 52B), the fluorescence of 
the NBD-Fab did not change upon incubation with vesicles devoid of PS (FIG 
56A, left-center panel). Changes in NBD emission were more marked when 
vesicles composed of PC:PS were used as model membranes instead (FIG 
56A, right panels), reinforcing the idea that favorable electrostatic interactions 
promote 4E10 partitioning. 
 
 
FIG 56. Binding of 4E10 to LUVs monitored by changes in NBD fluorescence. A) Changes 
of NBD-4E10 fluorescence in the presence of increasing concentrations of liposomal lipid as 
indicated in the panels. 150 nM of NBD-Fab was used. B) Titration of NBD-labeled Fab with 
LUVs. The fraction of Fab bound was plotted as a function of the concentration of lipid 
accessible (half the total lipid concentration) for vesicles containing different mol percentages of 
PC:PS as follows: 90:10 (gray); 75:25 (magenta); 50:50 (green); 25:75 (blue); 0:100 (red). The 
molar fraction partition coefficients, Kx, were calculated from the best fit of Equation 1 to the 
data (curves). Each symbol on the plot represents an average of three independent 
experiments (±S.D. if larger than symbol). C) Plot of the free energy of partitioning versus the 
membrane-surface potential in the previous lipid vesicles. 
 
Titration experiments were next conducted to calculate the mole-fraction 
partition coefficients (Kx) with different mol percentages of monovalent acidic 
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phospholipid in the membrane (FIG 56B, left panel). Association with vesicles 
increased with the PS content, following the pattern expected from the 
contribution of favorable electrostatic interactions (Arbuzova et al., 1997). 
Plotting the observed partitioning free energy (ΔGobs) versus the surface 
potential calculated according to standard methodologies (McLaughlin, 1989), 
yielded a value of ca. -5 kcal mol-1 for membranes lacking net charge (FIG 
56C). This value indicates that, in the absence of anionic PS, a lipid 
concentration of ca. 15 mM would be required for 50 % of the Fab be bound to 
membrane. By comparison, the value measured for pure PS vesicle was ΔGobs 
= - 8.8 kcal mol-1. A simple calculation, reveals that lipid diluted three orders of 
magnitude (i.e., 17.5 µM) is sufficient to attain a similar extent of Fab binding. 
Interestingly, a Kx in the order of 0.6 × 106 was measured for the VL mixture 
(FIG 56B, right panel), which renders a ΔGobs value in the range of those 
measured in vesicles containing 50-25 mol % of PS (FIG 56C). This suggests 
that in VL vesicles, besides the electrostatic attraction, additional factors favor 
water-membrane partitioning of the antibody. 
 
7.3.5. Contribution of the electrostatic interactions with membrane 
to 4E10 epitope peptide binding 
 
To infer how electrostatically-driven membrane partitioning contributes to 
epitope recognition, we conducted experiments with PC:PS vesicles-containing 
the epitope peptide MPER(671-693) (FIG 57). Consistent with previous flotation 
results (FIG 55), comparison of NBD emission spectra obtained upon incubation 
with vesicles containing 25 or 50 % of PS reveals the favorable contribution of 
anionic phospholipids and peptide epitope to Fab partitioning (FIG 57A). 
Titration curves based on those spectra allowed determination of the actual Kx 
values (FIG 57B). Overall, the presence of peptide resulted in an increment of 
the partitioning constant, the effect being more pronounced with the highest 
proportion of PS.  
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FIG 57. Effect of electrostatic interactions on epitope recognition. A) Changes of NBD-
4E10 fluorescence emission spectra in the presence of increasing concentrations of vesicles 
(500-250-50 µM and 500-100-50-25 µM in the case of LUVs with 25 and 50 % PS, 
respectively), were measured in the absence (dotted lines) or in the presence of 1.7µM of 
MPER(671-693) peptide (solid lines). B) Effect of PS on promoting partitioning into vesicles with 
and without MPER(671-693) peptide. Solutions of NBD-Fab were titrated with PC:PS LUVs as 
indicated. Each data point is the average of three titrations (± SD) experiments as the one in 
the previous panel. C) Kinetics of NBD-Fab incorporation into bare vesicles containing 25 or 
50 % of PS (left panel) or into the same vesicles loaded with 1.7µM MPER(671-693) peptide (right 
panel). Peptide interaction with 25 % PS vesicles was confirmed by the presence of an adduct 
band in a photo cross-linking assay (insets). The arrow indicates NBD-Fab addition. Lipid 
concentration was 100 µM.  
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To study in more detail the combined effect of electrostatic interactions 
with membrane surface and peptide recognition, we next performed a kinetic 
analysis. FIG 57C displays the kinetic traces of the fluorescence intensity 
change that occurs upon injection of NBD-Fab (arrow) into buffer containing 
LUVs (left panel), or buffer containing LUV-peptide complexes (right panel). 
 
Inclusion of 25 or 50 mol % PS LUVs (top panel) resulted in a sudden 
increase of fluorescence intensity followed by a signal plateau, consistent with 
the fast process of membrane association (left panel). In contrast, upon addition 
of the same vesicles containing the peptide, the sudden increase was followed 
by a second phase, in which the fluorescence signal increased gradually, 
leveling off at later times (right panel). Thus, whereas the fast phase of the NBD 
change can be ascribed to spontaneous membrane insertion, the slower 
incorporation of Fab that remained in solution appears to be driven by specific 
peptide-recognition. Association of slow binding rates with peptide engagement 
was actually demonstrated by photo cross-linking experiments. To that end, the 
4E10 Fab was modified with the UV-sensitive unnatural amino acid pBPA (Abe 
et al., 2012; Young et al., 2010), which was genetically encoded at position 
Trp100bHC of the antibody as previously described in chapter 6. Adduct 
formation was detected by SDS-PAGE only when the lipid vecicles harboring 
the MPER(671-693) peptide were subjected to UV light (FIG 57C, insets). 
Interestingly, the peptide-dependent slower phase observed for the 50 % mol 
PS LUVs (right panel, red line) was faster than that observed with 25 % mol PS. 
Thus, the PS appeared to have two effects. On the one hand, and as previously 
described, PS promoted higher levels of spontaneous incorporation. On the 
other hand, PS promoted faster recognition of the epitope peptide by the 
fraction of the unbound Fab. 
 
Pre-attachment of 4E10 molecules to the membrane of pre-activated 
virions has been postulated as a mechanism favoring viral neutralization (Alam 
et al., 2009; Haynes et al., 2010). This two-step model assumes that the 
fraction of 4E10 antibody pre-bound to the membrane engages with gp41 upon 
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fusion activation. FIG 58 illustrates experiments performed to address the 
capacity of the Fab pre-bound to membrane for encountering and effectively 
engage the inserted epitope. To ensure that all added Fab actually bound first 
to membranes, we increased the lipid concentration in the assay, as well as the 
PS content in the vesicles. As explained in the diagram displayed in FIG 58A, 
under these conditions the slower process of peptide engagement can be 
subsequently scored by photo cross-linking assays. 
 
 
FIG 58. Epitope recognition of 4E10 antibody prebound to membrane A) Schematic 
representation of the assay showing the two possible events that can take place when 
negatively charged lipids drive fast and complete partitioning of the 4E10 antibody to the 
membrane surface of vesicles containing embedded epitope peptides. The upper right panel 
illustrates the movement of the antibody through the membrane surface until peptide encounter 
that results in efficient epitope engagement. The opposite situation is displayed in the lower 
right panel, where the 4E10 antibody remains bound to the membrane in the initial position and 
therefore far away from the peptide. B) Upper panel: kinetics of NBD-Fab incorporation into 
pure PS vesicles in the presence (red line) or absence of MPER(671-693) peptide (black solid 
line). The arrow indicates NBD-Fab addition to a sample of buffer (a), 250 µM LUVs (b) and 
250 µM LUVs containing 1.7 µM MPER(671-693) peptide. Lower panels: Photo cross-linking 
experiment of Fab 4E10-pBPA to MPER(671-693) peptide inserted into 250 µM of pure PS LUVs 
(top). In the bottom panel, the MPER(671-693)/W672A-F673A (CTL) peptide was used as a control 
for spontaneous cross-linking due to antibody-peptide proximity within the membrane. Protein 
bands were detected by Coomassie staining or Western-blot (right and left panels, 
respectively). 
 
As expected, Fab addition to vesicles composed of 100 % PS resulted in 
an abrupt increase of fluorescence both in the presence and in the absence of 
epitope peptides. The Fab-peptide complexes formed under these conditions 
were subjected to UV light and the formation of adducts analyzed by SDS-
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PAGE and WB. An additional band corresponding to cross-linked peptide 
(MPER(671-693)) and Fab HC was observed (FIG 58B, lower panel). The same 
cross-linking pattern was obtained when the peptide was added to pre-
incubated Fab-100 % PS vesicles to assure Fab-membrane pre-binding (data 
not shown). However in negative control samples that contained a peptide with 
crucial residues for antibody binding mutated to Ala (MPER(671-693) /W672A-
F673A) the additional band resulting from the cross-linking was absent  (FIG 
58B, lower panel). This control was included to assure that the signal came 
from specific peptide binding and discard spontaneous cross-linking arising 
from the high density of Fab-peptide pre-concentrated on the membrane 
surface. 
 
7.4. DISCUSSION 
 
The Env complex embodies the entry machinery of the HIV-1 and 
constitutes its main antigen (Karlsson Hedestam et al., 2008; Wyatt and 
Sodroski, 1998). The gp41 MPER is highly conserved across the different HIV-1 
strains and isolates, and is functionally involved in assisting the membrane 
fusion process that culminates with cell infection (Apellaniz et al., 2014b; Saez-
Cirion et al., 2002; Salzwedel et al., 1999). Due to its high degree of sequence 
conservation and the key role played by this element in the viral cycle, the 
bNAb 4E10 raised against the MPER exhibits an unusual neutralization breadth 
(Kwong and Mascola, 2012; Montero et al., 2008; Zwick, 2005). It has been 
hypothesized that affinity for membranes may sustain the neutralization 
capacity of the 4E10 antibody (Alam et al., 2009; Cardoso et al., 2005; Chen et 
al., 2014; Dennison et al., 2009; Finton et al., 2013; Huarte et al., 2008; Irimia et 
al., 2016; Matyas et al., 2009; Sanchez-Martinez et al., 2006b; Scherer et al., 
2010; Sun et al., 2008). However a systematic, quantitative assessment of 
4E10 partitioning into membranes, was so far lacking. Thus, a detailed 
examination of the process was important for two reasons: i) to establish the 
lipid specificity range, which allows contrasting the assumption that lipid auto-
reactivity can prevent the production 4E10-like antibodies through vaccination; 
  176 
and ii) to establish the contribution of membrane-assisted MPER engagement 
to the biological function of 4E10. 
 
7.4.1. Functional relevance of spontaneous partitioning 
 
Our data demonstrate that 4E10 partitioning into membranes is due to 
unspecific binding to negatively charged membrane surfaces promoted by basic 
residues exposed on the paratope, and not through the specific recognition of a 
particular phospholipid head-group. In this regard, 4E10 qualifies better as a 
peripheral membrane protein that uses electrostatic and hydrophobic forces in 
concert for translocating into membranes (see for reviews: (Gelb et al., 1999; 
McLaughlin and Aderem, 1995; Mulgrew-Nesbitt et al., 2006)). Through this 
work the dependence of 4E10 membrane partitioning on the electrostatic 
interaction has been assessed by employing two complementary approaches: i) 
altering the surface charge of the Fab paratope via mutagenesis (FIG 53 and 
55); and ii) altering the membrane density of monovalent anionic phospholipid 
(FIG 56).  
 
As expected from the unspecific nature of the interaction, mutation of 
basic residues to render R73E or K100eE variants hampered direct partitioning. 
However, albeit less potent, these mutants were still active in neutralization 
assays, an effect that correlated with lower binding to immobilized PsVs or VL 
vesicles containing peptide. Thus, although comprising a modulatory factor for 
the amount of membrane-bound antibody, and hence, potency, partitioning 
driven by electrostatic interaction was not absolutely required for the 
neutralizing activity of the antibody. 
 
Results obtained altering the charge surface density of the membrane 
further demonstrate that the combination of electrostatic and non-polar 
interactions can quantitatively explain the membrane binding behavior of 4E10 
(FIG 56). Contribution of both components to 4E10-membrane partitioning is 
qualitatively illustrated in FIG 59. To further isolate the electrostatic contribution 
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of the paratope surface from the contribution of the CDR-H3 hydrophobicity to 
membrane binding, we added to the comparison Fab-s with the H3 loop apex 
ablated (ΔLoop variants in FIG 59, right-most panels). The membrane binding 
of the WT Fab under the conditions of the flotation experiments is summarized 
in the left panel: predominant recovery of Fab bound to membrane in the 
absence of peptide (top), and full binding to VL-peptide complexes (bottom). 
Reducing negative charge at the paratope surface (K100eE mutant, top, 
center), ablates the spontaneous interaction with VL membranes, and 
diminishes the Fab fraction bound to VL-peptide complexes. The Fab fraction 
bound to VL-peptide complexes was even lower upon removal of the CDR-H3 
apex (K100eE/ΔLoop mutant, top, left). When the net surface charge of the 
membrane is set to 0, a similar trend can be observed for the Fab WT, i.e., 
absence of binding to LUVs devoid of peptide, and reduction of the bound 
amount in the case of LUV-peptide complexes (VL w/o PS, bottom center and 
left panels).  
 
All in all, these data support the spontaneous interaction of 4E10 with 
membranes, i.e., in the absence of peptide ligand anchored to the bilayer, and 
that such interaction can contribute to the more efficient recognition of the 
membrane-bound epitope. This is in contrast to the 10E8 interaction with 
membranes, which is strictly dependent on binding to the membrane-inserted 
epitope (chapter 5). However, the 10E8 bNAb displays higher potency than the 
4E10 antibody (IC50 mean values of 1.93 and 0.35 µg/mL for 4E10 and 10E8, 
respectively) and this phenomenon occurs without exhibiting binding to anionic 
phospholipid (Huang et al., 2012; Kwon et al., 2016a). This important difference 
suggests that 4E10 and 10E8 mechanisms for engaging MPER helix at 
membrane interfaces and exert neutralization are essentially different (see 
general discussion chapter). 
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FIG 59. Summary of electrostatic/hydrophobic interactions favoring 4E10 partitioning 
into membranes (A) and mechanisms to explain their involvement in MPER helix 
engagement (B). See text for details. 
 
7.4.2. Implications for the mechanism of neutralization 
 
The peripheral membrane interaction described in this chapter may 
condition the mechanism of neutralization. FIG 59B illustrates the three, non-
exclusive mechanisms that have been invoked to explain the role of membrane 
interactions in the process of neutralization by 4E10 antibody, namely:  
 
I) Structural adaptation (FIG 59B, left panel): the insertion of helical MPER 
epitope onto the membrane interface imposes structural adaptations to the 
mechanism of recognition within the two-dimensional membrane milieu 
(Sanchez-Martinez et al., 2006b; Scherer et al., 2010). It has been reported that 
PS becomes accessible at the external leaflet of membranes in mature virions 
(see for a discussion on this issue: (Huarte et al., 2016)). Our data suggest that 
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4E10 takes the advantage of favorable electrostatic interactions with PS to 
enhance affinity for the membrane-bound epitope ligand (FIG 54 and 57), most 
likely by providing an optimal orientation of the antibody with respect to the 
membrane. 
 
II) Avidity increase (FIG 59B, center): In the order of 10 Env complexes 
incorporate per virion, meaning that the non-immunogenic lipid component of 
the envelope constitutes the main structural-functional element of the HIV 
particle accessible from the external milieu (Zhu et al., 2006). The reduced 
epitope accessibility arising from the low spike density precludes bi-functional 
binding and has been thus regarded to as an evasion mechanism (Klein et al., 
2013b). Lipid polyreactivity could sustain an increase in IgG avidity by endowing 
4E10 with the capacity for directly interacting with membranes (Haynes et al., 
2010; Klein et al., 2013b). Although our data support this notion, they imply that 
4E10 interactions are driven by unspecific electrostatic interactions, which 
would be particularly intense at the high effective concentration of lipid that an 
unbound Fab would sense after engagement of the Env epitope by the other 
IgG Fab. 
 
III) Pre-concentration in the viral membrane (FIG 59B, right): several authors 
have proposed a two-step mechanism for neutralization according to which 
4E10 first attaches to the viral membrane (Alam et al., 2009; Haynes et al., 
2010). This reversible step would be required to ensure subsequent binding to 
target MPER epitope, which is transiently exposed after fusion activation. Pre-
attachment implies: a) sufficient free energy for driving spontaneous 
partitioning; and b) competence of the Fab pre-bound to membranes for 
subsequent specific binding of epitope ligand. Our data (FIG 56) are consistent 
with partitioning constants in the range of those measured for peripheral 
membrane proteins (Mulgrew-Nesbitt et al., 2006). Moreover, by combining 
fluorescence spectroscopy and photo-cross-linking assays we were able to 
demonstrate the specific epitope binding competence of pre-bound antibody 
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(FIG 58B). Thus, in principle our in vitro data employing model systems support 
the feasibility of this mechanism. 
 
Collectively, the data support the idea that direct membrane interaction is 
of high relevance for the activity of the 4E10 antibody. In addition to the 
previously proposed mechanisms by which membrane binding contributes to 
4E10-induced neutralization, our data suggest that the electrostatic component 
promoting membrane binding likely maximizes the efficiency of the antibody to 
target the pre-hairpin intermediate that emerges upon activation of the fusion 
process. 
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The high degree of conservation of the MPER together with the 
exceptional breadth of the antibodies that recognize this motif make the HIV-1 
MPER epitope an important target for vaccination purposes. However, MPER 
mimotopes incorporated in different vaccine formulation formats have failed to 
elicit broadly neutralizing responses. In this context, the identification of the 
relevant Env-antibody interactions that are crucial for neutralization might 
provide relevant information for future vaccine design. 
 
8.1. PROPOSED ROLES FOR THE CDR-H3 APEX OF ANTI-
MPER ANTIBODIES IN THE VIRAL NEUTRALIZATION 
MECHANISM. 
 
The hydrophobic and aromatic residues at the apex of the CDR-H3 loop 
have been proven essential for the biological function of anti-MPER antibodies. 
Several models have been postulated to explain the role of this element. Some 
proposals picture the CDR-H3 loop as an element whose only role is to confer 
the ability to bind membranes and, therefore, increase avidity (Klein et al., 
2013b) and/or pre-concentrate the antibody in the viral membrane prior to 
fusion (two-step model) (Alam et al., 2009). Others suggest a more specific role 
of the apex of CDR-H3 in mediating viral inhibition. One of the these alternative, 
non-exclusive, views known as structural fixation has proposed that the 
residues of the apex of CDR-H3 correctly align the antibody with respect to 
gp41 and the viral membrane. Hence, the membrane-bound state would 
represent the optimal conformation for specific recognition of the epitope, with 
lipid interactions playing stabilizing roles in the process (Sanchez-Martinez et 
al., 2006a; Scherer et al., 2010). 
 
In addition, an even more active role of the CDR-H3 has been proposed 
(Sun et al., 2008). According to this model, the initial attachment of the apex to 
the membrane facilitates the encounter with the epitope by recognition of 
certain exposed residues. These initial interactions, together with changes in 
the local environment of the peptide caused by the hydrophobic residues of 
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CDR-H3 would cause rotation of MPER. Reorientation of the side chains of key 
residues towards the antibody paratope would culminate with the extraction of 
the peptide from the membrane for a more complete and tight epitope binding. 
 
To shed light on the mechanism by which 4E10 and 10E8 exert 
neutralization, in this thesis we sought to determine (i) the implication of the 
CDR-H3 loop in viral blocking (chapters 3-6) and (ii) the biological function of 
the membrane-binding phenomenon (chapters 5 and 7). 
 
8.2. THE MEMBRANE TOPOLOGY OF THE MPER/TMD 
REGION CONDITIONS THE ANGLE OF APPROACH TO THE 
EPITOPE. 
 
Information about the neutralization competent structure of the region of 
Env targeted by the 4E10 and 10E8 antibodies is crucial for understanding the 
neutralization mechanism of these antibodies. The epitopes of these two bNAbs 
have been initially described to contain MPER residues prior to Lys/Arg683. A 
model based on hydrophobicity distribution (Dennison et al., 2009; Huarte et al., 
2008; Kim et al., 2013; Lorizate et al., 2006; Schibli et al., 2001; Sun et al., 
2008) assumed an interfacial MPER helix inserted parallel to the membrane 
plane, a 90º kink at position Lys683, and the TMD inserting in perpendicular 
orientation with respect to the membrane plane (FIG 60, left). This model has 
been recently challenged by an NMR study of overlapping peptides that 
suggested a continuous helical structure of the MPER/TMD region that inserts 
into the membrane with a tilted orientation, until residue Gly690, where it twists 
to follow a direction parallel to the bilayer normal (Apellaniz et al., 2015). 
 
The data presented in chapters 5 and 6 of this thesis work indicate that 
the epitopes of 4E10/10E8 extend beyond residue Lys/Arg683, encompassing 
the N-terminus of the TMD. The high-resolution crystal structure of a peptide 
comprising the MPER/TMD junction in complex with the 10E8 antibody (chapter 
5) revealed that this region adopts a continuous α-helix in agreement with the 
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previously reported NMR data (Apellaniz et al., 2015) (FIG 60). Moreover, photo 
cross-linking assays described in these chapters, demonstrated the formation of 
additional interactions between the Trp100bHC of antibodies 4E10 and 10E8 
with residues of the TMD in a membrane environment, thereby strengthening 
the notion that residues within the N terminus of the TMD are part of the 
4E10/10E8 epitope. Hence, our results are not consistent with the MPER 
resting parallel to the membrane plane when targeted by the 4E10 or 10E8 
antibodies because that topology would place the Trp100bHC pointing away 
from the TMD, i.e., precluding the formation of additional interactions between 
this residue and the TMD. 
 
 
FIG 60. Proposed models for MPER/TMD topology in the lipid bilayer and implications 
for antibody binding. Left panel: attending to the hydrophobicity distribution of individual 
helices (which do not consider the possibility of oligomeric states), the MPER helix would sit on 
the membrane interface with its main axis parallel to the membrane plane. A kink at position 
Lys683 allows perpendicular insertion of the TMD and places residues from this domain away 
from the Trp100bHC. Hence, this topology would preclude additional interactions between the 
antibody and the TMD. Right panel: topology based on the recent NMR characterization of this 
region (Apellaniz et al., 2015). This topology allows the formation of additional interactions 
between the antibody and the TMD in concordance with the photo cross-linking results 
described in chapters 5 and 6. The atomic coordinates for the 10E8 structure described in 
chapter 5 were used to infer the orientation of the antibody CDR-H3 loop in both cases (insets). 
 
Furthermore, the alternative MPER topology supported by our data 
revises the proposed angle of interaction of the anti-MPER antibodies targeting 
the MPER/TMD junction (Cardoso et al., 2005; Kwon et al., 2016b; Lorizate et 
G690 
✖
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al., 2006; Ofek et al., 2004; Song et al., 2009; Sun et al., 2008). Hence, the data 
presented in this thesis disagree with the assumption that the 4E10 and 10E8 
antibodies approach their epitope from top, with the longitudinal axis of the Fab 
adopting an orientation perpendicular to that of the MPER α-helix in the 
membrane interface (FIG 60, left). Instead, our data rather support an oblique 
angle of docking, in agreement with the recent Cryo-EM structure of a full 
gp160 trimer in complex with the 10E8 antibody (Lee et al., 2016) and the 
structural data of the 4E10 antibody co-crystalized with a PA lipid (Irimia et al., 
2016) (FIG 60, right). 
 
8.1. MODEL PROPOSED FOR ANTIBODY 4E10 DOCKING TO 
THE MPER/TMD HELIX 
 
Binding of the 4E10 antibody to native Env trimers varies between HIV-1 
isolates depending on the neutralization-sensitivity. This phenomenon has been 
explained attending to the different degrees of epitope exposure that arise from 
Env packing (Chakrabarti et al., 2011). Hence, pre-attachment is limited to 
sensitive virus isolates (tier 1a/1b), which are characterized by partially open 
conformations of the Env proteins. However, in spite of the inability of this 
antibody to bind neutralization-resistant isolates (tier 2 and 3), the 4E10 
antibody can neutralize a wide range of these virus variants by targeting the 
pre-hairpin intermediate that emerges upon activation of the fusion process 
(Frey et al., 2008; Gustchina et al., 2008). Hence, 4E10 mAb is effective only 
for a restricted period of time during viral infection (Binley et al., 2003; Dimitrov 
et al., 2007). Due to the requirement of receptor engagement to gain access to 
its MPER epitope, it is likely that the 4E10 antibody has evolved to maximize its 
activity during the short time of the fusion process. Attending to the results 
presented in chapter 7, we propose that the 4E10 antibody increases its on-rate 
against receptor-activated gp41 through membrane binding (FIG 61). 
 
4E10-membrane interactions are driven by the combination of 
hydrophobic (mainly due to the Trp residues at the CDR-H3 apex) and 
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electrostatic interactions. Defined lipid-binding sites have been proposed either 
to coexist in the apo and holo forms of 4E10 (Irimia et al., 2016) or to be 
present only in the apo form (Finton et al., 2013). While the former allows 
simultaneous accommodation of the phospholipid head-group moieties and the 
epitope peptide, the latter assumes the requirement of large conformational 
changes in the antibody paratope for peptide binding. Structural, 
thermodynamic and kinetic evidences gathered from three different versions of 
the CDR-H3 (WT, delta-loop and WDWD; see chapter 2) were essentially 
indistinguishable among the three constructs examined, therefore discarding 
mayor conformational changes of the combining site of the antibody after 
binding. Besides, the crystal structure of the ligand-free version of 4E10 was 
consistent with the classical view postulating a limited flexibility for the paratope 
of mature antibodies. Specifically, the structure of the unbound antibody is in 
agreement with a mechanism in which gains of affinity are the consequence of 
the regular BCR maturation process, and supports simultaneous lipid and 
peptide binding. 
 
Mutational and biophysical analyses described in chapter 7 revealed the 
less obvious role of non-specific electrostatic interactions with the lipid 
membrane. Although non-specific, a mutational characterization of surface-
charge Fab variants performed in that chapter revealed that several positively 
charged residues in the proximity of the antibody-binding site play a role in the 
neutralization mechanism of 4E10. 
 
The data in chapter 7 further suggest that the positively charged surface 
of the 4E10 antibody may have evolved during antibody maturation as a tool to 
accelerate the binding kinetics to the epitope in the short time interval of fusion. 
We speculate that the long-range electrostatic interactions between the 
paratope surface of the antibody and anionic lipids of the viral membrane may 
favor the capture of the transiently exposed epitope by increasing the 
association constant rate (kon) of the process (FIG 61) and, consequently, 
enhance the overall affinity (decrease KD). Thus, in the absence of such 
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electrostatic interactions, a slower association to gp41 might result in a less 
efficient neutralization by the antibody. 
 
 
 
FIG 61. Proposed mechanism for MPER helix engagement by 4E10 at the membrane 
interface. 4E10-MPER binding occurs in a narrow time-window, after activation of the fusion 
process and before 6-HB formation. Electrostatic interactions (dashed lines) take place 
between basic residues on the paratope surface (blue spheres) and acidic lipids in the viral 
membrane (red). Antibody binding induces the conformational change of the CDR-H3 loop 
leading to membrane penetration of the apex residues. Trp100bHC sits close to I686 and M687 
(in red) of the gp41 TMD (in gray), stabilizing a 4E10-gp41 complex after binding. Fixation of 
the MPER/TMD region inhibits phospholipid extraction and therefore fusion with the target 
membrane. 
 
8.1. MODEL PROPOSED FOR ANTIBODY 10E8 DOCKING TO 
THE MPER/TMD HELIX 
 
In comparison to other anti-MPER antibodies, the mAb 10E8 accesses 
its epitope more efficiently in the native Env trimer (Huang et al., 2012). 
General discussion 
Chapter-8-  
 
 189 
Although 10E8 can engage pre-activated virions (FIG 62), it has been proposed 
that 10E8 neutralizes HIV-1 in large part by binding to fusion intermediates that 
arise after receptor engagement (Kim et al., 2014). The 10E8 antibody shows 
no direct membrane binding through electrostatic interactions since it lacks a 
localized net charge on the antibody surface. Consequently, 10E8 cannot 
beneficiate from long distance interactions to maximize binding to the short-
lived pre-hairpin intermediate that is formed during the fusion step.  
 
 
FIG 62. Proposed mechanism for MPER helix engagement by 10E8 at the membrane 
interface. Env breathing alternatively may alternatively 10E8 key binding residues occluded 
inside the trimeric-TMD structure (close), or a more exposed orientation (relaxed). The relaxed 
Env pre-fusion state can be targeted by 10E8. This antibody gains access to MPER by bending 
its constant region towards the membrane in a way that the entire base of the antibody sits 
parallel to the surface of the membrane. 10E8-gp41 binding includes specific interactions of the 
Trp100bHC residue (purple) with residues I686 and M687 (red) of the TMD inside the 
membrane. 10E8 binding stabilizes MPER/TMD in a lifted position, thus interfering with the 
subsequent structural transitions required for fusion.  
 
However, 10E8 interaction surface might also involve elements besides 
the linear MPER and the lipid membrane. Additional contacts between the 
antibody and gp120 or with the C-terminus of the FP from a neighbor gp41 has 
been recently suggested (Lee et al., 2016). Supporting the interaction of 10E8 
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with such surfaces, glycans N88 and N625, located at the base of the trimer, 
sterically obstructed the binding of the antibody to MPER (Kim et al., 2014; Lee 
et al., 2016). Hence, cross-reactivity of 10E8, which permits simultaneous 
binding to gp41 and gp120, could represent an additional mechanism employed 
by the 10E8 antibody to exert viral neutralization. Establishment of these 
additional interactions might require specific adaptations to recognize the 
epitope in the membrane millieu. In this regard, the unusually large “swinging-
like” movement of the constant domain relative to the variable domain, reported 
in chapter 5, might facilitate access to the MPER epitope in the native Env 
trimer (FIG 62). Hence, the higher neutralization potency reported for the 
antibody 10E8 may be explained, at least in part, by a higher accessibility to the 
epitope in the native trimeric Env. Interestingly, the conformation resulting from 
the swinging movement defines a surface plane at the base of the antibody 
where the crystal structure revealed several phosphate ion groups. This 
observation suggests a possible orientation of the Fab with respect to the 
surface of the viral membrane when bound to native Env trimers (FIG 62).  
 
8.1. RELEVANCE OF THE INTERACTIONS BETWEEN A TRP 
RESIDUE AND THE MPER/TMD FOR HIV NEUTRALIZATION.  
 
Despite of the several differences encountered between the 4E10 and 
the 10E8 antibodies, the neutralization potency of both antibodies relies on Trp 
residues located at the apex of their CDR-H3 loops (Alam et al., 2009; Apellaniz 
et al., 2014b; Huang et al., 2012; Scherer et al., 2010). As proposed by the 
mechanisms outlined in FIG 61 and 62 the apex residues of the CDR-H3 loops 
of 4E10 and 10E8 antibodies would increase the binding affinity to their 
membrane-embedded epitopes through the establishment of direct interactions 
with the TMD. Hence, it is reasonable to think that these interactions increase 
the epitope-binding affinity in a membrane context by decreasing the 
dissociation constant rate (koff). Formation of a stable antibody-peptide-lipid 
complex may block MPER-induced decrease in membrane surface hydration 
and electrostatic repulsion, which is required for initial lipid mixing in the fusion 
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event and also, interrupt the conformational changes required for 6-HB 
completion.  
 
Moreover, tight interaction with an MPER/TMD protomer would likely 
interfere with the trimeric conformation of the TMD. Amino acid modification in 
the gp41 MPER/TMD region was argued to alter the neutralization sensitivity of 
the mutated PsV to anti-gp120 antibodies inferring important implications of this 
region in the overall trimeric conformation of the Env glycoprotein (Bradley et 
al., 2016; Dev et al., 2016). Residues I686 and M687 are located within the 
TMD residues that form the coiled-coil motif holding the trimeric architecture of 
the native gp160. Env breathing between a close and a slightly more open 
conformation might probably increase exposure of key epitope residues for 
antibody engagement, including M687. We propose that M687 binding is further 
stabilized by I686 resulting in a more open trimer conformation of Env. The 
formation of such stable complex would halt the cell infection process by either 
interfering with the membrane structural transition required for fusion or by 
disrupting the labile gp41-gp120 subunit association, resulting in slow 
irreversible gp120 shedding (Kim et al., 2014; Ruprecht et al., 2011). 
Collectively, these mechanisms would strengthen the neutralization potency of 
the antibody. 
 
8.2. CONCLUDING REMARKS 
 
Structural, kinetic and sequence-based properties of 4E10 and 10E8 
antibodies determine the distinct MPER binding rates and accessibilities, 
explaining, at least in part, the neutralization mechanism of each antibody. The 
data presented in this thesis, however, underscore a common trend: the 
importance of preserving a continuous α-helical MPER/TMD junction for 
efficient 4E10/10E8 antibody binding. We believe that formation of a tight 
complex involving: i) the aromatic residue Trp100bHC at the apex of the CDR-
H3; ii) residues of the gp41 TMD; and iii) viral membrane lipids, is instrumental 
for neutralization by both antibodies. In that context, stabilization of the 
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protomer would interrupt the progression of fusion and hence, cell infection 
inhibition. Impediments in designing successful immunogens for elicitation of 
anti-MPER-like antibodies are partly attributed to an incomplete understanding 
of the structural and binding characteristics of this class of antibodies. All in all, 
the findings presented in this thesis might contribute to the development of 
more efficient vaccines against HIV infection. Furthermore, they may help 
delineate the functional elements that should be preserved in efficient 
immunotherapeutic agents. 
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MPER peptide Sequence 
(656-683) NEQELLELDKWASLWNWFNITNWLWYIK-amide 
(656-683)R RRR-NEQELLELDKWASLWNWFDITNWLWYIR-RRR-amide 
(671-683) NWFDITNWLWYIK-KKK-amide 
(671-683)R NWFDITNWLWYIR-RRR-amide 
(671-686) KKK-NWFDITNWLWYIKLFI-KKK-amide 
(671-690) NWFNITNWFNITNWLWYIKLFIMIVG-KKKKK-amide 
(664-690)sol KKKK-DKWASLWNWFNITNWLWYIKLFIMIVG-KKKKK-amide 
(664-690)insol KK-DKWASLWNWFNITNWLWYIKLFIMIVGKKK-amide 
(671-693) KKK-NWFDITNWLWYIKLFIMIVGGLV-KK-amide 
(671-693)/W672A-F673A KKK-NAADITNWLWYIKLFIMIVGGLV-KK-amide 

 4E10 
A
ntibody 
C
D
R
-H
3 
M
PER
 
K
D  
(nM
) 
ΔG
° 
(kcal m
ol -1) 
ΔH
° 
(kcal m
ol -1) 
-TΔS° 
(kcal m
ol -1) a 
n
b 
T
m  
(ºC
) 
ΔT
m  
(ºC
) 
ΔH
 
(kcal m
ol -1) 
H
XB
2- IC
50  
(µg/m
L) 
JR
C
SF- IC
50  
(µg/m
L) 
4E
10_W
T 
E
G
TTG
W
G
W
LG
K
P
IG
 
(656-683) 
119 ± 9 
-9.4 ± 0.1 
-19.2  ± 0.2 
9.8 
0.9 ± 0.1 
n.d. 
 
n.d. 
0.21 ± 0.02 
1.3 ± 0.1 
(671-683) 
167 ± 21 
-9.2 ± 0.1 
-15.9 ± 0.3 
6 
0.8 ± 0.1 
69.9 
0.1 
-339 
(671-686) 
48 ± 4 
-10.0 ± 0.1 
-17.9 ± 0.1 
7.9 
0.8 ± 0.1 
n.d. 
 
n.d. 
(671-690) 
4.8 ± 0.5 
11.3 ± 0.1 
-14. 3 ± 0.1 
3.0 
1.1 ± 0.1 
n.d. 
 
n.d. 
(664-690) 
4.6 ± 1.5 
-11.4 ± 0.2 
-15.1 ± 0.2 
3.7 
1.0 ± 0.1 
73.2 
2.5 
-427 
(671-693) 
22 ± 2 
-10.4 ± 0.1 
-12.4 ± 0.1 
1.9 
1.3 ± 0.1 
n.d. 
 
n.d. 
- 
 
 
 
 
 
69.8 
n.a. 
-362 
4E
10_Δ
loop 
E
G
TTG
S
G
G
K
P
IG
 
(671-683) 
45 ± 5 
10.0 ± 0.1 
-20.9 ± 0.2 
10.8 
1.0 ± 0.1 
73.1 
0.8 
-362 
> 100 
> 100 
(664-690) 
7.1 ± 1.2 
-11.1 ± 0.1 
-15.0 ± 0.1 
3.8 
1.2 ± 0.1 
74.3 
2.0 
-392 
(671-693) 
31 ± 4 
-10.2 ± 0.1 
-10.9 ± 0.1 
0.7 
1.3 ± 0.1 
n.d. 
 
n.d. 
- 
 
 
 
 
 
72.3 
n.a. 
-325 
W
/D
-W
/D
 
E
G
TTG
D
G
D
LG
K
P
IG
 
(671-683) 
96 ± 6 
-9. 6 ± 0.1 
-18.2 ± 0.1 
8.6 
1.2 ± 0.1 
72.9 
0.5 
-337 
> 100 
> 100 
(664-690) 
13.9 ± 2.2 
-10.7 ± 0.1 
-12.6 ± 0.1 
1.9 
1.1 ± 0.1 
74.1 
1.7 
-384 
- 
 
 
 
 
 
72.4 
n.a. 
-334 
3W
 
E
G
TTG
W
G
W
W
G
K
P
IG
 
(664-690) 
10.0 ± 1.4 
-10.9 ± 0.1 
-11.8 ± 0.1 
0.89 
1.1 ± 0.1 
73.0 
4 
-360 
0.47 ± 0.02  
2.9 ± 0.4 
- 
 
 
 
 
 
69.0 
n.a. 
-269 
W
/Y
-W
/Y
 
E
G
TTG
Y
G
Y
LG
K
P
IG
 
(664-690) 
6.3 ± 0.9 
-11.2 ± 0.1 
-14.2 ± 0.1 
3.0 
1.1 ± 0.1 
73.1 
2.8 
-319 
10.1 ± 3.6 
19.8 ± 2.9 
- 
 
 
 
 
 
70.3 
n.a. 
-300 
S
cr-1 
E
G
TTG
LG
W
W
G
K
P
IG
 
(664-690) 
3.6 ± 0.5 
-11.5 ± 0.1 
-13.1 ± 0.1 
1.6 
1.1 ± 0.1 
72.2 
3.1 
-387 
3.3 ± 0.6 
7.0 ± 0.3 
- 
 
 
 
 
 
69.1 
n.a. 
-277 
S
cr-2 
E
G
TTG
G
W
W
LG
K
P
IG
 
(664-690) 
5.3 ± 0.9 
-11.3 ± 0.1 
-15.2 ± 0.1 
3.9 
1.1 ± 0.1 
73.1 
4.8 
-377 
0.81 ± 0.04 
6.3 ± 0.6 
- 
 
 
 
 
 
68.3 
n.a. 
-282 
2F5loop 
E
G
TTG
LFG
V
G
K
P
IG
 
(664-690) 
12.5 ± 2.6 
-10.8 ± 0.1 
-11.9 ± 0.1 
1.1 
1.1 ± 0.1 
72.9 
2.7 
-361 
18.4 ± 7.8 
36 ± 14 
- 
 
 
 
 
 
70.2 
n.a. 
-230 
N
_prol 
E
G
TTP
P
G
W
G
W
LG
K
P
IG
 
(664-690) 
6.2 ± 1.3 
-11.2 ± 0.1 
-12.8 ± 0.1 
1.6 
1.1 ± 0.1  
73.9 
5.3 
-376 
0.30 ± 0.08 
6.5 ± 1.6 
- 
 
 
 
 
 
68.6 
n.a. 
-288 
C
_prol 
E
G
TTG
W
G
W
LG
P
P
K
P
IG
 
(664-690) 
6.9 ± 1.5 
-11.1 ± 0.1 
-15.2 ± 0.2 
4.0 
1.0 ± 0.1 
72.9 
5.4 
-350 
6.4 ± 1.4 
17.1 ± 4.3 
- 
 
 
 
 
 
67.5 
n.a. 
-245 
W
100 /C
 
E
G
TTG
C
G
W
LG
K
P
IG
 
- 
 
 
 
 
 
n.d. 
 
n.d. 
5.9 ± 1.0  
48 ± 39 
W
100b /C
 
E
G
TTG
W
G
C
LG
K
P
IG
 
- 
 
 
 
 
 
n.d. 
 
n.d. 
4.6 ± 0.6 
15.1 ± 2.0 
 

 4E10 
A
ntibody 
C
D
R
H
3 
A
dditional 
m
utation 
M
PER
 
K
D  
(nM
) 
ΔG
° 
(kcal m
ol -1) 
ΔH
° 
(kcal m
ol -1) 
-TΔS° 
(kcal m
ol -1) a 
n
b 
H
XB
2- IC
50  
(µg/m
L) 
JR
C
SF- IC
50  
(µg/m
L) 
B
S
 
E
G
TTG
W
G
W
LG
K
P
IG
 
S
28
LC /A
 S
30
LC /A
 
(664-690) 
12.2 ± 2.5 
-10.8 ± 0.1 
-11.7 ± 0.1 
0.9 
1.3 ± 0.1 
0.38 ± 0.03 
1.59 ± 0.27 
R
73E
 
E
G
TTG
W
G
W
LG
K
P
IG
 
R
73
LC /E
 
(671-693) 
12.8 ± 3.5 
-10.8 ± 0.1 
-14.7 ± 0.2 
3.9 
1.1 ± 0.1 
5.3 ± 0.4 
13.2 ± 3.5 
K
100eE
 
E
G
TTG
W
G
W
LG
K
P
IG
 
K
100e
LC /E
 
(671-693) 
91 ± 14 
-9.6 ± 0.2 
-10.4 ± 0.2 
0.7 
1.4 ± 0.1 
2.5 ± 0.3 
12.7 ± 4.0 
Δ
loop_K
100eE 
E
G
TTG
S
G
G
K
P
IG
 
K
100e
LC /E
 
(664-690) 
44 ± 11 
10.0 ± 0.2 
-17.5 ± 0.4 
7.5 
1.1 ± 0.1 
> 100 
> 100 
 
10E8 
A
ntibody 
C
D
R
-H
3 
(M
PER
) 
K
D  
(nM
) 
ΔG
° 
(kcal m
ol -1) 
ΔH
° 
(kcal m
ol -1) 
-TΔS° 
(kcal m
ol -1) a 
n
b 
T
m  
(ºC
) 
ΔT
m  
(ºC
) 
ΔH
 
(kcal m
ol -1) 
H
XB
2- IC
50  
(µg/m
L) 
JR
C
SF- IC
50  
(µg/m
L) 
10E
8_W
T 
G
K
Y
Y
D
FW
S
G
Y
P
P
G
E
E
 
(656-683) 
93 ± 13 
9.6 ± 0.1 
-5.4 ± 0.1 
-4.2 
0.9 ± 0.1 
65.8 
4.3 
-118 
0.27 ± 0.01 
0.29 ± 0.02 
(671-683) 
746 ± 307 
-8.3 ± 0.3 
-3.3 ± 0.3 
-5.0 
0.9 ± 0.1 
62.1 
0.6 
-76 
(671-686) 
369 ± 84 
-8.7 ± 0.1 
-9.6 ± 0.5 
0.9 
0.9 ± 0.1 
n.d. 
 
n.d. 
(671-690) 
10 ± 1.6 
-10.9 ± 0.1 
-8.4 ± 0.1 
-2.5 
0.8 ± 0.1 
68.2 
6.7 
-216 
(664-690) 
9.6 ± 1.0 
-10.9 ± 0.1 
-9.6 ± 0.1 
-1.3 
1.0 ± 0.1 
69.2 
7.7 
-303 
(671-693) 
9.4 ± 2.0 
-10.9 ± 0.1 
-9.0 ± 0.1 
-1.9 
1.3 ± 0.1 
n.d. 
 
n.d. 
 
 
- 
 
 
 
 
 
61.5 
n.a. 
-78 
10E
8_P
/A
 
G
K
Y
Y
D
FW
S
G
Y
A
P
G
E
E
 
(656-683) 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
61.1 
0.7 
-57 
8.6 ± 4.2 
0.68 ± 0.06 
(664-690) 
161 ± 22 
-9.2 ± 0.1 
-11.1 ± 0.2 
1.9 ± 0.3 
0.8 ± 0.1 
62.4 
2.0 
-58 
- 
 
 
 
 
 
60.4 
n.a. 
-67 
10E
8_W
/Y
 
G
K
Y
Y
D
FY
S
G
Y
P
P
G
E
E
 
(656-683) 
277 ± 39 
-8.9 ± 0.1 
-8.7 ± 0.3 
-0.25 
0.7 ± 0.1 
63.2 
1.7 
-88 
8.1 ± 0.9 
7.0 ± 0.5 
(664-690) 
52 ± 12 
-9.9 ± 0.1 
-8.9 ± 0.1 
-1.0 ± 0.2 
1.1 ± 0.1 
65.0 
3.5 
-82 
- 
 
 
 
 
 
61.5 
n.a. 
-101 
10E
8_W
/A
 
G
K
Y
Y
D
FA
S
G
Y
P
P
G
E
E
 
(656-683) 
568 ± 139 
8.5 ± 0.1 
-6.2 ± 0.1 
-2.28 
0.8 ± 0.1 
63.2 
1.1 
-88 
 
 
(664-690) 
361 ± 82 
-8.8 ± 0.1 
-10.0 ± 0.5 
1.2 
1.0 ± 0.1 
63.7 
1.6 
-82 
> 100 
19.5  ± 6.9 
- 
 
 
 
 
 
62.1 
n.a. 
-75 
 
 
10E
8_W
/D
 
G
K
Y
Y
D
FD
S
G
Y
P
P
G
E
E
 
(656-683) 
376 ± 76 
-8.7 ± 0.2 
-4.6 ± 0.2 
-4.1 
1.2 ± 0.1 
63.7 
0.6 
-124 
> 100 
> 100 
(664-690) 
375 ± 66 
-8.7 ± 0.1 
-6.5 ± 0.3 
-2.2 
1.0 ± 0.1 
64.0 
0.9 
-33 
- 
 
 
 
 
 
63.1 
n.a. 
-43 
a Tem
perature w
as 298 K
. 
b n refers to the m
olar ratio peptide/protein 
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